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1 ABSTRACT / KURZFASSUNG 
English 
Introduction: Melatonin, known as the hormone of darkness, is a versatile substance 
produced in the pineal gland from its precursor substance serotonin. Melatonin plays a 
role in many processes including regulation of the body’s internal clock, appetite, sleep, 
radical scavenging, and supposedly in behavior, tumor suppression, blood pressure 
and many more. Because of its sleep promoting effect, melatonin is used as a mild 
hypnotic, even though the effects of orally administered melatonin are limited. During 
the course of its metabolization, melatonin can scavenge a great number of reactive 
oxygen species, which is the cause for the extremely potent antioxidative capabilities of 
this substance. Apart from numerous other binding sites, two G-protein coupled 
receptors (GPCRs), MT1 and MT2, exist in mammals which recognize melatonin as 
ligand and mediate many of its functions. Both receptors are coupled to Gi-proteins, but 
while MT1 is almost ubiquitously expressed in many tissues, MT2 is restricted to few 
regions of the body, like eye and brain. These GPCRs show circadian expression 
patterns in some tissues. Importantly, MT1 and MT2 are expressed in the 
cardiovascular system, however these data are conflicting and the influence of the 
GPCRs on, and their expression and location in the cardiovascular system are still not 
completely understood and remain to be fully characterized. It was suggested that MT1 
mediates vasoconstriction through direct activation of smooth muscle cells, while MT2 
mediates vasodilation through activation of nitric oxide synthase in the endothelium of 
the blood vessels. In any case, exogenous melatonin lowers blood pressure, both of 
healthy and hypertensive animals and humans. The mechanisms involved in this blood 
pressure regulating properties include melatonin’s antioxidative capabilities, a 
dampening influence of melatonin on the central nervous system and the melatonin 
GPCRs. Aims: 1) Establish methods for RT-PCR and RT-qPCR experiments for 
investigation of MT1 and MT2 mRNA expression levels. 2) Investigate whether there is 
expression of MT1 and MT2 mRNA in the rat aorta. 3) Investigate the difference 
between melatonin GPCR mRNA expression levels in aortas from rats of two different 
time points. 4) Investigate the difference between melatonin GPCR mRNA expression 
levels in aortas from spontaneously hypertensive rats (SHR) and control rats. 5) 
Establish and perform immunofluorescence (IF) stainings to investigate the location of 
the melatonin GPCRs in the rat aorta. Methods: RNA was extracted and reversely 
transcribed using standard protocols. PCR with diverse primer pairs either retrieved 
from literature or custom designed was performed for MT1 and MT2. RT-qPCR 
experiments were performed using commercially available assays for rat MT1 and MT2. 
For method establishment, pre-frozen rat tissue samples of various organs were used. 
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16 aorta samples from two different time points – eight from day and eight from the 
night – were investigated to assess the difference in melatonin GPCR mRNA 
expression levels depending on the circadian phase state. 16 aorta samples of SHR 
and control rats – eight each – were investigated to evaluate the difference in 
melatonin GPCR mRNA expression levels between normotensive and hypertensive 
animals. Paraffin embedded sections and cryo-sections were used for localization of 
MT1 by IF-staining, which was done using two different antibodies directed against 
MT1. Two mouse tissues, brain and intestine, were used as positive controls. Results: 
Observed expression levels of MT1 and MT2 in the rat organs did not exactly correlate 
with the levels in the literature, indicating rat-strain or interindividual differences. MT1 
mRNA was present in almost all aorta samples and showed a high interindividual 
variability in expression levels, while MT2 mRNA was not present in aortas at all. There 
was no significant difference in MT1 mRNA levels between the daytime and nighttime 
groups, though a trend toward higher expression in the nighttime group might be 
observed with a larger sample number. However, a significant difference in expression 
was found between aortas from SHR, which exhibited about 4 times (0–8) more mRNA 
for MT1, and the aortas from control rats, supporting a function of melatonin in blood 
pressure reduction. Immunofluorescence showed weak staining for MT1, but 
surprisingly in the tunica adventitia of the aortas, while a strong, region specific, 
staining in the positive controls was found. This was in contrast to the expected 
localization of MT1 in the tunica media. Conclusion: We could demonstrate that MT1 is 
indeed expressed in the rat aorta as model for the vascular system, while MT2 is not 
present at all. It seems that the expression levels for MT1 mRNA are not dependent on 
the time of day, although the sample size was too low and the number of time points 
too few for any final statement. We found a significant difference in expression of MT1 
between normotensive and hypertensive animals, supporting a function of MT1 in the 
blood pressure modulating capabilities of melatonin. MT1 seemed to be mainly located 
in the tunica adventitia of the aorta and not, as expected, in the tunica media. This 
localization of MT1 and the absence of MT2, however, are in conflict with the current 
hypothesis on the influence of the melatonin GPCRs on blood pressure regulation by 
melatonin and ask for further investigation.  
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Deutsch 
Einleitung: Melatonin ist eine sehr vielseitige Substanz, die in der Zirbeldrüse aus 
Serotonin entsteht und auch als „das Hormon der Dunkelheit“ bezeichnet wird. Zu den 
vielfältigen Einflussbereichen von Melatonin im Körper gehören zum Beispiel die 
Regulation der inneren Uhr, des Appetites und des Schlafs sowie das Abfangen freier 
Radikale. Vermutet wird auch ein Einfluss auf Verhalten, Tumorsuppression, Blutdruck 
und andere Funktionen des Körpers. Wegen seines schlafvermittelnden Effektes wird 
Melatonin als mildes Hypnotikum eingesetzt, allerdings ist seine Effektivität bei oraler 
Anwendung begrenzt. Im Rahmen des Abbaus von Melatonin im Körper können eine 
große Menge freier Radikale gebunden und somit unschädlich gemacht werden, was 
die starke antioxidative Wirkung von Melatonin erklärt. Für Melatonin gibt es mehrere 
Bindungsstellen; zwei davon, MT1 und MT2, sind G-Protein gekoppelte Rezeptoren, die 
auch in Säugetieren vorkommen. Obwohl beide Rezeptoren vom Gi-Typ sind, ist MT1 
fast in allen Teilen des Körpers exprimiert, wohingegen MT2 nur in bestimmten 
Geweben, wie z.B. Auge oder Gehirn, zu finden ist. Die Expression dieser Rezeptoren 
zeigt in manchen Geweben einen zirkadianen Rhythmus. Zwar sind MT1 und MT2 auch 
in Blutgefäßen vorhanden, die Datenlage zu deren Lokalisation, Funktion und 
Expression im vaskulären System ist allerdings widersprüchlich und noch abzuklären. 
Es wird angenommen, dass MT1 für Vasokonstriktion durch direkte Aktivierung der 
glatten Gefäßmuskulatur verantwortlich ist, während MT2 durch Aktivierung der NO-
Synthase in Endothelzellen Vasodilatation vermittelt. Verabreichung von Melatonin 
führt jedenfalls zu Blutdrucksenkung. Dies wurde sowohl am gesunden und 
hypertensiven Menschen, wie auch am Tiermodell festgestellt. Diese blutdruck-
regulierende Wirkung von Melatonin wird unter anderem durch seine antioxidativen 
Eigenschaften, einen dämpfenden Effekt auf das Zentralnervensystem und die 
Wirkungen der G-Protein-gekoppelten Rezeptoren erklärt. Ziele: 1) Etablierung der 
Methoden für die RT-PCR und RT-qPCR zur Untersuchung der MT1- und MT2-
Expression. 2) Feststellung, ob MT1 und MT2 mRNA in der Ratten-Aorta exprimiert 
sind. 3) Feststellung des Unterschiedes in der mRNA-Expressionsrate von MT1 und 
MT2 zwischen zwei Gruppen von Ratten-Aorten, die zu unterschiedlichen Tageszeiten 
gewonnen wurden. 4) Feststellung des Unterschiedes in der mRNA-Expressionsrate 
von MT1 und MT2 zwischen Aorten von spontan-hypertensiven-Ratten (SHR) und 
Kontroll-Ratten. 5) Etablierung und Durchführung von Immunfluoreszenz- (IF) 
Färbungen, um die Lokalisation von MT1 und MT2 zu bestimmen. Methoden: Die RNA 
der einzelnen Proben wurde nach Standard-Protokollen isoliert und revers transkribiert. 
PCR-Experimente wurden mit verschiedenen Primer-Paaren, die entweder der 
Literatur entnommen oder selbst erstellt waren, durchgeführt, um MT1 und MT2 mRNA 
in den Proben nachzuweisen. RT-qPCR wurde mit kommerziell erhältlichen 
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Testsystemen für MT1 und MT2 durchgeführt. Zur Etablierung der einzelnen Methoden 
wurden Proben von verschiedenen Ratten-Geweben verwendet. Um den Unterschied 
in der mRNA-Expressionsrate von MT1 und MT2 abhängig von der Tageszeit zu 
überprüfen, wurden 16 Ratten-Aorten, wovon acht bei Tag und acht bei Nacht 
gewonnen wurden, verwendet. Ebenfalls wurden 16 Ratten-Aorten, acht von SHR und 
acht von Kontroll-Ratten, verwendet, um den Unterschied in der mRNA-
Expressionsrate von MT1 und MT2 zwischen hypertensiven und normotensiven Tieren 
zu bestimmen. Paraffin- und Gefrier-Schnitte von Ratten-Aorten wurden benutzt, um 
die Lokalisation von MT1 mittels IF-Färbung zu bestimmen, wobei zwei 
unterschiedliche Antikörper gegen Ratten-MT1 verwendet wurden. Als Positiv-
Kontrollen kamen Maus-Gehirn und Maus-Darm zum Einsatz. Resultate: Die 
beobachteten Expressionsraten von MT1 und MT2 in den Ratten-Organen divergieren 
teilweise von den in der Literatur beschriebenen, was auf interindividuelle 
Abweichungen oder Unterschiede zwischen verschiedenen Ratten-Arten hindeuten 
könnte. Es konnte kein signifikanter Unterschied der mRNA-Expressionsraten 
zwischen den Aorten-Gruppen von zwei unterschiedlichen Tageszeiten festgestellt 
werden. Dem Trend der Daten folgend, wäre es allerdings möglich, dass eine höhere 
Expression von MT1 mRNA in der „Nacht“-Gruppe bei einer größeren Anzahl von 
Proben in beiden Gruppen zu sehen gewesen wäre. Im Gegensatz dazu konnte ein 
eindeutiger Unterschied in der Expressionsrate von MT1 mRNA zwischen den Aorten 
von SHR und Kontroll-Ratten festgestellt werden, wobei SHR ungefähr 4-mal mehr (0–
8) mRNA exprimierten als Kontroll-Ratten. Dies unterstützt den postulierten Einfluss 
von Melatonin auf die Blutdruckregulation über den G-protein-gekoppelten Rezeptor 
MT1. Die IF-Experimente zeigten eine schwache Färbung von MT1-Protein in der 
Ratten-Aorta, erstaunlicherweise überwiegend in der Tunica adventitia. Die Positiv-
Kontrollen zeigten eine starke, region-spezifische Färbung. Schlussfolgerung: Wir 
konnten nachweisen, dass MT1 mRNA tatsächlich in der Ratten-Aorta – als Modell für 
das Gefäßsystem – exprimiert ist. MT2 mRNA hingegen wird in der Ratten-Aorta 
überhaupt nicht exprimiert. Es scheint, als wäre die Expressionsrate von MT1 mRNA 
nicht von zirkadianen Rhythmen abhängig, allerdings war die Anzahl der Proben wohl 
zu gering, um eindeutige Schlussfolgerungen zu ziehen. Ein eindeutiger Unterschied in 
der Expressionsrate von MT1 zwischen normotensiven und hypertensiven Tieren 
konnte nachgewiesen werden, was eine Funktion von MT1 im Rahmen der Blutdruck 
regulierenden Eigenschaften von Melatonin unterstützt. MT1 scheint hauptsächlich in 
der Tunica adventitia exprimiert zu sein und nicht, wie angenommen, in der Tunica 
media. Diese Lokalisation und die Abwesenheit von MT2 stehen im Gegensatz zu 
derzeitigen Hypothesen über den Einfluss der Melatonin-Rezeptoren MT1 und MT2 und 
bedürfen weiterer Untersuchung. 
2 Introduction 
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2 INTRODUCTION 
2.1 General information about melatonin 
Melatonin (chemical name N-acetyl-5-methoxytryptamine or N-[2-(5-methoxy-1H-indol-
3-yl)-ethyl]-ethanamide, see Figure 1) is commonly known as the “darkness hormone” 
because melatonin levels are highly dependent on lighting conditions, being low at day 
and high at night [1-2]. Melatonin is (in vertebrates) produced in the pineal gland [3] but 
also in various other areas such as the suprachiasmatic nucleus (SCN) [4], leucocytes 
[5] the retina, the bone marrow, the skin, the gastro intestinal tract, the skin, and 
probably others [6-7]. It was first discovered in the year of 1958 by Lerner et al. [8]. 
Melatonin was named after its ability to lighten the color of melanocytes in certain 
animals and its precursor serotonin [7-9]. 
 
 
Figure 1: Structure of melatonin. 
Melatonin has a variety of roles, like control of circadian rhythms and sleep by 
playing an essential part in the body’s internal clock. Thereby, the main function of 
melatonin is to inform various parts of the body about photoperiods (= day length), so 
that changes in pigmentation, appetite, sleep etc. can be organized. Other functions of 
melatonin include vascular and blood pressure (BP) modulation, scavenging of free 
radicals and reduction of oxidative stress, stimulation of the immune system, regulation 
of seasonal reproduction and body temperature, inhibition of tumor proliferation, 
osteolysis inhibition, behavior regulation and others [6-7, 10-12]. 
Because of this multitude of functions and because of numerous other facts – 
melatonin’s non receptor-dependent antioxidative capability, synthesis in organs other 
than the pineal gland, and that melatonin can be taken up with food supplementing the 
endogenous production – Tan et al. [7] point out that melatonin could not only be 
described as a hormone, but as a vitamin, too.  
Melatonin not only occurs in animals, but also in unicellular organisms and fungi 
[13] as well as in plants, where it exhibits a similar circadian rhythm like in animals, 
although the data on its function is yet not very conclusive. Various roles, such as that 
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of an antioxidant, have been hypothesized. The first definite job of melatonin in plants 
seems to be that of a growth promoter [9].  
2.2 Melatonin biosynthesis 
Melatonin is synthesized from serotonin in two steps (see Figure 2). The first step is 
acetylation of serotonin to the intermediate N-acetylserotonin by the arylalkylamine-N-
transferase (AANAT). The acetyl group is supplied by AcCoA. The second step is 
methylation of N-acetylserotonin to N-acetyl-5-methoxy-tryptamine (melatonin) by the 
hydroxyindole-O-methyltransferase (HIOMT) [1]. The methyl group is carried over from 
S-adenosyl-methionine [2]. Melatonin synthesis is highly dependent on environmental 
light and therefore follows a circadian rhythm. In low light conditions, melatonin levels 
are greatly increased, with correspondent increase of AANAT activity. HIOMT activity, 
on the other hand, is not increased or, at most, to a lesser extent. Nocturnal melatonin 
synthesis also rapidly diminishes again after exposure to light (see Figure 2) [1, 14]. 
 
 
Figure 2: Daily rhythm of indoles in the rat pineal gland. Molecular changes are highlighted with red 
rectangles / lines. Periods of darkness are indicated by gray shading. Nocturnalyl increased activity of 
AANAT results in decreased serotonin and increased NAS-levels. HIOMT activity is also increased during 
nighttime, but to a much lesser extent. As a result, melatonin concentration is greatly elevated during the 
night. Modified after [1]. 
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2.2.1 Adrenergic control of melatonin biosynthesis 
Melatonin synthesis in the pineal gland is strongly controlled by adrenergic stimulation 
via the SCN. The SCN is the main controller of all circadian rhythms in mammals and 
synchronizes the various more or less autonomous “clocks” in mammals [15]. It is the 
driving element of the circadian rhythm of melatonin. In the rat, the SCN is largely 
controlled by lighting conditions [16], but can also function autonomously, when left in 
complete darkness. Nerves emerging from the SCN ultimately activate sympathetic 
fibers which in turn innervate the pineal gland [1]. 
Stimulation of α1-adreno-receptors activates proteinkinase C (PKC) via increased 
Ca2+ and diacylglycerol (DAG) concentrations in the pineal cells (see Figure 3).  
 
 
Figure 3: Adrenergic regulation of melatonin synthesis. Norepinephrine (NE) binds to α1 or β1 receptors. 
α1 stimulation potentiates the effect of β1 stimulation by activating protein kinase C (PKC) which in turn 
activates the adenylate cyclase (AC) of the β1 receptor. The AC produces cyclic AMP (cAMP) which 
activates protein kinase A (PKA). PKA has now two different methods of raising AANAT-activity: 1) by 
phosphorylization of cAMP-response-element-binding-protein (CREB) which then promotes transcription of 
the AANAT-gene, and 2) by phosphorylization of AANAT which leads to a complex of AANAT with 14-3-3, 
rendering AANAT insensitive to proteasomal proeteolysis. Modified after [1]. 
While stimulation of α1 alone has no effect on AANAT activity [17], the increased 
Ca2+ influx potentiates the effect of protein kinase A (PKA). PKA is activated by cAMP 
generated through 1-stimulation, therefore acting as an amplifier for the 1-adrenergic 
signal [18]. A cAMP-responsive element binding protein (CREB) has been identified 
[19], which, together with an adjacent 5-base-box function, acts as a promoter for the 
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AANAT-gene. Furthermore, PKA acts via direct phosphorylation of AANAT [17], 
leading to the formation of an AANAT-complex with a 14-3-3 protein, a kind of 
“shielding protein” which protects the AANAT from proteolysis [20]. 
In summary, there are two mechanisms for regulation of AANAT activity: increased 
transcription of AANAT-mRNA and inhibition of preoteolysis by coupling with 14-3-3 
proteins [14]. 
2.2.2 Melatonin metabolism 
Melatonin is metabolized mainly in the liver via the cytochromes CYP1A2 and CYP1B2. 
Metabolic pathways are 6-hydroxylation to 6-hydroxy-melatonin with subsequent 
sulfatation and excretion, O-demethylation to N-acetyl-5-hydroxy-tryptamine and non-
enzymatic deacetylation to 5-methoxytryptamine [21]. This last, non-enzymatic way for 
metabolism of melatonin is also called kynuric pathway. It is essential for melatonin's 
antioxidative abilities. In its course, free radicals such as O2˙, CO3˙, NO˙ or H2O2 are 
scavenged [6] (see Figure 4). 
 
 
Figure 4: Simplified kynuric pathway of melatonin metabolism. After [6]. 
2.3 Melatonin receptors and other melatonin binding 
proteins 
2.3.1 MT1 and MT2 – G-protein coupled receptors 
In 1994 the first melatonin receptor Mel1C was found in Xenopus laevis (African clawed 
frog) and discovered to be a G-protein coupled receptor (GPCR) of the Gi-type, 
therefore reducing cAMP levels by inhibiting the adenylyl cyclase. It was shown that the 
receptor was highly affine to melatonin and had a structure of 420 amino acids grouped 
in 7 hydrophobic elements [22], typical of GPCRs [23]. However, Mel1C is not 
expressed in mammals, but only in fish, amphibiae or birds. Two other melatonin 
receptors have been found shortly afterwards, which were originally called Mel1A and 
Mel1B, respectively, but then re-named melatonin receptor 1 (MT1) and Melatonin 
receptor 2 (MT2) [24]. 
MT1 was first discovered in sheep and humans. [25]. The receptor has a size of 
350 amino acids (in rats: 353 amino acids [26]) with 7 transmembranic domains [27] 
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and is also a G-protein coupled receptor of the Gi-type. The expression of MT1 is, at 
least partly, regulated by circadian rhythms controlled by the SCN [24]. 
One year later, MT2 was found in humans. The receptor comprises 362 amino 
acids (in rats: 364 amino acids [26]) and is, again, a G-protein coupled receptor of the 
Gi-type [28]. 
Depending on the cell type in which the receptors are expressed, they also seem 
to exhibit coupling with Gq-proteins, indicating possible parallel signaling pathways for 
these receptors [27]. See Figure 5 for an overview of the proposed signaling pathways 
of the melatonin receptors. 
 
Figure 5: Melatonin GPCR signaling cascade. Modified after [27]. Q. v. for detailed information. 
The human MT1 and MT2 receptors show a different affinity for melatonin (Ki 80.7 
vs 383 pM) [29] and other compounds. Some of these substances are important for 
studies on receptor-mediated melatonin effects. Luzindole (2-benzyl-N-
acetyltryptamine), an unselective antagonist for both melatonin GPCRs, was identified 
by Dubocovich [30] and is often used in studies to suppress receptor-mediated 
melatonin effects. 4P-ADOT (4-phenyl-2-acetamidotetraline) and 4P-PDOT (4-phenyl-
2-propionamidotetralin) serve as relatively selective antagonists of MT2 [31]. More 
recently, N-butanoyl-5-methoxy-1-methyl-β,β-trimethylene-tryptamine, which is an 
antagonist at MT1, but an agonist at MT2 and N-butanoyl-5-methoxy-1-methyl-β,β-
tetramethylene-tryptamine, which is an antagonist at MT1 not showing any interaction 
with MT2, thus being selectively antagonistic at MT1 [32], have been identified and will 
allow further studies on the function of melatonin’s GPCRs. 
  
2 Introduction 
 10 
Distribution and functions 
The distribution of melatonin GPCRs has been investigated in many studies. For 
humans, studies on mRNA expression via RT-PCR as well as protein expression via 
western blot or immunohistochemical methods revealed MT1 and, to a lower extent, 
MT2 to be present in regions of the brain, ovary, kidney, intestine and various other 
organs and cell types [33]. However, while well characterized antibodies are available 
against human MT1 and MT2, no reliable antibodies for other species have been 
reported yet. Therefore, most studies concerning melatonin GPCR expression in other 
species than human, e.g. rat, were performed on the mRNA level [24].  
Earlier studies investigating MT1 and MT2 mRNA expression in the rat used only 
incomplete sequences of the receptor’s mRNA as template for primer design [34-36]. 
Addressing these issues, Ishii et al. [26] identified the gene structures including the 
whole mRNA sequence for both rat MT1 and MT2. Using newly designed exon-
spanning primers, designed from the identified mRNA sequences for both receptors, 
they demonstrated occurrence of MT1 and MT2 mRNA – without the risk of false 
positives through genomic DNA – in a great variety of rat tissues, like lung, kidney and 
intestine (see Figure 6). 
 
Figure 6: RT-PCR analysis of MT1, MT2 and β-actin expression in various rat tissues. Both MT1 and MT2 
were detected in all tissues. β-actin is used as control. Modified after [26]. 
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Melatonin exhibits an enormous multitude of functions via its known G-protein-
coupled-receptors. An extensive discussion of all the effects of the melatonin receptors 
would go beyond the scope of this introduction. An overview can be seen in Figure 7, 
details can be found e.g. in [33], [37] or [6]. The expression, distribution and 
functionality of MT1 and MT2 in the cardiovascular system will be discussed in 2.6. 
 
 
Figure 7: MT1, MT2 and MT3 (see 2.3.2) responses in the CNS and peripheral tissue [37]. Q.v. for detailed 
information. 
Structure and functionality 
Both the human and rat MT1 gene consist of two exons. The rat MT2 gene consists of 
three exons, whereas the human MT2 gene contains only two. This suggests that 
regulation of MT2 receptor expression might be species specific [26]. 
All melatonin GPCRs, Mel1C, MT1 and MT2, show a high degree of homology with 
each other: 60 % for the complete sequences, 73 % within the transmembrane 
sections [28]. The rat receptors exhibit 84.1 % and 78.3 % identity with their human 
counterparts [26]. As of yet there are no x-ray crystallographic structures available for 
any of these receptors. The predicted membrane topologies of human MT1 and MT2 
are shown in Figure 8. 
. 
- 
2 Introduction 
 12 
 
Figure 8: Predicted membrane topology of MT1 and MT2 with deduced amino acid structures. Y = potential 
N-linked glycosilation site. Solid dots = identical amino acids in MT1 and MT2. MT1: [38]; MT2: [28]. 
The C-terminal tails of both MT1 and MT2 are necessary for interaction with the  
G-protein and receptor internalization [27, 39]. For details see [40] and [39]. The  
C-terminal tail of MT1 also interacts with the protein MUPP1 amongst others, which 
joins MT1 to cAMP regulation and nitric oxygen synthase (NOS). This could explain the 
fact that NO production is inhibited by melatonin [24]. However, at least in endothelial 
cells, not the melatonin GPCRs seem to be involved in the reduction of nitric oxide 
(NO) production [41-42], but interaction with intracellular Ca2+ mobilization [41] or NF-
κB inhibition [42]. In addition to the G-proteins, MT1 and MT2 interact with a number of 
other proteins, like the actin binding protein filamin A, and insulin receptor substrate 4 
(IRS4), proteins commonly associated with other GPCRs [24].  
GPCRs generally tend towards di- or oligomerization [23] and the melatonin 
GPCRs are no exception [24]. It was demonstrated that the relative propensity of the 
MT1 / MT2 heterodimer and the MT1 / MT1 homodimer is similar, but for the MT2 / MT2 
dimer it is three to four times lower. Heterodimers also interact with selective ligands for 
MT1 and MT2, resulting in a possible problem with data interpretation of ligand affinities 
or receptor expression patterns [43]. 
In 1996, G protein-coupled receptor 50 (GPR50), an orphan GPCR belonging to 
the melatonin receptor family (45 % identical to MT1 and MT2), but not interacting with 
melatonin or any other known ligand, was discovered. It has an unusually long C-
terminal tail consisting of over 300 amino acids, but no N-linked glycosylation sites [44]. 
See Figure 9 for predicted membrane topology. 
. 
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Figure 9: Predicted membrane topology of GPR50, with deduced amino acid structure. Modified after [44]. 
Ten years later, it was shown that GPR50 is as likely to engage in homodimers as 
in heterodimers with MT1 or MT2 but not with β2-adrenoreceptors or CC chemokine 
receptors (CCR). Heterodimers of GPR50 with MT2 did not change the activity of MT2, 
but dimers with MT1 strongly inhibit receptor function. It seems that the C-terminal tail 
inhibits the interaction of MT1 with the G-protein and β-arrestin [24]. Since MT2 dimers 
with GPR50 show no decreased activity, MT2 could act as an endogenous antagonist 
for GPR50, thus inhibiting the inhibition of MT1 by GPR50 [45]. For an overview of 
melatonin GPCR dimerizations see Figure 10. 
 
Figure 10: Melatonin GPCR dimerizations. Modified after [27]. 
2.3.2 Other melatonin binding sites 
Another protein binding and reacting to melatonin is MT3, originally named ML2 and 
discovered in 1988 [24, 46]. Compared to MT1 and MT2, it exhibits a relatively low 
affinity for melatonin and fast kinetics [24, 47]. In the year 2000, MT3 could be identified 
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as the quinone reductase 2 (QR2), a well known enzyme with oxidoreductive properties 
[48]. X-ray structural analysis of the melatonin / QR2 complex proved the interaction 
between melatonin and QR2 [49]. QR2 seems to increase cytotoxic effects caused by 
reactive quinones, seeing that, for example, QR2 knockdown cells are 42–48 % less 
sensitive to menadione poisoning [50]. While the mechanisms of QR2 and its 
regulation are still somewhat unclear [27], it seems very probable that some of the 
beneficial aspects of melatonin such as its antioxidative capability are connected with 
its binding affinity to the QR2 binding site [24]. 
In addition to the GPCRs MT1 and MT2 as well as QR2, melatonin interacts with 
numerous other targets. In 1993, Benitez-King et al. [51] demonstrated affinity of 
melatonin for calmodulin, thus modulating intracellular Ca2+ functions. It was proved 
recently that melatonin has a very significant influence on calcium / calmodulin-
dependent protein kinases in rat INS-1 cells [52]. Calreticulin, another calcium binding 
protein, has high affinity for melatonin, too. Calreticulin is a protein of the 
endoplasmatic reticulum with various functions like chaperon activity or integrin 
function. There are speculations that melatonin might influence calreticulin’s 
internalization in the nucleus [53].  
Melatonin has an (albeit low) affinity for nuclear receptors such as Retinoid-related 
orphan receptor alpha (RORα) 1, 2, and retinoid Z receptors (RZR). While the RORs 
are probably involved in regulating effects on leucocytes, little is known about RZR [6]. 
For more details on these nuclear receptors see [27].  
Finally, melatonin seems to have some influence on mitochondria; while it seems 
to modulate electron flux and leakage [27], it also inhibits the mitochondrial transition 
pore (mtPTP), which plays a role in the development of ischemia. Melatonin reduces 
infarct volume and neuron loss, so that the inhibition of mtPTP might be a very 
important feature of the anti-apoptotic effect of melatonin [54]. 
2.4 Antioxidative effects of melatonin 
One of melatonin’s most prominent features is its antioxidative capacity. Melatonin is 
most efficient in scavenging free radicals with almost no pro-oxidant side effects [6]. It 
was discovered that the O-methyl and N-acetyl groups (see Figure 1) are most 
important for melatonin’s extraordinarily strong direct radical scavenging ability [55]. 
During the metabolism of melatonin to AFMK (N1-acetyl-N2-formyl-5-methoxy-
kynuramine), the metabolite apparently most important for radical scavenging, up to 
four free radicals can be eradicated (see Figure 4). Other metabolites of melatonin or 
their reactions of formation and degradation accordingly exhibit radical scavenging 
properties as well [6]. Additional to this antioxidant mechanism are indirect effects via 
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inhibition of NO production [42], up-regulation of antioxidant enzymes like catalase [56] 
and down-regulation of pro-oxidant enzymes like myeloperoxidase [57], inducible NO-
synthase [56] or superoxide dismutase [58].  
Various in vivo studies have confirmed melatonin’s antioxidative capacity and 
capability to reduce oxidative stress. For example, it was demonstrated that melatonin 
reduces renal damage from oxidative stress in rats with artificially induced chronic renal 
failure [59]. Another example is reduced damage, caused by alcohol induced oxidative 
stress, in the aorta of melatonin treated rats [60]. 
Further examples for and information on the oxidative stress related effects of 
melatonin can be found in a variety of reviews, e.g. [6, 61-63]. 
2.5 Pharmacological aspects of melatonin 
As a medication, melatonin has phase shifting effects for sleep or body temperature. 
This might be beneficial for e.g. jet lag or shift work [64], although the observed effect 
of oral melatonin has been relatively slim [65]. A large meta-analysis showed an 
average increase in sleep duration of 12.8 minutes and reduced sleep onset by 4.0 
minutes [66]. However, a recent study performed on autistic children showed greater 
benefits of melatonin on sleep onset (47 minutes) as well as sleep duration (52 
minutes) when compared to placebo [67]. Melatonin also shows positive effects when 
treating depression [64]. 
Another interesting application for melatonin might be the treatment of poisoning 
with – or toxic side effects of – various substances like sulfur mustard [68], arsenite 
[69], mercuric chloride [70-71], nickel [72] or carbon tetrachloride [73], the 
chemotherapeutic drugs adriamycin [74] and doxorubicin [75] as well as the 
immunosuppressant cyclosporine A [76]. For doxorubicin, simultaneous treatment with 
melatonin seems not only to ameliorate the cytotoxic side effects of the doxorubicin, 
but melatonin also increases the drug’s apoptosis inducing effect in hepatoma cells in 
vitro [77]. 
One more field of application for melatonin might be the treatment of glaucoma 
[78]. While melatonin does not decrease intraocular pressure, it reduces the destructive 
effects of ocular hypertension [79]. 
Many melatoninergous substances have been developed [80], however, few are 
available for human use. Melatonin itself, available as over-the-counter-medicine in the 
US and available on prescription in the European Union, is probably safe in low 
dosages [64]. Agomelatine, an agonist at MT1 and MT2 and an antagonist at 5-HT2C 
receptors, is used primarily as an antidepressant with good efficacy even in severely 
depressed patients, and exhibits relatively few adverse effects [81]. Ramelteon, a 
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selective MT1 and MT2 agonist, is effective in promoting sleep in animals and patients 
with insomnia by regulating the body’s natural clock. Unlike other hypnotics, it does not 
cause withdrawal symptoms or dependence and has only mild side effects [82]. Finally, 
another new compound, Tasimelteon, a high affinity MT1 and MT2 agonist, has proved 
in clinical trials to improve sleep quality, onset and duration in patients with transient 
insomnia. Adverse effects were similar for Tasimelteon and placebo [83]. 
A very promising field for melatonin treatment might be the prevention or alleviation 
of damage from cardiovascular diseases. Various studies have shown that in patients 
with acute myocardial infarction [84], coronary heart disease [85-86] or cardiac 
syndrome X [87], nighttime melatonin levels are reduced. Therefore, it was 
investigated, whether exogenous melatonin has a beneficial effect on these conditions. 
Indeed, on artificially ischemic rodents, exogenous melatonin exhibits dramatic effects: 
animals pre-treated with melatonin 10 minutes before artificially induced ischemia 
exhibit more than 50 % reduction of the total number of premature ventricular 
contractions, duration of ventricular fibrillation and ventricular tachycardia. Infarct size 
was reduced as well. Mortality decreased from 59 % in rats without melatonin 
treatment to 0–10 % in rats with pre-occlusion melatonin administration. All these 
effects were attributed to melatonin’s antioxidative capabilities [57]. The protective 
action of melatonin has been demonstrated by similar studies (e.g. [58]) or studies 
performed on different organs in similar ischemic conditions (e.g. [88]). Because of 
these promising results, the phase II MARIA trial is being undertaken to confirm the 
cardioprotective capability of melatonin for patients with acute myocardial infarction 
undergoing primary angioplasty [89-90]. 
For more information about melatonin and its protective influence on the 
cardiovascular system see [91] or [92]. 
2.6 Melatonin and blood pressure (BP) regulation 
2.6.1 General overview on BP regulation 
The regulatory mechanisms of BP are manifold. Three parameters influence BP: heart 
activity (heart rate and contractile force), blood volume and peripheral resistance of the 
arterioles and capillaries. Through vasoconstriction of arterioles, BP is elevated, while 
vasodilation reduces BP[93]. To describe all these parameters and the mechanisms 
that influence them would go beyond the scope of this work. A simplified overview is 
given in Figure 11. The reader is directed to the pertinent literature for details [94]. 
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Figure 11: Simplified overview of the complex regulatory mechanisms of BP. Red arrows: inhibition; green 
arrows: stimulation; dashed black lines: direct influence of the BP on the regulatory mechanisms. 
In humans, hypertension is defined as a BP of > 140 (systolic) or > 90 (diastolic) 
mm Hg. Hypertension is a key risk factor for development of cardiovascular events like 
myocardial infarction, edema, ischemia or other diseases. Over 20 % of the adult 
population of the USA take antihypertensive drugs [95]. Hypertension can be caused 
by a variety of factors, but in most cases the cause is unknown – this condition is 
referred to as essential hypertension. 
2.6.2 The aorta 
In contrast to the capillaries and arterioles, the aorta contributes very little to BP 
formation [93]. Its smooth muscles mainly provide stiffness and elasticity. Nevertheless, 
the aorta is often used as a model system for all blood vessels, since the arterioles and 
capillaries are almost impossible to prepare because of their sheer minuteness. 
The aorta is the largest blood vessel in the mammalian body, and is very similar in 
structure among all mammalian species [96]. The aorta, like all blood vessels, consists 
of three layers or tunicas. The innermost layer (nearest to the lumen of the vessel) is 
called tunica intima, or tunica interna. It consists of the endothelium of the vessel and 
connective tissue. The outer border of the tunica intima is the internal elastic lamina, 
which is the first of many elastic fibers, alternating with layers of smooth muscle cells. 
Together, they form the second tunica, the tunica media. The outermost “ring” of elastic 
fibers delimits it from the tunica adventitia, or tunica externa, which is comprised mainly 
of connective tissue and, as the name suggests, connects the aorta to the surrounding 
tissue [97-98]. See Figure 12 for a schematic of a blood vessel and a histological 
section of an aorta. 
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Figure 12: Anatomical structure of the aorta. Left panel: schematic depiction of the aorta. Right panel: 
Histological section of the aorta. TI: tunica intima, end: endothelium, el: elastic lamellae, n: smooth muscle 
tissue, TM: tunica media, TA: tunica adventitia. Left panel modified after [97], right panel modified after 
[99]. 
An important function of the endothelium in blood vessels is the production of nitric 
oxide (NO), which was identified as the endothelial derived relaxing factor. NO is 
produced in endothelial cells via NO-synthase and then diffuses in gaseous form in the 
tunica media where it activates the guanylyl cyclase, which leads to subsequent 
relaxation of the smooth muscles [100]. Activation of the NO-synthase can be mediated 
through a variety of factors, including melatonin [61]. 
In contrast, vasoconstriction is mediated only through direct activation of receptors 
on the smooth muscle cells. Examples for these substances include norepinephrine or 
angiotensin II [101], but probably also melatonin [61].  
2.6.3 Reduced melatonin levels lead to hypertension 
Melatonin’s physiological function in BP regulation is revealed by the fact that in 
pinealectomized rats BP increases significantly. Interestingly, the effect is only 
temporary, as the elevated BP returns to normal values 90 days after the operation 
[102]. A possibly BP related side effect of pinealectomy is reduced release of 
vasopressin (a peptide hormone secreted by the pituitary gland regulating water 
retention and vasoconstriction). Vasopressin levels are significantly lower in 
pinealectomized rats than in sham operated animals. The osmotic threshold for 
vasopressin release remains unchanged and only the quantity of released hormone is 
reduced. This indicates that it is not the actual release of vasopressin that is mediated 
by melatonin, but the magnitude of the response to altered osmotic conditions, possibly 
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via some central mechanism not yet discovered [103]. However, since vasopressin 
action seems to be lower in rats with less melatonin, this fact cannot add to the 
explanation of the elevated BP in pinealectomized rats.  
In patients with nocturnal hypertension, melatonin levels are decreased [104]. This 
adds to the hypothesis that inhibited melatonin secretion leads to elevated BP, thus 
suggesting a BP reducing effect of melatonin. Because of this, it seems irritating at first 
that in other studies, patients with essential hypertension exhibited significantly 
increased melatonin levels. However, treatment with lacidipine, an antihypertensive 
drug, not only reduces BP, but the elevated melatonin levels, too [105]. Taken together 
with the observation that melatonin restores contractile and relaxing functionality in the 
aorta [106-108], this suggests that BP is not elevated because of the elevated 
melatonin levels, but in spite of them. Natural melatonin secretion might be increased 
in hypertensive patients to counteract the elevated BP. 
Because of these findings, the use of exogenous melatonin to combat 
hypertension seems promising.  
2.6.4 Influence of melatonin on animal models of hypertension 
Exogenous melatonin exerts a profound influence on hypertension in animals. 
However, the mechanism of this influence on the BP remains somewhat unclear. As 
discussed already, melatonin exerts direct influence on smooth muscle tone in blood 
vessels – and therefore possibly peripheral resistence –, although the data on this 
influence is conflicting (see 2.6.6). 
Apart from this direct influence, melatonin may play a role in mediating central BP 
regulation as well. Baroreflex responses are improved under melatonin treatment as 
sympathetic output is decreased. Inhibition via GABAergic fibers from the SCN of areas 
in the central nervous system responsible for BP regulation might be a possible 
explanation [61, 109]. In a study performed on rats with stress induced hypertension by 
electric shocks for two weeks, pre-treatment with melatonin reduced caudal arterial 
pressure almost to control values. Associated with this reduction was a decrease of 
angiotensin II levels which was possibly caused by GABAA signaling, since the BP and 
angiotensin II reducing effect of melatonin was nullified when given in combination with 
bicuculine, a GABAA antagonist [109]. This central regulatory mechanism might be 
receptor-mediated, as another study on the same model of hypertension showed. 
Under melatonin influence GABA levels in the central nervous system were elevated, 
while luzindole nullified the effect of melatonin completely [110]. The angiotensin II 
dependent decrease of BP mentioned before was also observed in rats with 
angiotensin II levels artificially increased by means of a renal artery clip. Melatonin 
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treatment reduced the elevated BP and improved the angiotensin II dependent reduced 
cardiac function [111].  
Another factor in melatonin’s BP reducing activity might be its antixodative 
capability, which prevents structural damage in blood vessels, therefore helping to 
retain their dilative capabilities [61]. In spontaneously hypertensive rats (SHR; see 
below), melatonin treated animals exhibit decreased aortic [76] and cardial [112] 
collagen content (as opposed to “normal” development of untreated SHR [113]) and 
thus heart fibrosis is prevented The apoptosis rate of blood vessel cells is elevated, 
too, which might be an indicator for increased remodeling of vasculature in response to 
melatonin [114].  
Melatonin treatment of these genetically predisposed hypertensive rats also results 
in greatly decreased BP in the melatonin treated group (systolic: 149 vs 195 mm Hg in 
the untreated group). As expected, superoxide and NF-κB levels are reduced [115] in 
treated animals. Additionally, melatonin improves maximum response of mesenteric 
arteries of SHR to endothelium dependent vasodilating stimuli like acetylcholine [116]. 
SHR are a model for essential hypertension; they were originally bred from normal 
Wistar-Kyoto rats by Okamoto [117]. After reaching adulthood, the systolic BP of SHR 
reaches 180–200 mm Hg, while after about 40–50 weeks, SHR develop hypertension 
associated cardiovascular diseases [118]. The cause for this development of 
hypertension is believed to be of higher central origin [119]. 
SHR as model of hypertension were also used in the thesis at hand to study the 
difference in melatonin receptor expression levels in the vascular system between 
normotensive and hypertensive animals. 
2.6.5 Influence of melatonin on the BP of humans 
Orally administered melatonin significantly reduced BP together with norepinephrine 
levels without affecting the heart rate in healthy men [120] and reduced BP in women 
by about 9 mm Hg [121]. Similar studies on healthy subjects confirmed these findings 
[122-123]. Prolonged nocturnal melatonin treatment did not change diurnal BP 
variations [123]. 
In patients with essential nocturnal hypertension, repeated melatonin treatment at 
bedtime reduced nocturnal BP by 6 (systolic) and 4 (diastolic) mm Hg. The reduction is 
most significant during the night (see Figure 13) [124].  
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Figure 13: Effect of melatonin treatment on the BP of hypertensive patients. The reduction of the diastolic 
BP is most significant during the night [124]. 
Similar results were obtained in a study performed on so-called “non-dipper” 
patients who exhibit an abnormal circadian BP profile, manifesting in elevated BP 
during the night, but normal BP during the day. Starting from the observation that 
melatonin levels are decreased during the night in non-dippers [104], 5 mg of melatonin 
were administered daily before sleep. 35 % of the patients showed complete pattern 
normalization (vs 15 % in the control group). This effect was not only caused by 
nighttime BP reduction, but also by daytime BP elevation. Because of these results, the 
authors of the study recommend close monitoring of the circadian BP profile when 
using melatonin as antihypertensive medication to avoid the risk of induced arterial 
hypertension [125]. Another dilemma with long time, high dose melatonin treatment 
adds to this problem: chronic treatment leads to reduced ROS levels in the blood, but 
in a long term view this is not only beneficial, since ROS also play important regulatory 
functions. Reduced ROS levels might lead to reduced NO-synthetase induction and 
therefore reduced blood vessel dilation, thus again leading to elevated BP [126]. 
 
 
 
  
2 Introduction 
 22 
2.6.6 Contribution of MT1 and MT2 to BP regulation 
Expression of MT1 and MT2 in the vasculature 
MT1 and MT2 were detected in the human vascular system using RT-PCR and western 
blot [127-128]. MT1 receptor expression was shown to be highly dependent on 
circadian rhythm, with the lowest values at night and the highest values in the 
afternoon [129]. 
The data on the rat vascular system is conflicting. Pharmacological studies 
indicated that MT1 is indeed expressed in the rat’s cardiovascular system. Lartaud et 
al. [56] demonstrated a clear effect of melatonin on rat aortic rings. Melatonin 
prevented incubation induced loss of contraction which was reversible by the melatonin 
receptor antagonist luzindole, therefore suggesting present and functional receptors. 
Similarly, melatonin effects direct vasoconstriction in rat cerebral arteries [130], and the 
vasoconstriction effect can be reversed by luzindole in rat arterioles. This clearly points 
to melatonin GPCRs as the responsible element for vasoconstriction in these arteries 
[131]. 
 Then again, Chucharoen et al. [132] could detect neither MT1, nor MT2 mRNA in 
rat cerebral arteries, while Masana et al. [36] reported MT1 and MT2 mRNA to be 
present in the rat caudal artery; however, because the primers used in both studies 
were located only on one exon, it is possible that amplification of genomic DNA 
influenced the findings. To address this problem, experiments with exon spanning 
primers are necessary, so that false positives due to amplification of genomic DNA can 
be excluded. 
 If MT1 is indeed expressed in the vasculature of the aorta, the circadian 
expression pattern observed in humans [129] seems to be organ and / or species 
specific, as MT1 expression levels in the rat heart and aorta do not exhibit a diurnal 
rhythm, as observed on the protein level by Benova et al. [108]. In this study, MT1 was 
identified in the aorta of Wistar rats on the protein level by western blot, but of course 
the problem with antibody specificity [24] remains, putting the results into perspective. 
Investigations on the mRNA level are necessary to confirm or discard these results on 
circadian expression of MT1 and were performed in the course of this thesis.. 
Mechanisms of melatonin influence on the vasculature 
There have been many different reports on melatonin’s influences on vasculature and 
the pathways explaining these influences. 
It was suggested that melatonin effects vasoconstriction through blockage of BKCa 
channels, probably via MT1 [61], as blockage of these channels inhibited further 
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constriction by melatonin but not by compounds using a different mechanism of action 
like the NO-synthase inhibitor L-NAME (N-nitro-L-arginine-methyl-ester) [131]. 
In contrast to MT1, MT2 seems to mediate vasodilation: Doolen et al. [133] noted 
that isolated rat caudal segments showed increased constriction in presence of the 
MT2 antagonist 4-phenyl-2-acetamidotetraline.  
These findings were confirmed in 2002 by Masana et al. [36] by comparing the 
contractile responses of the rat arteries in presence of melatonin alone, melatonin 
compared with 6-chloro-melatonin (10-fold less sensitive to MT1 than MT2) and 
melatonin plus 4-Phenyl-2-propionamidotetralin, an antagonist for MT1 and MT2, which 
is selective for MT2 in concentrations of about 10 nM. 6-chloro-melatonin (MT2 agonist) 
was 10 times less effective in potentiating vasoconstriction than melatonin (Figure 14, 
left panel), suggesting that MT1 and not MT2 is responsible for potentiation of 
exogenously induced vasoconstriction (in this case by phenylephrine). Selective 
antagonistic concentrations of 4-Phenyl-2-propionamidotetralin for MT2 (10 nM) 
markedly increased the contractile response to melatonin (Figure 14, right panel). This 
strongly suggests that MT2 attenuates MT1 mediated vasoconstriction. Nevertheless, 
the vasodilating influence of MT2 is covered by the contracting effect of MT1, as 
melatonin alone had a contracting effect. 
 
Figure 14: Left graph: effect of low affinity MT1 agonist 6-chloro-melatonin (6-Cl-melatonin) on contractile 
response compared to melatonin, demonstrating MT1 dependent increase in contractile force. Right graph: 
effect of melatonin in presence of a MT2 selective concentration of 4-Phenyl-2-propionamidotetralin (4P-
PDOT) compared to melatonin alone, demonstrating generally elevated contractile force and increased 
maximum response to melatonin which suggests an attenuating influence of MT2 on MT1. Modified after 
[36]. 
So, in summary, MT1 mediates vasoconstriction and MT2 vasodilatation, but 
probably to a lesser extent. It has been proposed that vasoconstriction is triggered 
through Gq mediated Ca
2+ efflux from the sarcoplasmatic reticulum directly into smooth 
muscle cells. Vasodilation on the other hand is mediated indirectly via melatonin 
induced activation of NOS in endothelial cells of the blood vessels (see Figure 15). 
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Details can be found in [61]. See chapter 2.6.2 for basic information on blood vessels. 
For understanding of these proposed pathways, it is essential to know whether both 
melatonin receptors are present in the cardiovascular system. The thesis at hand 
confronts this question. 
 
Figure 15 Left panel: potential pathway mediating melatonin induced vasoconstriction in vivo. Melatonin 
activates MT1 (and MT2) directly on smooth muscle cells which both activate a Gq-protein, leading to Ca
2+
 
efflux from the sarcoplasmatic reticulum and subsequent muscle contraction. At the same time MT1 
activates a Gi-protein which inhibits the formation of cAMP and subsequent muscle relaxation. Right panel: 
potential pathway mediating melatonin induced vasodilatation in vivo. Melatonin activates MT2 on 
endothelial cells, which leads to activation of NOS through increased Ca
2+
 concentrations. At the same 
time, melatonin scavenges ROS that normally intercepts NO in the tissue. Both modified after [61]. Q. v. 
for abbreviations, literature and detailed information. 
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3 AIMS 
Melatonin is known to influence BP and this influence is, at least partly, mediated by 
the G-protein coupled receptors (GPCRs) MT1 and MT2 [61].  
Because the vascular system plays an integral role in BP regulation and melatonin 
is known to influence vascular tone, both dilating and contracting (e.g. [36, 56, 108, 
131, 134]), it is of interest to know how these responses are mediated. The data on 
melatonin GPCR expression in the vascular system in general and the aorta as a 
model is conflicting. Both MT1 and MT2 have been found as well as not found in various 
studies with various vascular models including the aorta [56, 108, 127, 132, 135]. Most 
of these experiments were performed on the protein level or via pharmacological 
studies and it has to be noted that the antibodies for rat melatonin GPCRs are not well 
characterized [24]. The few RT-PCR studies [36] were performed with intra-exon 
primers designed from non-complete sequences of the mRNA of both receptors. 
Recently, Ishii et al. [26] demonstrated the expression of rat MT1 and MT2 mRNA in 
many rat tissues by RT-PCR using exon spanning primers derived from the complete 
mRNA sequences. Starting from the findings and methods of that study [26], in the 
thesis at hand the expression of MT1 and MT2 in the rat aorta were to be characterized, 
pursuing the following aims. 
1)  Establishment of molecular biological methods for demonstrating MT1 and 
MT2 mRNA expression 
The first aim of the thesis was to establish the RT-PCR and RT-qPCR protocols for 
detection of rat MT1 and MT2 mRNA. To achieve this goal, we had to establish the 
method for RNA extraction and reverse transcription and test the published RT-PCR 
method by Ishii et al. [26] and an RT-qPCR method on various rat organs as well as 
adjust the methods as necessary to achieve consistent results. 
2)  Investigating the expression of MT1 and MT2 in the rat aorta 
Following the establishment of the methods, RT-PCR experiments to investigate the 
expression of MT1 and MT2 mRNA in the rat aorta as a model system for arterial blood 
vessels were performed. 
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3)  Quantification of MT1 and MT2 mRNA expression difference in the rat aorta 
depending on the time of day 
The melatonin GPCRs are known to exhibit circadian expression patterns in some 
organs [136]. Because BP is subjected to high diurnal variations [137] and the 
regulating influence of melatonin on BP is known [61], it was of interest to assess 
whether the expression levels of MT1 and / or MT2 were different in the vascular system 
depending on the time of day. The data on this is conflicting, as a diurnal variation has 
been demonstrated for human coronary arteries [129], while in the rat aorta, no 
circadian rhythms were observed at the protein level [108]. Consequently, as a third 
aim of the thesis, we performed RT-PCR and RT-qPCR experiments to evaluate a 
possible difference in receptor expression at the mRNA level between rat aortas of two 
time groups. 
4)  Quantification of MT1 and MT2 mRNA expression difference in the rat aorta 
depending on BP 
Because the mechanisms of BP regulation by melatonin are still somewhat unclear 
[61], it is of interest to know whether there is an expression difference of melatonin 
GPCRs – if they are present – in the vascular system between normotensive and 
hypertensive animals. As of yet, the only data available is from L-NAME induced 
hypertensive rats, where no difference in expression was found on the protein level 
[108]. Therefore, as a fourth aim of the thesis, we performed RT-PCR and RT-qPCR 
experiments on aortas of control and spontaneously hypertensive rats (SHR) to assess 
if there was such a difference at the mRNA level. 
5)  Localization of MT1 and MT2 protein in the rat aorta 
If the melatonin GPCRs can be found on the mRNA level because of the proposed 
different signaling and regulating mechanisms of MT1 and MT2 [61], it is of interest to 
know the allocation of MT1 and / or MT2 within the aorta. Some studies on the 
localization of the melatonin GPCRs have been performed [135, 138], but so far only 
on human and chicken samples and using immunohistochemistry and radio assays 
respectively. To better understand the effects of melatonin on MT1 and MT2
 in blood 
vessels, immunofluorescence (IF) stainings to localize MT1 and MT2 in the structure of 
the rat aorta were performed as the fifth aim of the thesis. 
 
  4 Materials and methods 
27 
4 MATERIALS AND METHODS 
4.1 Samples 
4.1.1 Various rat organs for PCR method establishment 
Various rat organs (brain, eye, heart, intestine, kidney, liver, lung, skeletal muscle, 
testes and thymus) have been prepared and frozen in 2008 by M. Svoboda 
(Department of Pathophysiology, Medical University Vienna). These tissues were used 
for establishing the methods for RNA-isolation, RT-PCR, RT-qPCR. 
4.1.2 Rat aortas from two different time points 
Sixteen prepared aortas of normal (Wistar) rats were kindly provided by Professor M. 
Zeman, Comenius University of Bratislava, Slovakia. Prior to dissection, the animals 
were kept in a 12 / 12 day / night rhythm (lights off at 22:00 hours and lights on at 10:00 
hours). Half of the aortas were obtained in operations 2 hours before lights on 
(nighttime group; A75, A76, A77, A79, A81, A82, A83, A88) and 2 hours before lights 
off (daytime group; A31, A32, A33, A34, A35, A36, A37, A38), respectively. The aortas 
were then frozen at -80 °C and finally transferred to Vienna on dry ice. 
These aortas were used to examine whether melatonin receptor expression follows 
a circadian rhythm in the rat aorta by usage of PCR experiments. 
The names of the aortas are taken from the nomenclature used by the Comenius 
University of Bratislava and kept for better traceability of the samples. 
4.1.3 Rat aortas from SHR and control rats 
Sixteen prepared aortas of SHR (ASHR 01–ASHR 08) and control (Wistar; ACTRL 01–
ACTRL 08) rats were kindly provided by Professor M. Zeman, Comenius University of 
Bratislava, Slovakia. After dissection, a part of each aorta was fixated in HOPE® 
solution (DCS, Hamburg, Germany) and transferred to Vienna on blue ice, while the 
other part was frozen at -80 °C and transferred to Vienna on dry ice. The HOPE® 
fixated parts of the aortas were then paraffin-sectioned by H. Uhrova (Department of 
Pathophysiology, Medical University Vienna), while the other part was used for RNA 
extraction and the subsequent PCR experiments.  
These aortas were used to examine whether the expression of MT1 and MT2 is 
different in the aortas of hypertensive and normotensive rats by usage of PCR and IF 
experiments with paraffin-sections. 
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4.1.4 Additional rat aortas for IF experiments 
These aortas were prepared for cryo-sectioning in 2008 by M. Benova (Comenius 
University of Bratislava, Slovakia; during a research stay at Department of 
Pathophysiology, Medical University Vienna) and stem from SHR (A_cryo4–A_cryo6) 
and control (Wistar; A_cryo1–A_cryo3) rats. These tissues were used for IF method 
establishment to examine the difference in melatonin receptor expression by usage of 
IF experiments with cryo-sections.  
4.1.5 Mouse organs for IF experiments 
The organs (brain and intestine) were prepared by H. Uhrova, R. Stumberger and  
C. Brünner-Kubath and then HOPE® fixated and paraffin-sectioned by H. Uhrova (all 
Department of Pathophysiology and Allergy Research, Medical University Vienna). 
These organs were used as positive controls in some IF experiments. 
4.2 RNA isolation from frozen tissues 
4.2.1 Background 
After [139]. 
In order to demonstrate the occurrence of specific mRNA, the first step is to isolate 
the total RNA of all tissues that are to be investigated. The total RNA of a tissue is 
isolated by extracting it from deep frozen or freshly prepared tissue samples, which are 
first pulverized and then subjected to peqGOLD TriFast™ treatment. PeqGOLD 
TriFast™ treatment is an optimized guanidineisothiocyanate / phenol method, suitable 
for RNA, DNA and protein extraction. After extraction and homogenization with 
PeqGOLD TriFast™, chloroform is added to the mixture, where the DNA and protein 
fraction will enrich, while the more hydrophilic RNA will stay in the aqueous phase. The 
RNA can then be precipitated using isopropanol, washed with ethanol and finally 
solved in DNAse, RNAse, DNA free water (“PCR water”). The isolated and purified 
RNA can then be stored over a long period of time at -80 °C. 
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4.2.2 Materials 
 Box with ice 
 Chloroform (Merck, 2445) 
 Coolable Centrifuge (Eppendorf, Centrifuge 5415R) 
 DNAse, RNAse, DNA free distilled water, “PCR water”, (Gibco, 0977035) 
 DNAse, RNAse, DNA free pipette tips  
o 1250 µL (Biozym, Safe seal tips® professional, 770600) 
o 200 µL (Biozym, 770280) 
 DNAse, RNAse, DNA free tubes 1,5 mL (Biozym, 710310) 
 Ethanol 70% (diluted from Ethanol absolute, VWR Prolabo, 20821.310) 
 Forceps  
 gloves for cryogenic work (handling of liquid N2, Tempshield, Cryogloves®) 
 Heating block (Eppendorf, Thermomixer 5436) 
 Homogenizer (IKA® Werke, T10 basic Ultra Turrax®, 3420000) 
 Isopropanol (Merck, 1.09634.1011) 
 Latex gloves (Hartmann, Peha-Soft® powderfree, 942162) 
 Liquid N2 
 Mortar + pistil 
 Paper towels 
 peqGOLD Trifast™ (peqLAB, 30-20XX) 
 Polystyrene (styrofoam) boxes (two) with lids 
 Polystyrene rack 
 Protective glasses 
 Small flasks (Greiner bio-one, scintillation vial 27.0/60.0 mm, 619301; saw off 
neck) 
 Vortexer (Labinco, L24) 
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4.2.3 Method 
1. Preparation 
a. Fill the Styrofoam boxes with liquid N2 
b. Put the Styrofoam rack in the box  
c. Put the small flasks in the styrofoam rack 
d. Put the sample(s) (from -80 °C cooling unit) in the styrofoam box  
e. Put the mortar into the second styrofoam box and fill mortar and box 
with some liquid N2 
2. Sample preparation 
a. Put 50–100 mg or about 5x5x1 mm of tissue (break if necessary) into 
the mortar (with liquid N2) 
b. Pulverize the tissue with the pistil and avoid complete evaporation of the 
N2 in the mortar  
c. Transfer the crushed tissue plus some liquid N2 into a flask (scintillation 
vial with sawed off neck) 
d. Keep the flask containing the sample in the Styrofoam box with liquid N2 
and avoid drying out of the liquid N2 in the flask 
3. TriFast™ utilization 
a. When all samples are homogenized, let the N2 in the flask evaporate 
and add 1 mL of Trifast™ reagent (per max. 100 mg of tissue) to the 
flask (one flask at a time!) 
b. Transfer the flask from the Styrofoam box to ice 
c. Homogenize for 30 seconds with UltraTurrax® (avoid excess heat 
generation) 
d. Transfer the homogenated tissue into one 1.5 mL tube (per 1 mL 
Trifast™) and … 
e. … put the tube immediately on ice and incubate for 5 min 
f. Incubate for 5 min at rt – from now on, work in a bench designated for 
RNA extraction (storage is now possible at -80 °C) 
4. RNA isolation 
a. Add 200 µL chloroform 
b. Vortex for 15 sec 
c. Incubate for 5 min at rt 
d. Centrifuge for 15 min at 12,000 x g / 4 °C  phase separation 
e. Transfer the upper aqueous phase (containing RNA) to a fresh tube 
f. Centrifuge again for 15 min at 12,000 x g / 4 °C, meanwhile … 
5. RNA precipitation 
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a. … prepare a fresh tube and fill it with 500 µL isopropanol 
b. Transfer the aqueous phase (containing RNA) to the tube with 
isopropanol 
c. Vortex for 10 sec 
d. Incubate for 10 min on ice 
e. Centrifuge for 15 min at 12,000 x g / 4 °C 
f. Remove the isopropanol from the precipitate 
6. RNA washing 
a. Wash the pellet with 1 mL ethanol 70 % (v / v) by vortexing 
b. Centrifuge for 10 min at 12,000 x g / 4 °C 
c. Remove the ethanol thoroughly from the pellet  
d. Repeat steps 6a through 6c once, then continue to step 7a 
7. Solving and storing 
a. Dry the pellet in a heating block at 55 °C for 1 (max. 3) min with opened 
lid 
b. Add 20 µL PCR water 
c. Pipette up and down a few times until the RNA is dissolved 
d. Incubate at 55 °C for 5 min 
e. Store RNA at -80 °C 
4.3 Quantification and purity assessment of RNA and DNA 
4.3.1 Background 
The quantity of RNA or DNA is then determined by UV/VIS spectrophotometry. The 
ratio of the samples’ absorbance at 260 nm and 280 nm (A260 / A280) is used to assess 
its purity. For extracted RNA, the PeqGOLD TriFast™ instruction manual [139] 
specifies an achievable ratio of 1.60–2.00, depending on the type of tissue and certain 
other factors. 
4.3.2 Materials 
 Box with ice (for transportation of samples) 
 DNAse, RNAse, DNA free pipette tips 
o 10 µL (Biozym, 770010) 
o 20 µL (Peqlab, 81-1020) 
 Paper towels 
 Soft paper wipes (Kleenex®) 
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 Solvent, 10 µL (here: DNAse, RNAse, DNA free distilled water, “PCR water”; 
Gibco, 0977035) for blank measurements  
 Spectrophotometer (Thermo Fisher Scientific, NanoDrop™ 1000) 
 Vortexer (Labinco, L24) 
4.3.3 Method 
1. Start the ND-1000 program 
2. Choose the appropriate user name from the drop down menu (enter a 
password if necessary) and then choose the button “Nucleic Acid” 
3. The software prompts to load a water sample 
4. Sample loading procedure 
a. Open the instrument’s arm 
b. Apply a volume of the sample (1–2 µL) to the lower measurement 
pedestal 
c. Carefully close the instrument’s arm (do not use force) 
5. Click “OK” 
6. Load a water sample (PCR water) 
7. After initialization of the instrument is complete, wipe the residue from the upper 
and lower pedestals with a soft wipe. 
8. Select the appropriate calculation method (DNA-50 or RNA-40) for the type of 
sample (DNA or RNA) using the drop down menu 
9. Load a blank sample (here: 1 µL PCR water)  
10. Click “Blank” 
11. Clean the pedestals 
12. Load 1 µL of sample 
13. Click “Measure” 
14. Take down the readings (concentration, A260 / A280 ratio) 
15. Clean the pedestals 
16. Repeat steps 11–14 for all samples 
17. Load a blank sample (here: 1 µL PCR water) 
18. Click “Measure” – the spectrum should exhibit a relatively flat bottom line 
19. Clean the pedestals and do not forget to close the sample arm 
20. Click “Exit”, then “Exit” again to close the program 
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4.4 Agarose gel-electrophoresis (GE) 
4.4.1 Background 
GE is employed to separate nucleic acids like RNA and DNA by their size. As the name 
suggests, the gels employed in this method are made of dissolved and re-solidified 
agarose in TRIS-acetic-acid-EDTA (TAE) buffer. The samples are mixed with loading 
dye, which contains dyes that migrate at the same speed as nucleotides of a certain 
length and also serves the purpose of increasing the samples’ specific weight, so it will 
not be washed out of the gel pocket. The sample-loading dye mixtures are then loaded 
in the pockets of the gel, which is submerged in TAE buffer. After the loading 
procedure, a current is applied along the gel. Because RNA and DNA are negatively 
charged, they will be drawn to the anode. The gel retains this migration, larger nucleic 
acid molecules being more strongly retained than smaller ones. After a certain time, the 
current is switched off and the separated nucleic acids appear as bands along the 
migration route. 
To make these bands visible, the gel contains ethidium bromide, which intercalates 
with DNA or RNA molecules. This intercalation results in orange fluorescence if the 
molecule complex is subjected to UV light. Therefore, while (trans-)illuminating the gel 
with UV light, nucleic acid bands can be seen and photographed.  
When used for testing the intactness of isolated total RNA, two distinct bands will 
appear for the 28S and 18S rRNA (ribosomal RNA, accounting for over 98 % of the 
total RNA in a cell) if the RNA is not degraded. If the RNA is degraded – through 
contamination with RNAse – GE will show a smear of low molecular weight bands. 
When used for analysis of (RT-) PCR products, a marker, containing a defined 
amount of DNA fragments of several defined lengths, should be used to assess the 
size of the PCR product. 
4.4.2 Buffers and solutions 
0.5 M EDTA solution 
Materials 
 Aqua bidest. 
 EDTA, Na-salt (Merck, 1.08418.1000) 
 NaOH (Merck, 1.06498.1000) 
 pH-meter (Metrohm, pH-Lab 827) 
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Method  
1. Solve 93.05 g EDTA, Na-salt in 400 mL aqua bidest. 
2. Adjust the pH to 8.0 with NaOH 
3. Adjust the volume to 500 mL with aqua bidest. 
4. Store at rt 
TAE stock solution (50x) 
Materials 
 0.5 M EDTA solution (see above) 
 Aqua bidest. 
 Glacial acetic acid (Merck, 8.18755.2500) 
 Tris (Merck, 1.08382.1000) 
Method 
1. Solve 242 g of Tris in 750 mL aqua bidest. 
2. Add 57.1 mL of glacial acetic acid 
3. Add 100 mL of 0.5 M EDTA 
4. Fill to 1000 mL with aqua bidest. 
5. Store at rt 
1x TAE buffer 
Materials 
 TAE stock solution (50x) (see above) 
 Aqua bidest. 
Method 
1. Dilute one part TAE stock solution (50x) with 49 parts aqua bidest. (1 : 50) 
2. Store at rt 
Ethidium bromide solution 10 mg / mL 
Materials 
 Aqua bidest. 
 Ethidium bromide (Amresco, 0492-56) 
 Latex gloves (Hartmann, Peha-Soft® powderfree, 942162) 
 Nitrile gloves (Meditrade Medicare, Senso Nitril®, 1421I) 
  4 Materials and methods 
35 
Method 
1. Solve 10 mg ethidium bromide in 1 mL aqua bidest. 
2. Store at rt 
6x loading dye 
Materials 
 Bromphenolblue (Amresco, 0449) 
 Xylene cyanol FF (Amresco, 0819) 
 Glycerol (Merck, 1.04094.0500) 
 DNAse, RNAse, DNA free distilled water, “PCR water” (Gibco, 0977035) 
 Latex gloves (Hartmann, Peha-Soft® powderfree, 942162) 
Method 
1. Mix 0.25 % (w / v) of bromphenolblue 
2. 0.25 % (w / v) xylene cyanol FF 
3. 30 % (v / v) glycerol 
4. and 69.5 % (v / v) PCR water 
5. Store in aliquots at -20 °C 
4.4.3 Preparation of agarose gels 
Materials 
 1x TAE buffer (see 4.4.2) 
 Agarose (Invitrogen, 10975-035) 
 Combs and walls fitting for the GE chamber 
o Wall (Peqlab, 41-1325-Wall) 
o Comb 28 well (Peqlab, 41-1325-28D) 
o Comb 20 well (Peqlab, 41-1325-20D) 
o Comb 16 well (Peqlab, 41-1325-16D) 
 Ethidium bromide solution 10 mg / mL (see 4.4.2) 
 GE chamber (Peqlab, 41-1325) 
 Latex gloves (Hartmann, Peha-Soft® powderfree, 942162) 
 Microwave oven (Moulinex® Micro-Chef Mo 55) 
 Nitrile gloves (Meditrade Medicare, Senso Nitril®, 1421I) 
 Saran wrap 
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Method 
1. Prepare the GE chamber (combs and side walls) 
2. According to the desired concentration of the gel, mix the respective amount of 
agarose with 1x TAE buffer (e.g. 2.625 g agarose in 175 mL 1x TAE buffer for a 
1.5 % gel) 
3. Microwave the solution until the first boiling appears 
4. Shake the solution and let it cool down until it is not steaming any more 
5. Add 0.007 % of ethidium bromide solution (10 mg / mL; e.g. 12.5 µL in 175 mL 
gel solution) 
6. Pour the gel into the prepared GE chamber and let the gel solidify 
7. Add walls to the GE chamber if applicable 
8. Remove the gel(s) and store them in plastic foil at 4° C 
4.4.4 Electrophoresis 
Materials 
 GE chamber (Peqlab, 41-1325) 
 GE power supply (Peqlab, EV231) 
 Agarose gel with ethidium bromide (see 4.4.3) 
 UV transillumination imaging equipment (Biozym, ChemiImager 4400) 
 Latex gloves (Hartmann, Peha-Soft® powderfree, 942162) 
 Ladder (Fermentas, GeneRuler™, SM0323) 
 Nitrile gloves (Meditrade Medicare, Senso Nitril®, 1421I) 
 DNAse, RNAse, DNA free pipette tips 
o 10 µL (Biozym, 770010) 
o 20 µL (Peqlab, 81-1020) 
o 100 µL (ART®, 100E, 2065E) 
 DNAse, RNAse, DNA free distilled water, “PCR water” (Gibco, 0977035) 
 6x loading dye (see 4.4.2) 
 Sterile 96 well plates (Greiner Labortechnik, PS-Mikrotiterplatte, 96K, 
kobaltsteril, 655161) 
 Aqua bidest. 
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Method 
1. Gel-electrophoresis 
a. Mix a volume of sample (depending on the size of the gel pockets) with 
one sixth of loading dye in a well of a 96 well plate (pipette up and down 
to mix) 
b. Repeat step a. for all samples 
c. Load the gel 
d. Ensure correct alignment of the gel in the GE rack and close the lid 
e. Connect the GE electrodes to the GE power supply 
f. Run the gel (suggested conditions: 150 V, 1:30 h; check the propagation 
of the loading dye during the run) 
2. Analysis of the gel 
a. Open the hatch of the transilluminator and place the gel on the surface 
for UV illumination 
b. Start the chemi-Imager 4400 program 
c. Click on “Acquire” 
d. Activate epi-white, ensure that the aperture is not set too low 
e. Align the gel and magnification so that it fills the preview completely 
f. Click on “Exposure Preview”  
g. Close the hatch, deactivate epi-white and activate UV  
h. Change the exposure time and aperture so that the gel is correctly 
exposed 
i. Click on “Capture Image” 
j. After the image is taken, deactivate UV and click “Print” 
k. Exit the program 
l. Open the hatch, remove the gel, clean the UV surface with aqua bidest. 
and close the hatch again 
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4.5 Reverse Transcription 
4.5.1 Background 
After [140-141]. 
Because RNA itself is not suitable for PCR, it has to be converted to DNA first. This 
is done using reverse transcription, where RNA, e.g. total isolated RNA extracted from 
tissue, is reversely transcribed to single stranded complementary DNA (cDNA). This is 
done by adding dNTPs, random primers and reverse transcriptase, an enzyme gained 
from retro viruses, to the RNA sample. RNAse inhibitor can be added, too, to prevent 
the degradation of the template RNA due to minute contamination with RNAses. To 
avoid mix-ups and pipetting error, all components except for the samples are pre-mixed 
in a mastermix and added to the separate samples just before reaction. 
The reaction mixture is warmed to 37 °C for two hours, during which the random 
primers bind to the RNA and the reverse transcriptase synthesizes a complementary 
strand of cDNA in 3’ direction. After the two hours, the mixture is heated shortly to 85 
°C to permanently inactivate the enzyme. The cDNA can then be stored over a long 
period of time at -20 °C and used for subsequent PCR or qPCR experiments. 
4.5.2 Materials 
 -20 °C storage box (for reverse transcriptase and RNAse inhibitor) 
 Box with ice 
 DNAse, RNAse, DNA free distilled water, “PCR water” (Gibco, 0977035) 
 DNAse, RNAse, DNA free pipette tips 
o 10 µL (Biozym, 770010) 
o 20 µL (Peqlab, 81-1020) 
o 100 µL (ART®, 100E, 2065E) 
 DNAse, RNAse, DNA free tubes with flat lid 0.2 mL (Biozym, 710920) 
 Latex gloves (Hartmann, Peha-Soft® powderfree, 942162) 
 RT Kit (Applied Biosystems, “High capacity cDNA reverse transcription kit”, 
4368814), contains: 
o 10x RT buffer 
o 10x RT random primers 
o 25x dNTP Mix (100 mM) 
o Multiscribe™ Reverse Transcriptase 50 U / µL 
o RNAse inhibitor 
 Thermal cycler (Eppendorf mastercycler personal, 53332 000.014) 
 Vortexer (Labinco, L24) 
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4.5.3 Method 
1. Preparation of 10 µL of the RT 2x mastermix (per 20 µL reaction)  
a. Let the components thaw slowly on ice, do not take the enzymes out of 
the refrigerator yet! 
b. Calculate the necessary amounts of reagent according to the number of 
samples plus one aliquot in excess 
c. Prepare the RT 2x mastermix according to the following table (add the 
enzymes last, take them out of the refrigerator only in the -20 °C storage 
box and put them back in the refrigerator as soon as possible!) 
 
Table 1: Recipe for 10 µL 2x reverse transcription mastermix using the high capacity cDNA reverse 
transcription kit [142]. 
Vol [µL] Component 
2.0 10x RT buffer 
0.8 10x dNTP mix 
2.0 10x RT random primers 
3.2 PCR water 
1.0 Reverse transcriptase 
1.0 RNAse inhibitor 
 
d. Vortex the RT 2x mastermix for a short while and put it on ice 
2. Preparation of the samples 
a. Pipette an aliquot of RNA sample (containing 2 µg of RNA) in a 0.2 mL 
tube 
b. Add PCR water for a total volume of 10 µL 
c. Add 10 µL of RT mastermix and pipette up and down a few times to mix 
d. Keep the prepared sample on ice 
e. Repeat steps a–d for all samples 
3. Reverse transcription 
a. Put all the samples in the thermal cycler 
b. Use the following temperature program: 
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Table 2: Temperature program for reverse transcription using the high capacity cDNA reverse transcription 
kit [142]. 
Step Time T [°C] 
1 10 min 25 
2 120 min 37 
3 5 s 85 
4 Hold 4 
 
c. Run the program 
d. After the program is finished, store the transcription products (cDNA) at  
-20 °C 
4.6 PCR – Polymerase chain reaction 
4.6.1 Background 
After [143]. 
DNA or cDNA can be amplified using polymerase chain reaction (PCR). PCR was 
invented in 1983 and is now a fundamental tool in the life sciences [141]. dNTPs, target 
specific primers for the nucleotide sequence of interest, and the enzyme Taq-
polymerase (from the bacterium thermus aquaticus) are added to the (c)DNA of the 
sample. To stabilize the enzyme, MgCl2 is added to the reaction mixture. To avoid mix-
ups and pipetting error, all components except for the samples are pre-mixed in a 
mastermix and added to the separate samples just before reaction. 
Initially, the reaction mixture is heated to about 95 °C for a few minutes to 
completely denaturize all double strands of DNA.  
The samples are then subjected to three steps of different temperatures for 
different periods of time: 1) Denaturation: 95 °C for about 30 seconds to one minute for 
complete denaturation of the double strands of the DNA. 2) Annealing: a reaction-
specific annealing temperature (often about 55–60 °C) for about 30 seconds. At this 
temperature, the primers will anneal to the specific complement area of the target DNA 
strand. After the primer has annealed to its target, the Taq-polymerase will bind to the 
primer / target-complex and starts elongation of the template strand’s complement in 3’ 
direction. The annealing temperature depends on the primers and should be about 
5 °C lower than the lowest melting temperature (= temperature where the primer 
denaturizes from the template) of the primer pair’s two primers. If the temperature is 
too low, the PCR will become unspecific and multiple strands of DNA will be amplified, 
because the primers can bind to non-perfect complements. If the temperature is too 
high, the primers will not be able to anneal to anything at all, resulting in no 
  4 Materials and methods 
41 
amplification whatsoever. 3) Elongation: the temperature is raised to about 72 °C for 
about 30 seconds. At this temperature, the Taq-polymerase will work most efficiently, 
so that (at least in theory) the target sequence is doubled at the end of the elongation 
step. Then, the cycle starts over with denaturation again for a specified number of 
times, which depend on the amount of original template DNA and have to be 
determined empirically. After the last cycle, the sample is again incubated at 72 °C for 
a few minutes of final elongation and then stored at 4° C until removed from the 
thermocycler. 
After PCR, the amplified DNA can be examined by applying GE or stored at -20 °C 
over a long period of time. 
When amplifying cDNA obtained through RT, the complete procedure is 
consequently called RT-PCR. When performing RT-PCR, it is essential to keep the 
RNA and subsequent cDNA free from contaminating genomic DNA, which would cover 
up the presence or lack of cDNA obtained through RT. One way of ensuring that only 
cDNA is amplified is the use of specially designed primer pairs, where both primers lie 
on two different adjourning exons (exon spanning primers). When using such primers, 
only the amplicon from cDNA templates will be of the correct size, because the introns, 
which are present in the genomic DNA, will be spliced out in the mRNA and thus the 
respective cDNA. 
Because interpretation of GE can lead to false identifications of the bands (in case 
of unspecific amplification, amplicons can appear that seem to be at the same length 
as the target of interest), there are ways of ensuring an observed band’s identity.  
One possible method is the use of a so called “nested” PCR, where two PCRs are 
performed consecutively: the primer pairs for both PCRs lie, as the name suggests, 
nested in each other. The “outer” primers amplify their specific product. After this 
“outer” reaction is complete, a small aliquot of the reaction mixture is re-amplified using 
the “inner” primers, but with much fewer cycles. Because the target of the inner primers 
is the amplicon from the “outer” PCR, it should be greatly enriched if the amplification 
was specific. Therefore the “inner” PCR will result in a smaller product of high quantity. 
If both reactions were specific, GE of the “inner” product will show a band at a shorter 
length than GE of the “outer” product. If both products are of the expected size, it is 
highly probable that the amplification was specific. Another advantage of the nested 
PCR is that PCR products with very low yield can be amplified to a much greater 
extent, making bands visible that were not or hardly before [144]. 
Other ways to ensure specificity of a PCR is sequencing the respective PCR 
product (see 4.8) or restriction enzyme digestion (not performed in this thesis). 
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To ensure correct interpretation of the results from a PCR experiment, there are 
three types of control samples that can be included in every PCR reaction batch. The 
first type is a blind sample, containing no sample, but only PCR mastermix and water, 
to exclude that any observed bands derive from contamination of the reagents. This 
type of control should be included every time. The second type is the -RT sample, 
containing non-reversely transcribed RNA. This control sample is best prepared by 
performing an RT reaction with all components except the enzyme reverse 
transcriptase. It should be included in methods using intra-exon primers, to exclude 
amplification of genomic DNA and can be included in other methods as well. The third 
type of control sample is a positive control, which contains cDNA of the desired target 
in high and reliable concentration. This is very helpful if there is none or very little 
template in the samples of interest, so that one can ensure the success of the PCR. 
4.6.2 General procedure 
Materials 
 -20 °C storage box (for the Taq-polymerase) 
 10 mM dNTP Mix (Fermentas, R0192) 
 Box with ice 
 DNAse, RNAse, DNA free distilled water, “PCR water” (Gibco, 0977035) 
 DNAse, RNAse, DNA free pipette tips 
o 10 µL (Biozym, 770010) 
o 20 µL (Peqlab, 81-1020) 
o 100 µL (ART®, 100E, 2065E) 
o 200 µL (Biozym, 770280) 
 DNAse, RNAse, DNA free tubes with convex lid 0.2 mL (Biozym, 710900) 
 Forward and reverse primer (see 4.6.3) 
 Latex gloves (Hartmann, Peha-Soft® powderfree, 942162) 
 Taq-Polymerase (Fermentas, Taq DNA Polymerase (recombinant), EP0404), 
supplied with: 
o 10x PCR buffer (Taq Buffer with KCl or Taq Buffer with (NH4)2SO4) 
o 25 mM MgCl2 
 Thermal cycler (Eppendorf Mastercycler personal, 53332 000.014) 
 Vortexer (Labinco, L24) 
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Method 
1. Preparation of PCR 2x mastermix (per reaction) 
a. Let the components thaw slowly on ice, do not take the enzymes out of 
the refrigerator yet! 
b. Calculate the necessary amounts of reagent according to the number of 
samples plus one aliquot in excess 
c. Prepare the PCR 2x mastermix (add the enzymes last, take them out of 
the refrigerator only in the -20 °C storage box and put them back in the 
refrigerator as soon as possible!). See 4.6.3 for the mastermix recipes. 
d. Vortex the PCR 2x mastermix for a short while and put it on ice 
2. Preparation of the samples 
a. Pipette an aliquot of cDNA sample (containing the desired amount of 
corresponding RNA) 
b. Add PCR water to the desired total volume 
c. Prepare a blind sample (PCR water only) 
d. Add the appropriate amount of PCR 2x mastermix and pipette up and 
down a few times to mix 
e. Store the prepared sample on ice 
f. Repeat steps a–e for all samples (prepare only one blind!) 
3. Polymerase chain reaction 
a. Put all the samples in the thermal cycler 
b. Use the appropriate temperature program for the experiment (see 4.6.3) 
c. Run the program 
d. After the program is finished, store the PCR products at -20 °C 
4.6.3 Primers, mastermixes and temperature programs 
PCR method for MT1, MT2 and β-actin according to Ishii et al. [26] 
The sequences of the primers, the respective mastermix recipe and temperature 
program were taken from Ishii et al. [26]. These methods were originally supposed to 
suffice for all RT-PCR experiments in the course of this work. The primers are 
designed as exon spanning and therefore amplification of genomic DNA should be 
excluded. These primer pairs will be henceforth referred to as “Ishii primers”. 
Primers were custom synthesized by Eurofins, MWG operon (Ebersberg, 
Germany) 
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Primers 
Table 3: PCR primers according to Ishii et al. [26]. 
Name Sequence Product size 
rat MT1 fwd. 5’-ATGGCCCTGGCTGTGCTGCGGTAAG-3’ 
316 bp 
rat MT1 rev. 5’-TAAGTATAGACGTCAGCGCCAAGGGAAATG-3’ 
rat MT2 fwd. 5’-GGAGCGCCCCCAAGCAGTG-3’ 
390 bp 
rat MT2 rev. 5’-GGATCTCCCCAAGTACCCAACCGTCAT-3’ 
rat β-actin fwd. 5’-GTCCACACCCGCCACCAGT-3’ 
496 bp 
rat β-actin rev. 5’-CGTCTCCGGAGTCCATCACAAT-3’ 
 
Mastermix recipe 
25 µL reactions are used in this method, therefore, 12.5 µL mastermix are prepared per 
sample. All three primer pairs are used with the same temperature program and 
mastermix recipes. 
Table 4: Recipe for 12.5 µL of 2x PCR mastermix for PCR experiments acording to the method described 
by Ishii et al. [26]. 
C Vol [µL] Component 
0.2 mM 0.5 10 mM dNTP mix 
0.2 µM 0.05 forward primer 
0.2 µM 0.05 reverse primer 
 2.5 10x buffer with KCl 
1.5 mM 1.5 25 mM MgCl2 
 6.9 PCR water 
1 U 1.0 Taq-Polymerase 
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Modified mastermix recipe for MT2 
This mastermix recipe was only used in one experiment (see 5.1.2). 
Table 5: Modified recipe for 12.5 µL of 2x PCR mastermix for one PCR experiment concerning MT2 
according to the method described by Ishii et al. [26]. 
C Vol [µL] Component 
0.2 mM 0.5 10 mM dNTP mix 
0.2 µM 0.05 forward primer 
0.2 µM 0.05 reverse primer 
 2.5 10x buffer with (NH4)2SO4 
2.0 mM 2.0 25 mM MgCl2 
 6.4 PCR water 
1 U 1.0 Taq-Polymerase 
 
Temperature program 
Table 6: Temperature program for PCR experiments according to the method described by Ishii et al. [26]. 
This temperature program was used for β-actin, MT1 and MT2 in initial experiments, but was for MT2 
replaced by the one described in below because of unsatisfactory results (see 5.1.2). 
Step Cycles Time T [°C] 
1 1 2 min 95 
2 β-actin: 25 
MT1: 40 
(MT2: 40) 
30 s 95 
3 20 s 60 
4 30 s 72 
5 1 5 min 72 
6 1 Hold 4 
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Modified temperature program for MT2 
Table 7: Modified temperature program for PCR experiments according to the method described by Ishii et 
al. [26]. 
Step Cycles Time T [°C] 
1 1 2 min 95 
2 
40 
30 s 95 
3 20 s 57 
4 30 s 72 
5 1 5 min 72 
6 1 Hold 4 
 
PCR method for MT2 (modified after Sugden et al. [34]) 
The sequences of the primers, the respective mastermix recipe and temperature 
program were taken from [34]. The primers are designed for a nested PCR and as both 
pairs lie in one exon, amplification of contaminating genomic DNA is possible. The 
primer pairs will be henceforth referred to as “Sugden primers” in general or as “Sug 
out MT2” for the outer primers of the nested PCR and “Sug nes MT2” for the inner 
primers of the nested PCR. See 5.4.3 for the primer selection process. Primers were 
custom synthesized by Eurofins, MWG operon (Ebersberg, Germany). 
Primers 
Table 8: Primers for experiments conducted according to the method described by Sugden et al. [34]. 
Name Sequence Product 
Sug out MT2 fwd. 5’-ATCTGTCACAGTGCGACCTACC-3’ 
292 bp 
Sug out MT2 rev. 5’-TTCTCTCAGCCTTTGCCTTC-3’ 
Sug nes MT2 fwd. 5’-AGCCTCATCTGGCTTCTCAC-3’ 
154 bp 
Sug nes MT2 rev 5’-TTGGAAGGAGGAAGTGGATG-3’ 
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Mastermix recipe 
20 µL reactions are used in this method, therefore, 10 µL mastermix are prepared per 
sample. Both primer pairs are used with the same temperature program and mastermix 
recipes. 
Table 9: Recipe for 10 µL of 2x PCR mastermix for PCR experiments according to the method described 
by Sugden et al. [34]. 
 
C Vol [µL] Component 
0.1 mM 0.2 10 mM dNTP mix 
0.5 µM 0.1 forward primer 
0.5 µM 0.1 reverse primer 
 2.0 10x buffer with KCl 
1.5 mM 1.2 25 mM MgCl2 
 5.4 PCR water 
1 U 1.0 Taq-Polymerase 
 
Temperature program 
Table 10: Temperature program for PCR experiments according to the method described by Sugden et al. 
[34]. 
Step Cycles Time T [°C] 
1 1 2 min 94 
2 
Sug out MT2: 40 
Sug nes MT2: 20 
1 min 94 
3 1 min 55 
4 2 min 72 
5 1 10 min 72 
6 1 Hold 4 
 
PCR method for MT2 (self-designed) 
See 5.4.5 for the primer design process. The primer pairs will be henceforth referred to 
as MS1_rMT2 and MS2_rMT2. Both custom designed primer pairs share the same 
reverse primer. Primers were custom synthesized by Eurofins, MWG operon 
(Ebersberg, Germany). The mastermix recipe and temperature program were both 
custom designed, following the recommendations in the manufacturer’s instructions of 
the Taq-Polymerase [143]. 
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Primers 
Table 11: Self designed primers for rat MT2 amplification. MS1_rMT2 rev. and MS2_rMT2 rev. are 
identical. 
Name Sequence Product 
MS1_rMT2 fwd. 5’- TAGCACTTGCTGGGCGGGGA-3’ 
540 bp 
MS1_rMT2 rev. 5’- AGGCTCGGTGGTAGGTCGCA-3’ 
MS2_rMT2 fwd. 5’- GCGCATCTATCCCGGGCTGC-3’ 
483 bp 
MS1_rMT2 rev. 5’- AGGCTCGGTGGTAGGTCGCA-3’ 
 
Mastermix recipe 
Table 12: Self-designed recipe for 12.5 µL of 2x PCR mastermix for use with the self designed primers for 
rat MT2. 
C Vol [µL] Component 
0.2 mM 0.5 10 mM dNTP mix 
0.2 µM 0.05 forward primer 
0.2 µM 0.05 reverse primer 
 2.5 10x buffer with KCl 
1.5 mM 1.5 25 mM MgCl2 
 6.9 PCR water 
1 U 1.0 Taq-Polymerase 
 
Temperature program 
Table 13: Self-designed temperature program for use with the self-designed primers for rat MT2. 
Step Cycles Time T [°C] 
1 1 3 min 95 
2 
40  
1 min 95 
3 1 min 57 
4 1 min 72 
5 1 10 min 72 
6 1 Hold 4 
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4.7 DNAse treatment of RNA samples 
4.7.1 Background 
To avoid amplification of genomic DNA when using non exon spanning primers in PCR, 
the RNA is treated before the RT with DNAse, which should degrade present DNA 
contaminations in the isolated RNA samples but leaving the RNA intact. 
4.7.2 Materials 
 -20 °C storage box (for DNAse) 
 DNAse I, Amplification Grade (Invitrogen, 18068-015), supplied with: 
o 10x DNAse I Reaction buffer 
o 25 mM EDTA (pH 8.0) 
o DNAse I, Amp Grade, 1 U / µL 
 DNAse, RNAse, DNA free distilled water, “PCR water” (Gibco, 0977035) 
 DNAse, RNAse, DNA free pipette tips 
o 10 µL (Biozym, 770010) 
 DNAse, RNAse, DNA free tubes with flat lid 0.2 mL (Biozym, 710920) 
 Latex gloves (Hartmann, Peha-Soft® powderfree, 942162) 
 Thermal cycler (Eppendorf mastercycler personal, 53332 000.014) 
4.7.3 Method 
According to manufacturer’s instruction [145]. 
1. Pipette an aliquot of RNA sample in a 0.2 mL tube containing 1 µg of RNA 
2. Add 1µL of DNAse I reaction buffer 
3. Add 1 µL DNAse I, Amp Grade, 1 U / µL 
4. Fill with PCR water to 10 µL 
5. Incubate for 15 minutes at rt 
6. Add 1 µL of 25 mM EDTA solution 
7. Heat for 10 minutes at 65 °C (thermocycler) 
8. Add the RT mastermix (minus 1 µL of PCR water per sample) for direct RT or 
store at -20 °C 
 
Note that the total volume of the DNAse treated samples is 11 µL. The volume of PCR 
water in the RT-mastermix has therefore to be reduced by 1 µL (from 3.2 to 2.2 µL per 
reaction). See 4.5 for information about reverse transcription. 
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4.8 DNA extraction and purification from agarose gels 
4.8.1 Background 
After [146]. 
The length of the PCR product alone is not enough to safely determine the identity 
of observed bands from a PCR experiment, because a different fragment of similar size 
might be mistaken for the expected one. Therefore, in addition to performing a nested 
PCR, sequencing of the isolated amplicon is a safe way to ensure its identity. 
In order to sequence an isolated DNA band from an agarose gel, the band has to 
be excised from the gel, the gel has to be dissolved and the DNA extracted from the 
mixture, using a DNA gel extraction kit (QIAquick®, Gel Extraction Kit).  
The principle of the kit’s method of operation is a centrifugeable column filled with a 
silica membrane, which adsorbs the DNA, but not impurities and contaminations. The 
gel slice is first dissolved in lysis buffer, which contains a pH indicator to enable easy 
checking of the optimal pH (< 7.5). If the pH is too basic, the DNA will not adsorb on 
the silica membrane. Residual buffer and impurities are then washed away using 
washing buffer. Because adsorption of the DNA to the silica matrix occurs only at acidic 
pH, the DNA can be eluted from the column using pure water or 5 mM Tris.HCl (pH 
8.5) buffer. 
To ensure the success of the extraction, the concentration of the DNA is quantified 
using spectrophotometry (see 4.3) and a small amount of the DNA solution can be 
checked for intactness via GE (see 4.4). 
4.8.2 Materials 
 Centrifuge (Eppendorf, Centrifuge 5417R) 
 DNAse, RNAse, DNA free distilled water, “PCR water” (Gibco, 0977035) 
 DNAse, RNAse, DNA free pipette tips  
o 100 µL (ART®, 100E, 2065E) 
 DNAse, RNAse, DNA free tubes 1.5 mL (Biozym, 710310) 
 Heating block (Eppendorf, Thermomixer 5436) 
 Isopropanol (Merck, 1.09634.1011) 
 Latex gloves (Hartmann, Peha-Soft® powderfree, 942162) 
 Pipette tips 
o 1000 µL (Biozym, 721000) 
o 200 µL (Biozym, 720230) 
 QIAquick® Gel Extraction Kit (Qiagen, 28704), contains: 
o Buffer EB 
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o Buffer PE 
o Buffer QG 
o Spin colums + 2 mL collection tubes 
 Na-acetate (Merck, 6268) 
 Vortexer (Labinco, L24) 
4.8.3 Method 
1. Excise the DNA fragment(s) from the agarose gel (minimize excess gel) 
2. Weigh the gel slice(s) (approx.) 
3. Add 3 volumes of Buffer QG to per volume of gel (100 µg equals 100 µL) 
4. Note: If the concentration of the agarose gel is 2 % or higher, use 6 volumes 
of buffer QG 
5. Note: One spin column can take up to 400 mg of gel. If the weight of the gel 
slice(s) exceed(s) 400 mg, divide it in appropriate parts and use multiple spin 
columns 
6. Incubate at 50 °C for 10 min and vortex every 2–3 min until the gel slice(s) is 
(are) dissolved 
7. If the color of the mixture is orange or red, add 10 µL of 3 M Na-acetate (pH 5.0) 
8. Add 1 gel volume of isopropanol to the sample and vortex 
9. Place a QIAquick® spin column in a 2 mL collection tube 
10. Apply the sample to the column and centrifuge for 1 min at 17,900 x g 
11. If the volume of the sample exceeds 800 µL, centrifuge twice using the same 
column 
12. Discard the flow-through and place the column back in the collection tube 
13. Add 0.5 mL of Buffer QG to the column and centrifuge for 1 min at 17,900 x g 
14. Discard the flow-through and place the column back in the collection tube 
15. Add 0.75 mL of Buffer PE to the column and centrifuge for 1 min at 17,900 x g 
16. Discard the flow-through and centrifuge again for 1 minute at 17,900 x g 
17. Place the column in a DNAse, RNAse, DNA free 1.5 mL tube (cut off cap!) 
18. Add 50 µL of Buffer EB or PCR water to the center of the column membrane 
and centrifuge for 1 minute at 17,900 x g 
19. Note: alternatively, 30 µL might be used – the column should then stand for 
1 minute prior to centrifugation 
20. Transfer the eluate (with a DNAse, RNAse, DNA free 100 µL pipette tip) from 
the tube with the cut off cap to a fresh DNAse, RNAse, DNA free tube. 
21. Store at -20 °C. 
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4.9 DNA Sequencing and sequence comparison 
After extraction and purification from agarose gels (see 4.8) the DNA is sent to MWG 
Eurofins Operon (Ebersberg, Germany) for sequencing. The sequencing results are 
then analyzed by the BLASTn program from the National Center for Biotechnology 
Information [147-148]. 
4.10 Real time PCR (qPCR) 
4.10.1 Background 
After [149]. 
Real-time PCR, abbreviated as “qPCR” (for “quantitative PCR”) to avoid mix-ups 
with RT-PCR, is a technique to quantify the amount of amplicon accumulated during 
the PCR process. Therefore, the amplification can be tracked “live” (thus the name 
“real-time”), in contrast to qualitative PCR, where the result of the amplification can be 
analyzed only at the end of the complete reaction. Also, real-time PCR is much more 
sensitive, because the increase in amplicon is measured through increasing 
fluorescence by the machine and not through manual optical inspection of a gel, as in 
conventional qualitative PCR.  
With real-time PCR the concentration of the template can be measured as absolute 
(as copies of the template) or relative (compared to a standard gene). Real time PCR 
can of course also be used in conjecture with reverse transcription (RT-qPCR). 
As mentioned before, the amplification is detected through the increase in 
fluorescence of the sample. This is achieved through one of the following two methods: 
One possibility is the exploitation of unspecific intercalation of a fluorescent dye with 
the DNA (e.g. SYBR® green I). The second option is the usage of sequence specific 
DNA probes (e.g. Taq-Man®) which will bind to the DNA and release a fluorescent dye 
(reporter) from the vicinity of a quencher after the polymerase (exhibiting exonuclease 
activity) “cleaves” the probe off (see Figure 16). This increase in fluorescence is then 
measured by photodiodes in the real-time PCR machine. Because of the sensitivity of 
the method, the components of the reaction mixture have to be very carefully balanced, 
so normally pre-fabricated mastermixes and primer kits, as well as standardized 
reaction plates, are used.  
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Figure 16: The two methods for amplification measurement by increased fluorescence [149]. 
4.10.2 Materials 
 Box with ice 
 Centrifuge (Sigma 4K15C, 10742) 
 DNAse, RNAse, DNA free distilled water, “PCR water” (Gibco, 0977035) 
 DNAse, RNAse, DNA free pipette tips 
o 10 µL (Biozym, 770010) 
o 100 µL (ART®, 100E, 2065E) 
o 20 µL (Peqlab, 81-1020) 
 DNAse, RNAse, DNA free tubes with flat lid 0.2 mL (Biozym, 710920) 
 Fast 96-well reaction plate 0.1 mL (Applied Biosystems, 346907) 
 Latex gloves (Hartmann, Peha-Soft® powderfree, 942162) 
 MicroAmp™ Optical Adhesive Film (Applied Biosystems, 4311971) 
 StepOnePlus™ Real Time PCR System with Tower Computer (Applied 
Biosystems, 4376599) 
 Taq-Man® Gene Expression Assay(s) (20x Mix) 
 Taq-Man® Gene Expression Master Mix (Applied Biosystems, 4369016) 
 Vortexer (Labinco, L24) 
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4.10.3 Method 
20 µL reactions were used in this thesis. For other volumes (10–50 µL are possible), 
the respective volumes of the reaction components have to be adjusted accordingly.. 
Mastermix 
Table 14: Mastermix recipe for 20 µL qPCR reactions (after [150]). 
Vol [µL] Component 
10 Taq-Man® 2x Master Mix 
1 Taq-Man® Assay 20x 
4 PCR water 
 
Gene expression assays 
Table 15: Gene expression assays used in qPCR experiments in this thesis. VIC: Taq-Man® VIC; FAM: 6-
Carboxyfluorescein. 
Target Assay Reporter 
ACTB (β-actin) Rat ACTB (Applied Biosystems, 4352340E-0805007) VIC 
MT1 Rat Mtnr1a (Applied Biosystems 626218 G10) FAM 
MT2 Rat Mtnr1b (Applied Biosystems 626217 G5) FAM 
 
Instructions 
For detailed instructions consult the manufacturer’s manual [151]. 
1. Theoretical preparation 
a. Select the samples, targets of interest and number of repetitions. 
Include negative (-RT) and blind samples (water only) as well.  
b. Prepare a clearly laid out plate layout 
c. Calculate the amount of cDNA necessary for the sum of all respective 
wells of all targets. Add one aliquot of cDNA to compensate for pipetting 
errors. 
2. Practical preparation (work on ice) 
a. Prepare dilutions of the samples (the aspired amount of cDNA per 
sample should be contained in 5 µL of PCR water) 
b. Prepare the mastermixes for all targets; always add 1–2 aliquots to 
compensate for pipetting error 
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c. Pipette all diluted samples (and blinds / negatives) in their respective 
wells (use a fresh tip for each well to ensure volume conformity) in a 
96 well reaction plate 
d. Add the mastermixes to the respective wells 
e. Seal the reaction plate with the optical adhesive film 
f. Remove the opaque cover foil from the back of the film 
g. Place the film centered on the plate 
h. Use a scraper to flatten the film 
i. Remove the holding flaps of the film by holding down the film on the 
plate with the scraper with one hand and pulling on the flap with the 
other hand 
j. Make sure that the seal between plate and film is tight  
k. Centrifuge the plate at 2000 x g for 1 minute 
l. Remove dust from the bottom of the plate by blowing or a brush 
3. Real time PCR  
a. Insert the plate into the instrument and close the hatch 
b. Start the program “StepOne Software v2.0” 
c. Click on “Advanced Setup” 
d. Choose “Standard (~2 hours to complete a run)” under “rampspeed” 
e. Choose “Quantitation – Comparative CT (CT)” 
f. Name the experiment 
g. Go to “Plate Setup” 
h. Name all targets and choose the appropriate reporter (specified in the 
assays data sheet) 
i. Name all samples 
j. Click on the tab “Assign Targets and Samples” 
k. Select all wells of one target and activate the checkbox next to the 
respective target name 
l. Select the blind samples of the target and click on “N” next to the 
sample name 
m. Repeat steps k–l for all targets 
n. Select all wells of a sample and activate the checkbox next to the 
respective sample name 
o. Repeat step n for all samples 
p. Select the reference sample and the endogenous control 
q. Go to “Run Method” 
r. Set the reaction volume per well to 20 µL 
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s. Click on “START Run” 
t. Wait for the instrument to complete the run  
u. After completion of the run, take the plate out of the instrument and 
close the hatch again 
4. Subsequent work after the run is completed 
a. Select “Analysis” 
b. Go to “Amplification Plot” 
c. Select “Graph Type: Log” 
d. Check “Show threshold” 
e. Select a target 
f. Uncheck “Auto” and set the threshold within the exponential phase of 
the amplification (drag the line with the mouse) 
g. Repeat steps e–f for all targets 
h. Click on “Export” and save the data to an appropriate location 
(e.g. USB-stick) 
i. Close the program, when asked to save the unsaved data, click “yes” 
and save at an appropriate location 
4.10.4 Analysis of results 
After [149, 151]. 
The amount of quantified DNA can be expressed in multiple ways. One of the most 
common ones is the CT value. The CT (cycle threshold) value is the number of PCR 
cycles necessary for a template in a sample to become detectable (so the fluorescence 
of the sample exceeds the threshold of the background fluorescence). The CT value 
then specifies the difference between the CT of the template in question and a 
reference gene (e.g. beta actin) which is expressed equally in all the samples. Since 
the relative ratio of the standard and the template in question does not change, this 
difference (the CT value) is used to “normalize” the CT values and account for 
discrepancies in pipetting, sample concentration, etc. TheCT values can be 
conversed from base 2 to base 10 using the formula from Figure 17. 
CT
nE
 2
 
Figure 17: Conversion of the expression difference of a target to a the reference gene from the base 2 
CT values to the n-fold (En; base 10) value. 
The CT can then again be measured against other CT values, e.g. a placebo 
group against a verum group. This value is then called CT and specifies the 
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difference in gene (or mRNA in case of qRT-PCR) expression between the two groups. 
This difference can then be conversed from a base 2 system (CT) to a base 10 system 
using the formula from Figure 18. 
CT
nE
 2
 
Figure 18: Conversion of the expression difference of two targets from the base 2 CT values to the  
n-fold (En; base 10) value. 
Of course, this simple conversion works only if the expression efficiency of the 
amplification reaction is (near) 100 % and the same for all targets. For short amplicon 
lengths (< 150 bp, true for all TAQMan® Assays), these requirements are met (Applied 
Biosystems, User Bulletin #2: Relative Quantitation of Gene Expression (Applied 
Bioystems Inc., Part Number 4303859B). 
A standard sample (of all measured samples) can be chosen to act as a reference. 
The expression of various samples can then be indicated as En-fold expression of the 
reference.  
All samples should be measured at least in duplicates (better are triplicates or even 
quadruplicates) to increase the accuracy of the method. The CT values are then 
indicated as mean CT of the repeats. To ensure primer specificity and correct 
amplification, -RT and negative samples should be included for all template groups. 
4.11 Immunofluorescence (IF) 
4.11.1 Background 
IF is a method used to visualize the location or occurrence of proteins in tissues or cells 
by use of fluorescence microscopy. 
Staining of tissue sections is done in two steps: first, the primary antibody is 
applied to the tissue. The primary AB recognizes specific antigens (e.g. smooth muscle 
actin or the melatonin MT1 receptor) and binds to them. It is created in a host species 
and can be either poly- or monoclonal. After the primary antibody has bound to its 
target, a secondary antibody is applied, which recognizes the primary antibody based 
on the primary AB’s host species. This secondary antibody is conjugated with a 
fluorescent dye, which glows during excitation with light of a specific frequency. 
To exclude that the observed fluorescence stems from unspecific binding of the 
secondary antibody to the tissue, a negative control, with only the secondary antibody 
applied, should be included in each experiment. 
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Before the staining, the tissue has to be fixated. This can be done using a variety 
of methods; examples are the usage of formaldehyde (PFA) or the new HOPE®-
solution (DCS, Hamburg, Germany). For sectioning, the tissue needs to be either 
frozen (in liquid N2) or embedded in paraffin. Accordingly, the tissue is then either cryo-
sectioned or paraffin sectioned. Afterwards different steps are necessary to prepare it 
for staining depending on the method used for sectioning. In case of a cryo-sections 
the tissue only needs to be rehydrated (using PBS) and then bathed in an ammonium-
chloride (50 mM) solution to remove any excess PFA remaining in the tissue. With 
paraffin sections the procedure is more complex, because the paraffin has to be 
removed and the rehydration has to be done using a descending alcohol series. 
HOPE®-fixated paraffin sections are somewhat easier to rehydrate, as only two 
isopropanol and acetone steps are necessary. Also, if a tissue was embedded in 
paraffin, normally antigen retrieval has to be done, because paraffin in conjecture with 
PFA can mask antigens. This is done by boiling the sections in citrate buffer, citraconic 
anhydride, or by using proteases. 
After rehydration, the tissue has to be permeabilized to ensure that the primary 
antibody can “reach” its target and is not hindered by membranes, etc. Also, unspecific 
binding sites have to be blocked using blocking serum (serum from the animal the 
second antibody was derived from, or, if this is not possible, with a protein dissolved in 
buffer such as bovine serum albumin (BSA)) to reduce the background fluorescence. 
These two steps are normally done at the same time by incubating the tissue with 
serum containing small amounts of a detergent (Saponin, Triton-X 100 or Tween 20).  
If more than one protein, or if the relative positions of two proteins in a tissue, are 
of interest, double, triple, or even quadruple stainings are possible. The primary 
antibodies against the different proteins have to be derived from different species, of 
course. This can be achieved using two different approaches, which both have specific 
advantages and disadvantages. 
The first approach is parallel staining, where the primary and secondary antibodies, 
respectively, are mixed and applied together. The advantage is that the amount of time 
for the procedure is the same as for a single staining and that all primary antibodies 
can be applied overnight, so staining should be strong for all targets. However, the 
primary antibodies (and secondary antibodies, respectively) may influence each other if 
they are dissolved in the same solution. 
The second approach is sequential staining, where the staining procedure is 
repeated for each primary / secondary AB combination. The advantage is that the 
antibodies have less chance of influencing each other and the stainings are usually 
more reliable. The disadvantage is a proportional increase in time necessary for each 
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further target, since all washing and incubation steps have to be repeated for each 
antibody duo. 
After the staining procedure with all the antibodies is completed, the tissue is 
usually dyed for nucleic acids, therefore making the nuclei of the cells visible. This is 
done with chemicals which intercalate in DNA, which results in fluorescence. An 
example for such a “nucleic acid dye” is 4',6-diamidino-2-phenylindole (DAPI). 
When all dyeing steps are completed, the tissue is embedded in a mounting 
medium which is pervious for a broad range of light frequencies, ideally for the whole 
UV/VIS/IR spectrum. An example for such a medium is Mowiol. 
4.11.2 Tissue sectioning 
General remarks 
For IF staining, thin sections of tissue (1–15 µm) are necessary. This can be done by 
cryo-sectioning, where the tissue is cut in a frozen state. The tissue is embedded in 
TissueTek™, a substance based on polyvinyl alcohol, which is liquid at rt, but freezes 
to a solid, sliceable mass at low temperatures. All tissues cut and used for cryo-
sectioning in this work were fixated and frozen in TissueTek™ in 2008 by M. Benova 
(Institute for Pathophysiology, Medical University Vienna). Therefore, the method for 
fixating the tissue prior to initial freezing will not be discussed in this work.  
Alternatively, paraffin-sections, where the tissue is embedded in paraffin and cut at 
rt can be used. All paraffin sections used for IF experiments in this work were fixated, 
embedded and cut in 2010 by H. Uhrova (Institute of Pathophysiology and Allergy 
Research, Medical University Vienna). Therefore, the methods for paraffin embedding 
and sectioning will not be discussed in this work. 
Cryo-sectioning 
Materials 
 Acetone (Merck, 1.00014.2500) 
 Cryomicrotome (Microm, 500 O-M) 
 Cryomicrotome blade (Microm Sec 35, 152200) 
 Latex gloves (Meditrade Gentle Skin sensitive, 1221) 
 Paper towels 
 Positively precharged slides (Thermo Scientific Superfrost® Plus Gold, 
K5800AMNZ) 
 Scalpel, brush, forceps 
 TissueTek™ (Sakura, 4583) 
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Method 
1. Switch on the microtome by activating “Light”, “Motor”, and “Object” 
2. Mount the TissueTek™ embedded tissue on one of the stamps in the 
instrument by applying TissueTek™ on the stamp, letting it solidify for a 
moment, then adding the embedded tissue 
3. Check the orientation of the tissue, correct by thawing and reorientation if 
necessary 
4. Let the tissue with the TissueTek™ freeze completely inside the microtome 
5. Apply more TissueTek™ on the stamp so that a large area around the 
embedded tissue is covered with TissueTek™; avoid protruding parts of the 
tissue 
6. Repeat steps 3–5 for all samples 
7. Insert a microtome blade in the blade holder 
8. Insert a stamp with embedded tissue in the stamp-holder and fasten the 
holding screw 
9. Adjust the angle of the blade and / or the stamp, if necessary 
10. Move the stamp away from the blade by using the [↑] button 
11. Set the section thickness to 40 µm 
12. Use the motor to approach the blade with the section 
13. Slice off TissueTek™ at 40 µm until the tissue is cut together with the 
TissueTek™ 
14. Set the section thickness to 1–15 µM (7 µM for aorta sections) 
15. Slice off a few sections to adapt the microtome to the new thickness 
16. Carefully cut a section off using the hand-wheel (clockwise) – while the section 
is being cut, gently pull the section away from the blade using a brush; try to 
keep a flat, undisrupted section 
17. Lower a positively precharged slide parallel over the section – at about 10–5 
mm, the section will be “sucked” onto the slide 
18. Keep the slide with the tissue at rt for about 10 min 
19. Store the slide at -20 °C 
20. Repeat steps 16–19 for all sections of the sample 
21. Clean the blade every few sections with acetone  
22. Move the stamp away from the blade by using the [↑] button and remove the 
stamp after releasing the holding screw 
23. Remove the remaining tissue (still embedded in TissueTek™) from the stamp 
using the scalpel 
24. Store the remaining tissue at -80°C (still embedded in TissueTek™) 
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25. Repeat steps 8–24 for all samples 
26. Remove the microtome blade and store or discard it 
27. Clean the microtome using brushes and acetone soaked towels 
28. Switch off the microtome by deactivating “Light”, “Motor” and “Object”, but 
do not deactivate “Box” 
4.11.3 Buffers, solutions and reagents 
PBS (phosphate buffered saline) 
Materials 
 KCl (Merck, 4936.1000) 
 NaCl (Merck, 1.06404.1000) 
 KH2PO4 (Merck, 1.04873.1000) 
 Na2HPO4.2H2O (Merck, 1.06580.1000) 
 Aqua bidest. 
 Osmometer (Osmomat 030, Gonotec) 
 pH-meter (Metrohm, pH-Lab 827) 
Method 
1. Solve in 800 mL aqua bidest 
a. 0.2 g KCl 
b. 8.01 g NaCl 
c. 0.21 g KH2PO4 
d. 1.44 g Na2HPO4.2H2O 
2. Adjust pH to 7.4 with HCl or NaOH 
3. Fill to 1000 mL with aqua bidest. 
4. Osmolarity should be between 0.280–0.305 osmol / kg 
5. Store at 4 °C 
50 mM NH4Cl in PBS 
Materials 
 NH4Cl (Merck, 1.01142.1000) 
 PBS (see above) 
Method 
1. Dissolve 2.67 g of NH4Cl in 1000 mL aqua bidest. 
2. Store at rt 
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10 mM citrate buffer 
Materials 
 Aqua bidest. 
 Citric acid monohydrate (Merck, 244) 
 pH-meter (Metrohm, pH-Lab 827) 
 Tri-sodium citrate dihydrate (Sigma C-8532) 
Method 
1. Mix 
a. 8.5 mL of a 0.1 M solution of citric acid monohydrate: 
i. 21.06 g citric acid monohydrate 
ii. 1000 mL aqua bidest. 
b. 41.5 mL of a 0.1 M solution of tri-sodium citrate dehydrate: 
i. 29.41 g tri-sodium citrate dihydrate 
ii. 1000 mL aqua bidest. 
2. Adjust to 500 mL with aqua bidest. 
3. Adjust to pH 6 with solution a or b 
4. Store at 4 °C 
Mowiol mounting medium 
Materials 
 Centrifuge (Rotixa, Hettich) 
 Centrifuge tubes 50 mL (VWR, 50 ml Super Clear® Centrifuge tubes, 525-
0307) 
 Disposable sterile syinge filters, 25 mm, 0.20 Micron, cellulose acetate 
membrane acrylic (IWAKI 2052-025) 
 Glycerol 87 % (Merck 1.04094.0500) 
 Hydrochloric acid, fuming 37 % (Merck 1.00314.1000) 
 Magnetic hot plate stirrer 
 Mowiol 4-88 (FLUKA 81381) 
 NaN3 (Sigma S-8032) 
 Syringes, single use, 10 mL (B. Braun, Melsungen AG H4606108V) 
 Tris (Merck 1.08382.1000 
 Tubes 1.5 mL (Biozym, 710160) 
 Waterbath (GFL, 1083) 
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Method 
1. Mix in a 50 mL tube 
a. 6 g glycerol 
b. 2.4 g Mowiol 4-88 
2. Let the mixture disperse for 1 h at rt under frequent shaking 
3. Add 6 mL aqua bidest.  
4. Stir for 1 h at rt 
5. Add 12 mL 0.2 M Tris/HCl pH 8.5 + 0.02 % (v / w) NaN3 
6. Incubate for 2 h in the waterbath at 50 °C and stir every 20 min 
7. Centrifuge at 5,000 x g for 15 min 
8. Filtrate through a 0.2 µm syringe filter 
9. Prepare 1 mL aliquots 
10. Store at -20 °C 
4.11.4 Staining procedures for cryo-sections 
Materials 
 Aluminum foil 
 Blocking serum (sera) from host animal of secondary AB(s) (5 % in PBS + 
0.05 % saponin; see 4.11.6) 
 Antibodies (see 4.11.6) 
 Box with ice 
 Coolable Centrifuge (Eppendorf, Centrifuge 5415R) 
 Coverslips (Menzel-Gläser) 
 DakoPen (Dako, S2002) 
 DAPI (4',6-diamidino-2-phenylindole; Roche 10236276001) 1:10,000 in PBS 
 Dyeing trays (plastic or glass) 
 Forceps 
 Latex gloves (Meditrade Gentle Skin sensitive, 1221) 
 Mowiol (Roth, 07031) 
 pipette tips 
o 10 µL (Biozym, 720031) 
o 200 µL (Biozym, 720230) 
o 1000 µL (Biozym, 721000) 
 Solutions and buffers 
o 50 mM NH4Cl (see 4.11.3) 
o PBS (see 4.11.3) 
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 Tubes 1.5 mL (Biozym, 710160) 
 Vortexer (Labinco, L24) 
 Wet chamber 
Notes 
 Washing steps are performed in dyeing trays and always for 5 minutes unless 
otherwise stated  
 Incubation steps are always performed in a wet chamber, the solution the tissue 
is incubated with is applied directly on the tissue with a pipette 
 Always take the slides out of the trays very slowly to avoid detaching of the 
sections 
 Always keep the tissue wet 
 Antibodies (primary and secondary) are always diluted in blocking buffer (5 % 
animal serum of the respective secondary AB + 0.05 % saponin in PBS or 1 % 
BSA + 0.05 % saponin in PBS). Use the serum from the host animal of the 
secondary antibody. 
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Single-staining procedure 
1. Tissue preparation (rehydration and blocking) 
a. Wash once for 10 min in 50 mM NH4Cl 
b. Wash 3 times in PBS 
c. Draw a circle around the tissue(s) with the Dako-Pen 
d. Incubate with blocking buffer for 1 h at rt  
2. Primary antibody  
a. Centrifuge the antibody at 14.000 x g for 5 min 
b. Dilute the antibody in blocking buffer 
c. Incubate with primary antibody in a wet chamber for 1 h–24 h 
d. Wash 5 times in PBS 
3. Secondary antibody (work in the dark!) 
a. Centrifuge the antibody at 14.000 x g for 5 min 
b. Dilute the antibody in blocking buffer 
c. Incubate with secondary antibody in a wet chamber for 1 h 
4. Nuclei staining 
a. Wash twice in PBS  
b. Incubate for 10 min with DAPI  
c. Wash twice in PBS 
d. Rinse once in aqua bidest. (in and out) 
5. Embedding 
a. Apply an appropriate volume of Mowiol on the tissue and the slide 
b. Cover with coverslip 
c. Dry for 24 h in the dark at rt 
6. Store the slides at 4 °C in the dark 
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Double-staining procedures 
Parallel staining 
1. Tissue preparation (rehydration and blocking) 
a. Wash once for 10 min in 50 mM NH4Cl 
b. Wash 3 times in PBS 
c. Draw a circle around the tissue(s) with the Dako-Pen 
d. Incubate with blocking buffer (use 1 % BSA in PBS + 0.05 % saponin, if 
the host animals for the secondary ABs are not identical) 
2. Primary antibodies  
a. Centrifuge the antibodies at 14,000 x g for 5 min 
b. Dilute the antibodies in blocking buffer (use 1 % BSA in PBS + 0.05 % 
saponin, if the host animals for the secondary ABs are not identical) and 
mix them 
c. Incubate with primary antibody mixture in a wet chamber for 1 h–24 h 
d. Wash 5 times in PBS 
3. Secondary antibodies (from now on, work in the dark!) 
a. Centrifuge the antibodies at 14,000 x g for 5 min 
b. Dilute the antibodies in blocking buffer (use 1 % BSA in PBS + 0.05 % 
saponin, if the host animals for the secondary ABs are not identical) and 
mix them 
c. Incubate with secondary antibody mixture in a wet chamber for 1 h 
4. Nuclei staining 
a. Wash twice in PBS  
b. Incubate for 10 min with DAPI  
c. Wash twice in PBS and rinse once in aqua bidest. (in and out) 
5. Embedding 
a. Apply an appropriate volume of Mowiol on the tissue and the slide 
b. Cover with coverslip and dry for 24 h in the dark at rt 
6. Store the slides at 4 °C in the dark 
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Sequential staining 
1. Tissue preparation (rehydratization and blocking) 
a. Wash once for 10 min in 50 mM NH4Cl 
b. Wash 3 times in PBS 
c. Draw a circle around the tissue(s) with the Dako-Pen 
d. Incubate with blocking buffer (use the serum of the host animal for the 
first secondary antibody; if this is not possible because of cross 
reactions with the other antibodies, use 1 % BSA in PBS + 0.05 % 
saponin) 
2. First primary antibody  
a. Centrifuge the antibody at 14,000 x g for 5 min 
b. Dilute the antibody in blocking buffer (use the serum of the host animal 
for the first secondary antibody; if this is not possible because of cross 
reactions with the other antibodies, use 1 % BSA in PBS + 0.05 % 
saponin) 
c. Incubate with primary antibody in a wet chamber for 1 h–24 h 
d. Wash 5 times in PBS 
3. First secondary antibody (from now on, work in the dark!) 
a. Centrifuge the antibody at 14,000 x g for 5 min 
b. Dilute the antibody in blocking buffer (use the serum of the host animal 
for the second secondary antibody; if this is not possible because of 
cross reactions with the other antibodies, use 1 % BSA in PBS + 0.05 % 
saponin) 
c. Incubate with secondary antibody in a wet chamber for 1 h 
d. Wash 5 times in PBS 
4. Second primary antibody 
a. Centrifuge the antibody at 14,000 x g for 5 min 
b. Dilute the antibody in blocking buffer (use the serum of the host animal 
for the first secondary antibody; if this is not possible because of cross 
reactions with the other antibodies, use 1 % BSA in PBS + 0.05 % 
saponin) 
c. Incubate with primary antibody in a wet chamber for 1 h–24 h 
d. Wash 5 times in PBS 
5. Second secondary antibody 
a. Centrifuge the antibody at 14,000 x g for 5 min 
b. Dilute the antibody in blocking serum 
c. Incubate with secondary antibody in a wet chamber for 1 h 
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6. Nuclei staining 
a. Wash twice in PBS  
b. Incubate for 10 min with DAPI  
c. Wash twice in PBS 
d. Rinse once in aqua bidest. (in and out) 
7. Embedding 
a. Apply an appropriate volume of Mowiol on the tissue and the slide 
b. Cover with coverslip 
c. Dry for 24 h in the dark at rt 
8. Store the slides at 4 °C in the dark 
4.11.5 Staining procedures for HOPE®-fixated paraffin sections 
Materials 
 10 mM citrate buffer, pH 6 (see 4.11.3) 
 Acetone (Merck, 1.00014.2500) 
 Aqua bidest. 
 Dyeing trays (plastic and glass) 
 Isopropanol (Merck, 1.09634.1011) 
 Oven (Mammert, TV15u), kept at 60 °C 
 PBS (see 4.11.3) 
 Refrigerator 
 Steamer (Braun, MultiGourmet Type 3-216) 
 Further materials: see 4.11.4 
Method 
1. Deparaffination 
a. Incubate the slides with the sections for 10 min in warm isopropanol 
(60 °C) 
b. Wash with fresh, warm isopropanol (60 °C) 
2. Rehydration 
a. Incubate 2x for 10 min in 70 % cold (4 °C) acetone (keep in refrigerator) 
b. Wash 2x with aqua bidest. 
3. Incubate for 5 min in aqua bidest. 
4. Antigen retrieval 
a. Fill a plastic dyeing tray with 10 mM citrate buffer and put it in the 
steamer 
b. Pre-heat the citrate buffer for 20 min 
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c. Incubate the slides for 15 min in the hot citrate buffer in the steamer 
d. Take the tray out of the steamer and let it cool to RT 
e. Wash twice in PBS (5 min each) 
5. The further procedure is identical with the ones for single staining or double 
staining of cryo-sections (see 4.11.4) 
4.11.6 Antibodies and blocking buffers 
The respective antibodies used in the experiments are given in the results chapter 
(5.5). As blocking buffer, always 5 % animal serum of the respective secondary AB + 
0.05 % saponin in PBS is used. Santa Cruz is abbreviated as SC. 
Primary antibodies 
Table 16: Primary antibodies used in this thesis. All dilutions of the antibodies are given, as well as 
information about the origin of the respective antibody (modified after the datasheets of the respective 
antibodies [152-155]). 
Antibody Dilutions Information 
Goat Anti MT1 
(SC, sc-13186) 
1:50, 1:20, 1:10 
Affinity purified goat polyclonal antibody raised against 
a peptide mapping near the C-terminus of MT2 of rat 
origin; 200 µg / mL 
Rabbit Anti MT1  
(Abbiotec, 250761) 
1:50, 1:10 
Affinity purified rabbit polyclonal antibody raised 
against a KLH-conjugated synthetic peptide 
encompassing a sequence within the center region of 
MT1 of human origin 
Rabbit Anti Pecam-1  
(SC, sc-1506) 
1:50 
Affinity purified rabbit polyclonal antibody raised 
against a peptide mapping at the C-terminus of 
PECAM-1 of mouse origin; 200 µg / mL 
Mouse Anti SM Actin  
(Sigma, A2547) 
1:1000 
Mouse monoclonal antibody raised against a KLH-
conjugated synthetic decapeptide encompassing the 
N-terminus of α-smooth muscle actin 
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Secondary antibodies 
Table 17: Secondary antibodies used in this thesis. All dilutions of the antibodies are given, as well as 
information about the respective antibody (modified after the data sheets of the respective antibodies[156-
158]). All secondary antibodies are mixed 1:1 with glycerol (Merck, 1.04094.0500). 
Antibody Dilution Information 
Donkey Anti Goat Alexa 
Fluor® 568 
(Invitrogen, A11057) 
1:1000 
Affinity purified donkey antibodies against goat IgG heavy 
chains and all classes of Ig light chains, conjugated to 
Alexa Fluor® 568 dye; mixed 1:1 with glycerol 
Donkey Anti Goat Alexa 
Fluor® 647  
(Invitrogen, A21447) 
1:1000 
Affinity purified donkey antibodies against goat IgG heavy 
chains and all classes of Ig light chains, conjugated to 
Alexa Fluor® 647 dye; mixed 1:1 with glycerol 
Goat Anti Mouse Alexa 
Fluor® 568  
(Invitrogen, A21042) 
1:1000 
Affinity purified goat antibodies against mouse IgG heavy 
chains and all classes of Ig light chains, conjugated to 
Alexa Fluor® 568 dye; mixed 1:1 with glycerol 
Goat Anti Rabbit Alexa 
Fluor® 568  
(Invitrogen, A11011) 
1:1000 
Affinity purified goat antibodies against rabbit IgG heavy 
chains and all classes of Ig light chains, conjugated to 
Alexa Fluor® 568 dye; mixed 1:1 with glycerol 
Goat Anti Rabbit Alexa 
Fluor® 647  
(Invitrogen, A21244) 
1:1000 
Affinity purified goat antibodies against rabbit IgG heavy 
chains and all classes of Ig light chains, conjugated to 
Alexa Fluor® 647 dye; mixed 1:1 with glycerol 
 
Blocking buffers 
Materials 
 Animal serums / BSA 
o Donkey (Jackson Immuno Research, 017-000-121) 
o Goat (Jackson Immuno Research, 005-000-121) 
 PBS (see 4.11.3) 
 Saponin (Sigma S-1252) 
 50 mL tubes (VWR, 50 ml Super Clear® Centrifuge tubes, 525-0307) 
Method 
1. Mix 
a. 25 mL animal serum 
b. 400 mL PBS 
c. 250 µL saponin 
2. Adjust to 500 mL with PBS 
3. Prepare 50 mL aliquots 
4. Store at -20 °C 
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4.11.7 Photography of IF-stained sections 
Materials 
 ZEISS Axio Imager Z1 microsope equipped with TissueFAXS, TissueGnostics 
GmbH (TF) 
o Objectives 
 EC-Plan Neofluar 2.5 x / 0.07 
 EC-Plan Neofluar 20 x / 0.5 
o Camara (PCO Pixelfly) 
 Ethanol 70 % (v / v), diluted from Ethanol 96 % (v / v) (Merck, 1.00983.1000) 
Method 
1. Clean the slides using Ethanol 70 % (v / v) 
2. Insert the slides in the slide holder 
3. Insert the slide holder into the stage 
4. Start the TissueFaxs application 
5. Acquire all areas of interest* 
6. Remove the slides from the slide holder and store them at 4 °C 
 
*To describe the process of using the TF image acquisition system in detail would go 
beyond the scope of this work. See the instructions of the TF for detailed information. 
Notes 
 Images are saved as PNG 
 All parameters for image acquisition (exposure time, lamp intensity, 
thresholds, gain …) are recorded for each channel and each experiment and 
are stated with the respective image series in the results section.  
 The tonality of all IF-images in this work have been adjusted by the same 
amount for better clarity in print (10 / 1.25 / 200) in Adobe® Photoshop® 
 If not specified otherwise, all pictures consist of the overlay of the respective 
channel(s) of the secondary AB(s) and the DAPI channel 
 All images are captured using the 20 x objective 
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4.11.8 Experiment parameters 
Single stainings for SM-actin and pecam-1 
Table 18: Experiment parameters for single staining of aorta sections stained for SM-actin with Alexa 
Fluor® 568. Blocking buffer and ABs: see 4.11.6, incubation times and dilution(s) are stated; o/n: 
overnight; Tex: name of the channel for acquisition of 568 stained images; LT: lower threshold (parameter 
to reduce background in the TF software). 
Type Single staining 
Blocking buffer 5 % goat serum + 0.05 % saponin in PBS 
Primary AB o/n 1:500 Mouse Anti SM Actin  
Secondary AB  1 h 1:1000 Goat Anti Mouse Alexa Fluor® 568 
Acquisition parameters DAPI: 30 ms, Tex: 150 ms + LT 250 
 
Table 19: Experiment parameters for single staining of aorta sections stained for pecam-1 with Alexa 
Fluor® 568. Blocking buffer and ABs: see 4.11.6, incubation times and dilution(s) are stated; o/n: 
overnight; Tex: name of the channel for acquisition of 568 stained images; LT: lower threshold (parameter 
to reduce background in the TF software). 
Type Single staining 
Blocking buffer 5 % goat serum + 0.05 % saponin in PBS 
Primary AB o/n 1:50 Rabbit Anti Pecam 
Secondary AB  1 h 1:1000 Goat Anti Rabbit Alexa Fluor® 647 
Acquisition parameters DAPI: 30 ms, Tex: 150 ms + LT 250 
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Double stainings for SM-actin + pecam-1 
Table 20: Experiment parameters for double staining of aorta sections stained for SM-actin + pecam-1 
with Alexa Fluor® 568 and Alexa Fluor 647. Blocking buffer and ABs: see 4.11.6, incubation times and 
dilution(s) are stated; o/n: overnight; Tex: name of the channel for acquisition of 568 stained images; Cy5: 
name of the channel for acquisition of 647 stained images; LT: lower threshold (parameter to reduce 
background in the TF software); G: gain (parameter for signal amplification in the TF software). 
Type Double staining 
Blocking buffer 5 % goat serum + 0.05 % saponin in PBS 
1
st
 Primary AB o/n / 1h 1:500 Mouse Anti SM Actin  
1
st
 Secondary AB  1 h 1:1000 Goat Anti Mouse Alexa Fluor® 568 
2
nd
 Primary AB o/n / 1h 1:50 Rabbit Anti Pecam 
2
nd
 Secondary AB 1 h 1:1000 Goat Anti Rabbit Alexa Fluor® 647 
Acquisition parameters DAPI: 30 ms, Tex: 150 ms + LT 250, Cy5: 450 ms + G + LT 150 
 
Single stainings for MT1 protein expression on cryo-sections 
Table 21: Experiment parameters for single staining of aorta sections stained for MT1 using the Abbiotec 
AB with Alexa Fluor® 568. Blocking buffer and ABs: see 4.11.6, incubation times and dilution(s) are stated; 
o/n: overnight; Tex: name of the channel for acquisition of 568 stained images. 
Type Single staining 
Blocking buffer 5 % goat serum + 0.05 % saponin in PBS 
Primary AB o/n 1:200 Rabbit Anti MT1 (Abbiotec) 
Secondary AB  1 h 1:1000 Goat Anti Rabbit Alexa Fluor® 568 
Acquisition parameters DAPI: 50 ms, Tex: 400 ms 
 
Table 22: Experiment parameters for single staining of aorta sections stained for MT1 using the SC AB 
with Alexa Fluor® 568. Blocking buffer and ABs: see 4.11.6, incubation times and dilution(s) are stated; 
o/n: overnight; Tex: name of the channel for acquisition of 568 stained images. 
Type Single staining 
Blocking buffer 5 % donkey serum + 0.05 % saponin in PBS 
Primary AB o/n 1:50 Goat Anti MT1 (SC) 
Secondary AB  1 h 1:1000 Donkey Anti Goat Alexa Fluor® 568 
Acquisition parameters DAPI: 50 ms, Tex: 400 ms 
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Table 23: Experiment parameters for single staining of aorta sections stained for MT1 using the SC AB 
with Alexa Fluor® 647. Blocking buffer and ABs: see 4.11.6, incubation times and dilution(s) are stated; 
o/n: overnight; Cy5: name of the channel for acquisition of 647 stained images; G: gain (parameter for 
signal amplification in the TF software). 
Type Single staining 
Blocking buffer 5 % donkey serum + 0.05 % saponin in PBS 
Primary AB o/n 1:50, 1:20 Goat Anti MT1 (SC) 
Secondary AB  1 h 1:1000 Donkey Anti Goat Alexa Fluor® 647 
Acquisition parameters DAPI: 20 ms, Cy5: 400 ms + G 
 
Single stainings for MT1 potein expression on paraffin sections 
Table 24: Experiment parameters for single staining of aorta and control paraffin sections stained for MT1 
using the Abbiotec AB in two different concentrations with Alexa Fluor® 647. Blocking buffer and ABs: see 
4.11.6, incubation times and dilution(s) are stated; o/n: overnight; Cy5: name of the channel for acquisition 
of 647 stained images; G: gain (parameter for signal amplification in the TF software). 
Type Single staining 
Blocking buffer 5 % goat serum + 0.05 % saponin in PBS 
Primary AB o/n 1:50, 1:10 Rabbit Anti MT1 (Abbiotec) 
Secondary AB  1 h 1:1000 Goat Anti Rabbit Alexa Fluor® 647 
Acquisition parameters DAPI: 40 ms, Cy5: 500 ms + G 
 
Table 25: Experiment parameters for single staining of aorta and control paraffin sections stained for MT1 
using the SC AB in two different concentrations with Alexa Fluor® 647. Blocking buffer and ABs: see 
4.11.6, incubation times and dilution(s) are stated; o/n: overnight; Cy5: name of the channel for acquisition 
of 647 stained images; G: gain (parameter for signal amplification in the TF software); Trans: transmitted 
light. 
Type Single staining 
Blocking buffer 5 % donkey serum + 0.05 % saponin in PBS 
Primary AB o/n 1:50, 1:20 Goat Anti MT1 (SC) 
Secondary AB  1 h 1:1000 Donkey Anti Goat Alexa Fluor® 647 
Acquisition parameters DAPI: 20 ms, Cy5: 400 ms + G, Trans: 75 ms / 5.9 V 
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5 RESULTS 
5.1 Establishment of molecular biological methods to 
demonstrate expression of MT1 and MT2 mRNA in rat 
tissues 
In order to achieve the primary goal of this thesis, i.e. the confirmation of melatonin 
receptor mRNA expression in the rat aorta, the methods for RNA isolation, purity 
assessment, reverse transcription and PCR experiments had to be established. Ishii et 
al. [26] have recently demonstrated the occurrence of MT1 and MT2 mRNA in a variety 
of rat tissues. 
Accordingly, several rat organs where expression of either MT1 or MT2 had been 
established were used as positive control (see 4.1.1). The RNA from these organs was 
extracted (see 5.1.1), transcribed into cDNA (see 5.1.2) and MT1 as well as MT2 mRNA 
expression was demonstrated by subsequent PCR (see 5.1.2) and qPCR (see 5.1.3). 
5.1.1 RNA-Isolation 
The RNA of ten different rat organs (see 4.1.1) was isolated (see 4.2). Photometric 
measurement of all samples (see 4.3) revealed acceptable purity (A260 / A280 >1.6) of 
the isolated RNAs. Yields of total RNA (see Table 26) varied, even though the same 
amount of tissue from each organ was used for RNA extraction (about 70 mg). GE (see 
4.4) of the isolated RNA showed that it was intact for all organs and exhibited no signs 
of degradation (see Figure 19). 
Table 26: Concentration, purity and yield of extracted RNA from various rat organs. Skeletal m.: skeletal 
muscle. 
Organ C [ng / µL] A260 / A280 RNA yield [µg] 
Brain 827.1 1.68 16.54 
Eye 1212.5 1.77 24.25 
Heart 1529.4 1.80 30.59 
Intestine 3926.7 1.86 264.68 
Kidney 3116.2 1.75 65.11 
Liver 1880.6 1.97 188.06 
Lung 1012.1 1.80 20.24 
Skeletal m. 1978.8 1.88 39.58 
Testes 4050.8 1.90 133.55 
Thymus 545.5 1.65 10.91 
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Figure 19: Integrity control of total RNA from all extracted organs by GE. The isolated RNA of all organs is 
intact as judged by intact 28 S and 18 S rRNA bands. 
5.1.2 RT-PCR experiments on the isolated RNA  
Reverse transcription was performed (see 4.5). The obtained cDNAs were used for all 
following PCR experiments addressing β-actin, MT1 and MT2 expression in the rat 
organs. 
RT-PCR for β-actin mRNA expression to prove successful RT 
The first PCR experiment was executed for β-actin to confirm the success of the 
reverse transcription. β-actin is a so-called “housekeeping gene”, i.e. a gene that is 
common in all tissue and expressed ubiquitously in high concentrations. Primers and 
protocol were selected according to Ishii et al. [26]. 200 ng cDNA or water (no cDNA) 
were subjected to the PCR reaction. See 4.6.2 for the general protocol and 4.6.3 for 
experiment specific conditions. The experiment shows successful amplification of β-
actin mRNA in all samples (see Figure 20), confirming success of the RT and – once 
more – integrity of the isolated RNA. Strengths of the observed bands were similar. 
 
 
Figure 20: β-actin mRNA expression in various rat organs analyzed by RT-PCR, confirming the success of 
the reverse transcription. Expected length of the PCR product was 496 bp. 
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RT-PCR for MT1 mRNA expression 
The next step was amplification of MT1 mRNA in the rat organs, following the 
procedure from Ishii et al. [26]. However, using identical settings, only the eye and 
intestine samples showed very weak bands at the expected size. For all other organs 
(including e.g. testes, liver or kidney, which exhibited strong bands for MT1 in the 
original experiment by Ishii et al. [26]) there were no bands visible at all (data not 
shown). 
Because of this weak amplification, we conducted a new PCR experiment, using 
double the amount of template cDNA (400 ng instead of 200 ng; RNA equivalent) per 
sample, and more cycles (increased from 35 to 40). See 4.6.2 for the general protocol 
and 4.6.3 for experiment specific conditions. The results of this modification can be 
seen in Figure 21, which shows bands of varying intensity for MT1 in all tissues, with 
exception of the liver. Congruent with the results of the last experiment, eye and 
intestine samples show the strongest bands. 
 
 
Figure 21: MT1 mRNA expression in various rat organs analyzed by RT-PCR. Expected length of the PCR 
product was 316 bp. 
RT-PCR for MT2 mRNA expression 
All rat organs were next tested for MT2 expression, following exactly the procedure 
described by Ishii et al. [26]. 400 ng of cDNA (RNA equivalent) or water (no cDNA) 
were subjected to PCR. See 4.6.2 for the general protocol and 4.6.3 for experiment 
specific conditions. 
Unexpectedly, no bands appeared for any organ (data not shown). To exclude 
methodical error, the procedure was repeated and yielded the same negative results 
(data not shown). 
To address this problem, the protocol was modified using another PCR reaction 
buffer with NH4SO2, which should provide higher primer specificity and product yields 
[143]. To conserve material, this experiment was only performed on three selected 
samples (kidney, eye and intestine). However, this experiment again failed to 
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demonstrate MT2 expression in any of the three tested organs, as a PCR product was 
detected neither at the expected length of 390 bp nor at any other length (data not 
shown). 
As a final measure to verify MT2 mRNA expression in brain and eye [24, 26], in the 
next experiment the annealing temperature of the PCR was reduced from 60 °C to 57 
°C. See 4.6.2 for the general protocol and 4.6.3 for experiment specific conditions. 
 
 
Figure 22: MT2 mRNA expression in rat brain and eye analyzed by RT-PCR. Expected length of the PCR 
product was 390 bp. 
As shown in Figure 22 by the appearance of a major band at 390 bp, this time, 
amplification was successful for the eye and brain samples. Probably due to the 
decreased annealing temperature, some other (but much weaker) bands appeared for 
both samples. Nevertheless, since the main bands were clearly at the correct length 
and of great intensity, the adapted method with the decreased annealing temperature 
was chosen to demonstrate MT2 mRNA expression in the aorta. 
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5.1.3 RT-qPCR for ACTB, MT1 and MT2 mRNA expression 
Next, the method for qPCR was established according to the procedure described in 
4.10. Using qPCR, it is possible to discern the expression levels of various targets at a 
much greater sensitivity than with conventional “qualitative” PCR. 
ACTB (β-actin) was used as reference gene, as it seems to be evenly expressed in 
all tissues (see Figure 20). Both MT1 and MT2 were analyzed in this experiment. 
In addition to a negative sample (no cDNA), a -RT sample (intestine RNA treated 
like the other samples, except that no reverse transcriptase was added to the reaction 
mixture) was included as well. If the observed amplifications had been due to 
amplification of genomic DNA, the -RT sample would have shown the same or similar 
CT values as the reversely transcribed samples. 
All samples, each containing 100 ng of the cDNA synthesized in 5.1.2, were 
prepared in triplicates. The mean of all CT values was calculated (CTm) and used as 
base for the following data analysis. 
 
With respect to ACTB, the experiment went well for all samples except the eye, 
where ACTB did not show any expression. This can probably be attributed to a 
preparation error. Because of this, the ΔCT values for the eye could not be calculated, 
while CT values for all other samples are shown in Table 27. 
According to the calculation, MT1 mRNA expression was found in all samples at 
varying levels, highest in brain, lowest in lung (see Figure 23), correlating quite well 
with the expression levels observed in the qualitative PCR (see Figure 21). MT2 mRNA 
expression was found in brain, kidney, testes and thymus, while the other samples did 
not exhibit amplification. The highest CT value for MT2 was found in the eye, confirming 
MT2 mRNA expression, but as noted before, no CT values can be given because of 
the failed ACTB amplification. 
It is obvious that the CTm values for all samples were very high, especially for MT2, 
indicative of rather low expression of the receptors. They also exhibit relatively high 
standard deviations (CTSd) – therefore the comparison of expression levels is to be 
interpreted with caution. The -RT and negative samples showed amplification for ACTB 
as well, indicating some trace contamination. However, the difference in expression 
levels between them and the positively reverse-transcribed samples was so high (15–
19 CT) that the contaminants’ influence on the result is negligible. For MT1 and MT2, 
the -RT and negative samples showed no amplification. 
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Table 27: ACTB (β-actin), MT1 and MT2 mRNA expression in various rat organs analyzed by RT-qPCR. 
Amplification failed for ACTB in the eye sample, therefore no ΔCT values could be calculated. The 
respective values are printed in gray. Empty cells indicate failed amplification. CTm: mean CT value from 
three repeats; CTmSd: standard deviation for CTm; ΔCTm: mean ΔCT value based on the ACTB CTm 
values as reference; ΔCTmSd: cumulative standard deviation for ΔCTm; D(ACTB): decimal difference in 
expression related to ACTB (ΔCTm converted from base 2 to base 10, assuming a linear amplification 
efficiency of 100 %); ΔΔCTm: mean ΔΔCT value for MT2 related to MT1 (difference ΔCTm for MT1 and 
MT2); ΔΔCTmSd: cumulative standard deviation for ΔΔCTm; D(MT1): decimal difference in expression 
related to MT1 (ΔΔCTm converted from base 2 to base 10, assuming a linear amplification efficiency of 
100 %), only given for MT2 expressing samples. 
Sample Target CTm CTmSd ΔCTm ΔCTmSd D(ACTB) ΔΔCTm ΔΔCTmSd D(MT1) 
Brain ACTB 17.07 0.06        
Eye ACTB            
Heart ACTB 17.10 0.74        
Intestine ACTB 15.66 0.15        
Kidney ACTB 17.11 0.06        
Lung ACTB 15.10 0.41        
Liver ACTB 18.52 0.25        
Skeletal m. ACTB 19.15 0.24        
Testes ACTB 17.39 1.32        
Thymus ACTB 17.89 0.18        
No cDNA ACTB 34.22 0.32        
-RT ACTB 34.16 0.63        
Brain MT1 31.59 0.11 14.53 0.17 4.2E-05    
Eye MT1 32.43 0.14        
Heart MT1 35.61 0.35 18.51 1.09 2.7E-06    
Intestine MT1 32.25 0.16 16.60 0.31 1.0E-05    
Kidney MT1 35.32 0.47 18.21 0.53 3.3E-06    
Lung MT1 36.65 1.09 21.55 1.50 3.3E-07    
Liver MT1 38.34   19.82   1.1E-06    
Skeletal m. MT1 36.72   17.57   5.1E-06    
Testes MT1 34.45 0.98 17.06 2.31 7.3E-06    
Thymus MT1 35.42 0.60 17.53 0.78 5.3E-06    
No cDNA MT1            
-RT MT1            
Brain MT2 34.58 0.55 17.52 0.60 5.3E-06 2.99 0.77 1.3E-01 
Eye MT2 32.79 0.10         
Heart MT2             
Intestine MT2             
Kidney MT2 38.02   20.91   5.1E-07 2.70 0.53 1.5E-01 
Lung MT2             
Liver MT2             
Skeletal m. MT2             
Testes MT2 38.16   20.77   5.6E-07 3.71 2.31 7.6E-02 
Thymus MT2 38.39 0.60 20.50 0.77 6.7E-07 2.97 1.55 1.3E-01 
No cDNA MT2             
-RT MT2             
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Figure 23: The diagram shows the mean ΔCT values of MT1 and MT2 mRNA expression in relation to 
ACTB (β-actin) mRNA expression in various rat organs as calculated from the results of RT-qPCR. The 
lines on the top of the bars indicate the respective standard deviation; the indicators are missing in case of 
only one of the three repeats succeeding. Higher bars mean less expression. The missing bars for MT2 in 
many organs indicate failed amplification. ΔCTm: mean ΔCT value based on the ACTB CTm values as 
reference. 
For those samples where amplification for MT1 and MT2 was successful the ΔΔCT 
values for MT2 related to MT1 were calculated as reference. The difference in 
expression between MT1 and MT2 ranged from 2.7 to 3.7 CT (or 0.15–0.076 converted 
to base 10, assuming a linear amplification efficiency of 100 %), indicating an about 
ten-fold difference in expression on average (see Figure 24). 
 
 
Figure 24: The diagram shows the logarithmic difference in MT2 expression in relation to MT1 from RT-
qPCR analysis of ACTB (β-actin), MT1 and MT2 mRNA expression in various rat organs. Base MT1 
expression is 1.00. D(MT1): decimal difference in expression related to MT1 (ΔΔCTm converted from base 
2 to base 10, assuming a linear amplification efficiency of 100 %). 
To summarize, methods (RT-PCR, RT-qPCR) for demonstration of MT1 and MT2 
mRNA in rat tissues had been successfully established. 
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5.2 Preparation of rat aorta samples for subsequent PCR 
experiments 
Two different groups of aortas with two subgroups each were investigated (see 4.1.2 
and 4.1.3) The two groups each served as basis for the different aims (see chapter 3) 
of the thesis. 
5.2.1 RNA isolation 
Aortas from two different time points 
The RNA was extracted and measured by photometry in two batches (batch 1: A31, 
A32, A33, A75, A76 and A77, batch 2: A34, A35, A36, A37, A38, A79, A81, A82, A83 
and A88) according to the described procedures (see 4.2 and 4.3). Because the 
amount of tissue was in some cases very small, the concentrations and total isolated 
amounts of RNA were rather low (see Table 28). Five samples were below the 
specified range for the A260 / A280 ratio (1.6–2.0; A32, A33, A75, A76 and A77). 300 ng 
RNA were used for GE (see 4.4) to prove intactness of all samples’ RNA (see Figure 
25). 
Table 28: Concentration, purity and yield of RNA extracted from rat aortas from two different time points. 
Daytime group (orange): A31–A38; nighttime group (blue): A75–A88. 
Sample Group C [ng / µL] A260 / A280 Isolated amount [µg] 
A31 Daytime 730.1 1.82 14.60 
A32 Daytime 235.1 1.56 4.70 
A33 Daytime 136.3 1.52 2.73 
A34 Daytime 295.3 1.64 5.91 
A35 Daytime 711.7 1.80 14.23 
A36 Daytime 574.0 1.89 11.48 
A37 Daytime 703.9 1.83 14.08 
A38 Daytime 361.4 1.72 7.23 
A75 Nighttime 370.9 1.52 7.42 
A76 Nighttime 159.8 1.55 3.20 
A77 Nighttime 141.9 1.55 2.84 
A79 Nighttime 324.0 1.80 6.48 
A81 Nighttime 743.6 1.83 14.87 
A82 Nighttime 299.5 1.64 5.99 
A83 Nighttime 716.2 1.76 14.32 
A88 Nighttime 623.2 1.88 12.46 
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Figure 25: Integrity control of total RNA of rat aortas from two different time points by GE. The isolated 
RNA of all samples is intact as judged by intact 28 S and 18 S rRNAs. Because the RNA was extracted 
and analyzed in two batches (see main text), their respective lanes show different saturations. Daytime 
group (orange): A31–A38; nighttime group (blue): A75–A88. 
Aortas from SHR and control rats 
The RNA was extracted and measured by photometry according to the described 
procedures (see 4.2, 4.3 and 4.4). Because the amount of tissue was in some cases 
very small, the concentrations and total isolated amounts of RNA were so low that for 
four samples (ASHR 04, ASHR 08, ACTRL 01 and ACTRL 04), too little isolated RNA 
remained for further experiments (see Table 29). Therefore, they could not be used in 
any of the subsequent procedures concerning the SHR and control aortas.  
With exception of ASHR 07, all samples that were being used for further 
experiments lay within the specified A260 / A280 range (1.6–2.0). To conserve RNA, only 
100 ng were used for GE (see 4.4), which proved intactness of all samples’ RNA (see 
Figure 26). 
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Table 29: Concentration, purity and yield of RNA extracted from aortas of SHR and control rats. For four 
samples (ASHR 04, ASHR 08, ACTRL 01 and ACTRL 04) the total isolated amount was too low for further 
analysis (see main text). The respective entries in the table are printed in gray. 
Sample Group C [ng / µL] A260 / A280 Isolated amount [µg] 
ASHR 01 SHR 99,0 1,6 1,98 
ASHR 02 SHR 257,7 1,62 5,15 
ASHR 03 SHR 95,2 1,6 1,90 
ASHR 04 SHR 17,4 1,46 0,35 
ASHR 05 SHR 175,1 1,73 3,50 
ASHR 06 SHR 53,7 1,59 1,07 
ASHR 07 SHR 47,3 1,55 0,95 
ASHR 08 SHR 3,8 1,23 0,08 
ACTRL 01 Control 39,1 1,76 0,78 
ACTRL 02 Control 164,3 1,67 3,29 
ACTRL 03 Control 253,8 1,71 5,08 
ACTRL 04 Control 39,3 1,45 0,79 
ACTRL 05 Control 160,4 1,65 3,21 
ACTRL 06 Control 83,6 1,63 1,67 
ACTRL 07 Control 184,8 1,6 3,70 
ACTRL 08 Control 157,8 1,79 3,16 
 
 
Figure 26: Integrity control of total RNA of aortas from SHR (red) and control (green) rats by GE. The 
isolated RNA of all samples was intact as judged by intact 28 S and 18 S rRNAs. 
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5.2.2 Reverse transcription 
All samples of the aortas from two different time points were reversely transcribed 
according to the described procedure (see 4.5). Reverse transcription was performed 
in two batches (see 5.2.1 for the break-up). All samples from the SHR and control rats, 
excepting those with too little isolated RNA (see 5.2.1), were reversely transcribed 
according to the described procedure (see 4.5). 
5.2.3 RT-PCR for β-actin mRNA expression 
To demonstrate the success of the RTs, 50 ng of all aorta samples or water (no cDNA) 
were tested for β-actin mRNA expression. See 4.6.2 for the general protocol and 4.6.3 
for experiment specific conditions. The experiment shows successful amplification of β-
actin mRNA in all samples (see Figure 27 and Figure 28). To make sure that the 
observed amplicons were not caused by genomic DNA (which is thought to be 
impossible since the primers are exon spanning [26]), -RT samples (A35 and ASHR 
02, respectively) were included in the experiments as well. As shown in the respective 
figures, the -RT sample exhibited no amplification. 
 
 
Figure 27: β-actin mRNA expression in rat aortas from two different time points analyzed by RT-PCR, 
confirming the success of the reverse transcription. Expected length of the PCR product was 496 bp. 
Daytime group (orange): A31–A38; nighttime group (blue): A75–A88. 
 
Figure 28: β-actin mRNA expression in aortas of SHR (red) and control (green) rats analyzed by RT-PCR, 
confirming the success of the reverse transcription. Expected length of the PCR product was 496 bp. 
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5.3 Expression of MT1 mRNA in rat aortas  
5.3.1 Aortas from two different time points 
RT-PCR for MT1 mRNA expression 
Next, aortas from different time points were examined for the presence of MT1 mRNA 
in the rat aorta and for an overview of expression levels between the two aorta groups. 
400 ng of cDNA (RNA equivalent) per sample or water (no cDNA) were subjected to 
PCR. A -RT sample (A35) was included as well. See 4.6.2 for the general protocol and 
4.6.3 for experiment specific conditions. 
 
 
Figure 29: MT1 mRNA expression in aortas from two different time points analyzed by RT-PCR. Expected 
length of the PCR product was 316 bp. Daytime group (orange): A31–A38; nighttime group (blue): A75–
A88. 
Bands of the expected length for MT1 were present in all samples but one (A32). 
Taken together, the bands in the daytime group (A31–A38) appeared less intense than 
those in the nighttime group (A75–A88). Especially A83 and A88 (both of the nighttime 
group) exhibited very strong bands (Figure 29). It has to be noted that the varying 
intensities and absences could have resulted from outside factors as well, such as 
pipetting errors, varying cDNA concentrations after RT, contaminations, etc. To 
confront these possible sources of error, a qPCR was performed at a later stage (see 
below). 
Because there were no bands present in the -RT sample, amplification of genomic 
DNA could be excluded. The blind sample exhibits no bands either, excluding 
contamination of the reagents. 
To confirm the identity of the observed bands they were cut out of the gel and 
processed for sequencing. 
Sequencing of MT1 RT-PCR-products 
To extract a sufficient amount of DNA for sequencing, the excised bands of A33, A34, 
A38, A75, A83 and A88 were pooled and the DNA was extracted and purified 
according to the described procedure (see 4.8). Concentration measurement of the 
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eluated DNA by photometry (see 4.3) revealed a concentration of 8.8 ng / µL. 5 µL of 
the eluate were analyzed using GE to determine the extracted DNA’s purity. Only a 
single band at the expected length of 316 bp was visible (not shown). The eluate was 
then sent to MWG Eurofins Operon (Ebersberg, Germany) for sequencing (see 4.9) 
together with aliquots containing 30 pmol of each primer (rat_MT1_fwd and 
rat_MT1_rev, see 4.6.3). 
MT1    169  TGGCCCTGGCTGTGCTGCGGTAAGTCACCCAGGGGACCATGAAGGGCAATGTCAGCGAGC  228 
fwd    1                                                   AATGTCAGCGAGC  13  
rev    274  TGGCCCTGGCTGTGCTGCGGTAAGTCACCCAGGGGACCATGAAGGGCAATGTCAGCGAGC  215 
 
MT1    229  TTCTCAACGCCTCTCAGCAGGCTCCAGGCGGCGGGGAGGAAATAAGATCGCGGCCGTCGT  288 
fwd    14   TTCTCAACGCCTCTCAGCAGGCTCCAGGCGGCGGGGAGGAAATAAGATCGCGGCCGTCGT  73  
rev    214  TTCTCAACGCCTCTCAGCAGGCTCCAGGCGGCGGGGAGGAAATAAGATCGCGGCCGTCGT  155 
 
MT1    289  GGCTGGCCTCTACACTGGCCTTCATCCTCATCTTTACTATCGTGGTGGACATCCTGGGCA  348 
fwd    74   GGCTGGCCTCTACACTGGCCTTCATCCTCATCTTTACTATCGTGGTGGACATCCTGGGCA  133 
rev    154  GGCTGGCCTCTACACTGGCCTTCATCCTCATCTTTACTATCGTGGTGGACATCCTGGGCA  95  
 
MT1    349  ACCTGCTGGTCATCCTGTCTGTGTATCGCAACAAGAAGCTCAGGAACGCAGGGAATATAT  408 
fwd    134  ACCTGCTGGTCATCCTGTCTGTGTATCGCAACAAGAAGCTCAGGAACGCAGGGAATATAT  193 
rev    94   ACCTGCTGGTCATCCTGTCTGTGTATCGCAACAAGAAGCTCAGGAACGCAGGGAATATAT  35  
 
MT1    409  TTGTGGTGAGTTTAGCTGTGGCAGACCTCGTGGTGGCTATTTACCCATTTCCCTTGGCGC  468 
fwd    194  TTGTGGTGAGTTTAGCTGTGGCAGACCTCGTGGTGGCTATTTACCCATTTCCCTTGGCGC  253 
rev    34   TTGTGGTGAGTTTAGCTGTGGCAGACCTCGTGGT                            1   
 
MT1    469  TGACGTCTATACTTAA  484                                             
fwd    254  TGACGTCTATACTTAA  269                                             
 
Sequencing worked well and comparison with the published sequence for the rat 
MT1 mRNA ([26], RefSeq: NM_053676.1) showed 100 % identity over a length of 315 
bp (expected: 316 bp). This result confirmed the identity of the observed amplicons as 
MT1. 
RT-qPCR for quantification of MT1 mRNA expression 
Having proven that MT1 mRNA is indeed expressed in the rat aorta, a real-time PCR 
experiment was performed to investigate the suggestion from the qualitative PCR (see 
above) that there might be a difference in expression levels between aortas collected at 
different time points. 
RT-qPCR was executed after the described method (see 4.10) using 100 ng of 
cDNA (RNA equivalent) per sample. The samples were prepared in duplicates (ACTB) 
and triplicates (MT1). A positive control (eye) from the various rat tissues already 
investigated (see 5.1.2) was also included as reference. No -RT samples were included 
Figure 30: Comparison of the sequencing results from the MT1 RT-PCR products and the published 
sequence for MT1 mRNA (RefSeq: NM_053676.1). Combined length of the sequencing results of both 
primers: 315 bp. E-values: fwd = 6E-145, rev = 1E-147; fwd: rat_MT1_fwd; rev: rat_MT1_rev. 
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because the previous RT-qPCR experiment (see 5.1.3) had already proven that the 
assays are specific for cDNA. 
The blind samples were clean for MT1, but showed an expression of ACTB at very 
high CT levels. However, the difference in expression levels in comparison was so big 
that the contamination did not affect analysis of the data (see Table 30). 
Table 30: ACTB (β-actin), MT1 and MT2 mRNA expression in rat aortas from two different time points and 
rat eye as positive control analyzed by RT-qPCR. Empty cells indicate failed amplification. CTm: mean CT 
value from two (ACTB) or three (MT1) repeats; CTmSd: standard deviation for CTm; ΔCTm: mean ΔCT 
value based on the ACTB CTm values as reference; ΔCTmSd: cumulative standard deviation for ΔCTm; 
D(ACTB): decimal difference in expression related to ACTB (ΔCTm converted from base 2 to base 10, 
assuming a linear amplification efficiency of 100 %); ΔΔCTm: mean ΔΔCT value for MT1 related to eye as 
positive control (difference ΔCTm for MT1 in the aortas and MT1 in the eye); ΔΔCTmSd: cumulative 
standard deviation for ΔΔCTm; D(Eye): decimal difference in expression related to MT1 expression in the 
eye (ΔΔCTm converted from base 2 to base 10, assuming a linear amplification efficiency of 100 %). 
Sample Target CTm CTmSd ΔCTm ΔCTmSd D(ACTB) ΔΔCTm ΔΔCTmSd D(Eye) 
A31 ACTB 15.951 0.055       
A32 ACTB 15.733 0.064       
A33 ACTB 14.770 0.059       
A34 ACTB 15.582 0.004       
A35 ACTB 16.708 0.120       
A36 ACTB 15.736 0.022       
A37 ACTB 15.897 0.075       
A38 ACTB 14.878 0.072       
A75 ACTB 15.414 0.001       
A76 ACTB 15.048 0.085       
A77 ACTB 15.094 0.029       
A79 ACTB 16.617 0.070       
A81 ACTB 16.294 0.169       
A82 ACTB 15.692 0.008       
A83 ACTB 15.749 0.000       
A88 ACTB 15.730 0.000       
E2 ACTB 15.967 0.036       
No cDNA ACTB 32.387 0.371       
A31 MT1 36.960 0.716 21.008 0.771 4.7E-07 4.953 1.015 3.2E-02 
A32 MT1 38.158 0.096 22.425 0.160 1.8E-07 6.370 0.404 1.2E-02 
A33 MT1 37.477 0.162 22.707 0.221 1.5E-07 6.651 0.465 1.0E-02 
A34 MT1 36.753 1.287 21.171 1.290 4.2E-07 5.116 1.534 2.9E-02 
A35 MT1 37.739 1.238 21.031 1.358 4.7E-07 4.975 1.602 3.2E-02 
A36 MT1 38.352 0.132 22.616 0.154 1.6E-07 6.560 0.397 1.1E-02 
A37 MT1 37.010 0.412 21.113 0.487 4.4E-07 5.058 0.731 3.0E-02 
A38 MT1 37.537 0.824 22.659 0.896 1.5E-07 6.604 1.140 1.0E-02 
A75 MT1 37.200 1.831 21.786 1.832 2.8E-07 5.730 2.076 1.9E-02 
A76 MT1 37.133 0.933 22.086 1.018 2.2E-07 6.030 1.261 1.5E-02 
A77 MT1 38.052 1.076 22.957 1.104 1.2E-07 6.902 1.348 8.4E-03 
A79 MT1 38.180  21.564  3.2E-07 5.508 0.244 2.2E-02 
A81 MT1 38.175 0.637 21.882 0.805 2.6E-07 5.826 1.049 1.8E-02 
A82 MT1 36.914 0.614 21.222 0.622 4.1E-07 5.167 0.865 2.8E-02 
A83 MT1 37.054 0.984 21.304 0.984 3.9E-07 5.249 1.228 2.6E-02 
A88 MT1 35.752    9.4E-07 3.967 0.501 6.4E-02 
E2 MT1 32.023    1.5E-05    
No cDNA MT1         
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Calculated (see 4.10) decimal differences between MT1 expression in the eye and 
the samples can be seen in Figure 31. All aorta samples showed expression of MT1, 
the amount of expression varying strongly between the individual samples. The same 
observation had been made before in the course of the qualitative PCR. However, the 
individual discerned MT1 expression levels of the aortas did not correlate with the 
results from the qualitative PCR. The positive control (eye) showed the highest 
expression of MT1, which is again congruent with the results from the qualitative PCR 
(see above). As in the previous qPCR experiment, the CT values for MT1 in the aortas 
were very high (35–38), indicating low expression of MT1 mRNA. 
 
 
Figure 31: Diagram showing the logarithmic difference in MT1 mRNA expression in the aortas from two 
different time points in relation to MT1 mRNA expression in the eye. Base MT1 expression of the eye is 
1.00. The lines on the lower ends of the bars indicate the respective standard deviations. Lower reaching 
bars mean less expression. Groups: bars of samples belonging to the daylight group are printed in orange, 
bars of samples belonging to the nighttime group are printed in blue; D(Eye): decimal difference in 
expression related to MT1 in the eye (ΔΔCTm converted from base 2 to base 10, assuming a linear 
amplification efficiency of 100 %). 
Analysis of the mean expression levels shows a tiny elevation in MT1 mRNA 
expression in the nighttime group compared to the daytime group of CTm 21.60 (Sd 
0.82) vs 21.84 (Sd 0.84). See Figure 32 for a graphical representation. As a trend, this 
is indeed what was observed in the qualitative PCR, but the difference is minute and 
the standard deviations of the means are many times bigger. 
 
0.001
0.010
0.100
1.000
A31 A32 A33 A34 A35 A36 A37 A38 A75 A76 A77 A79 A81 A82 A83 A88 Eye
lo
g
 D
(E
y
e
)
5 Results 
90 
 
Figure 32: Diagram showing the mean ΔCTm values of the aortas from the two investigated time points. 
The lines on top of the bars indicate the respective standard deviations. ΔCTm: mean ΔCT value based on 
the ACTB CTm values as reference. 
In summary, MT1 mRNA is expressed in the rat aorta; however, there is no 
significant difference in expression levels between aortas from animals sacrificed at 
daytime or nighttime. 
5.3.2 Aortas from SHR and control rats 
RT-PCR for MT1 mRNA expression 
The experiments with the rat aortas from different time points had already established 
that MT1 is present in the rat aorta, and there was no significant difference in MT1 
mRNA expression found in the aorta that depends on the diurnal phase state. The 
remaining question was whether MT1 mRNA expression is different between 
hypertensive and normotensive rats. To investigate this issue, an RT-PCR was 
performed for MT1 mRNA expression in the SHR and control rat aortas. 
As the RNA yield from these samples was very low (see Table 29), only a small 
amount of cDNA was available for experiments. Therefore, 200 ng cDNA (RNA 
equivalent) per sample or water (no cDNA) were subjected to PCR. A -RT sample 
(ASHR 02) was included as well. See 4.6.2 for the general protocol and 4.6.3 for 
experiment specific conditions. 
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The majority of bands in the SHR group was much stronger than the bands in the 
control group (see Figure 33). Amplification succeeded in all SHR samples, with a 
particularly strong band for the ASHR 05 sample, but failed in ACTRL 06 and ACTRL 
07. These findings were confirmed by a repeat of the experiment, which yielded the 
same results (not shown). The variations in expression levels concur with the findings 
from the aortas from two different time points (see 5.3) and emphasize the possibility of 
interindividual differences in MT1 expression levels. This could also explain the 
observed difference in MT1 and MT2 mRNA expression between our experiment with 
various rat organs (see 5.1.2) and the experiment by Ishii et al. [26]. To further 
investigate this difference in mRNA expression between SHR and control rats, a qPCR 
was performed next. 
 
 
Figure 33: RT-PCR analysis of MT1 mRNA expression in aortas from SHR and control rats. Expected 
length: 316 bp. 
RT-qPCR for MT1 mRNA expression in aortas 
RT-qPCR was executed after the described method (see 4.10) using only 50 ng of 
cDNA (RNA equivalent), because of the very low yield of the RNA extraction already 
discussed.  
All samples were prepared in triplicates. A positive control (brain) from the various 
rat aortas already investigated (5.1.2) was used as reference. Also, -RT samples were 
included from both the SHR (ASHR 02) and control group (ACTRL 03).  
5 Results 
92 
Table 31: ACTB (β-actin), MT1 and MT2 mRNA expression in aortas from SHR and control rats and rat 
brain as positive control analyzed by RT-qPCR. Empty cells indicate failed amplification. CTm: mean CT 
value from three repeats; CTmSd: standard deviation for CTm; ΔCTm: mean ΔCT value based on the 
ACTB CTm values as reference; ΔCTmSd: cumulative standard deviation for ΔCTm; D(ACTB): decimal 
difference in expression related to ACTB (ΔCTm converted from base 2 to base 10, assuming a linear 
amplification efficiency of 100 %); ΔΔCTm: mean ΔΔCT value for MT1 related to brain as positive control 
(difference ΔCTm for MT1 in the aortas and MT1 in the brain); ΔΔCTmSd: cumulative standard deviation 
for ΔΔCTm; D(Brain): decimal difference in expression related to MT1 expression in the brain (ΔΔCTm 
converted from base 2 to base 10, assuming a linear amplification efficiency of 100 %). 
Sample Target CTm CTmSd ΔCTm ΔCTmSd D(ACTB) ΔΔCTm ΔΔCTmSd D(Brain) 
ACTRL02 ACTB 16.751 16.815 0.148      
ACTRL03 ACTB 16.180 16.061 0.103      
ACTRL05 ACTB 16.203 16.187 0.043      
ACTRL06 ACTB 16.271 16.112 0.152      
ACTRL07 ACTB 16.941 16.683 0.274      
ACTRL08 ACTB 16.610 16.411 0.319      
ASHR01 ACTB 17.283 17.277 0.060      
ASHR02 ACTB 16.671 16.718 0.068      
ASHR03 ACTB 17.038 16.954 0.075      
ASHR05 ACTB 17.298 16.906 0.420      
ASHR06 ACTB 17.090 17.163 0.064      
ASHR07 ACTB 16.810 16.860 0.098      
B2 ACTB 18.931 18.888 0.052      
Blind ACTB  38.639       
-RTCTRL ACTB 35.899 35.687 1.161      
-RTSHR ACTB 32.776 32.862 0.076      
ACTRL 02 MT1 37.745 37.255 0.692 20.440 0.840 7.0E-07 7.302 1.456 
ACTRL 03 MT1 38.611 38.611  22.549  1.6E-07 9.411 0.616 
ACTRL 05 MT1 36.731 37.619 1.255 21.432 1.298 3.5E-07 8.293 1.915 
ACTRL 06 MT1 39.039 39.039  22.927  1.3E-07 9.789 0.616 
ACTRL 07 MT1 38.961 38.961  22.278  2.0E-07 9.140 0.616 
ACTRL 08 MT1 38.179 37.371 1.143 20.959 1.463 4.9E-07 7.821 2.079 
ASHR 01 MT1 36.889 37.144 0.221 19.867 0.281 1.0E-06 6.729 0.897 
ASHR 02 MT1 36.835 36.496 0.331 19.778 0.399 1.1E-06 6.640 1.015 
ASHR 03 MT1 36.552 37.014 0.711 20.060 0.786 9.1E-07 6.922 1.402 
ASHR 05 MT1 35.862 34.589 1.473 17.682 1.893 4.8E-06 4.544 2.509 
ASHR 06 MT1 38.928 38.247 1.257 21.084 1.321 4.5E-07 7.946 1.937 
ASHR 07 MT1 37.540 36.944 0.600 20.084 0.698 9.0E-07 6.946 1.315 
Brain MT1 31.650 32.026 0.565 13.138 0.616 1.1E-04   
No cDNA MT1         
-RTCTRL MT1         
-RTSHR MT1         
 
Like in the other RT-qPCR experiments (see 5.1.3 and 5.3.1), a signal for ACTB 
occurred even in the blind and -RT samples, although again at much higher CT values 
(35–38 versus 16–17 in the positive groups), which means the contamination will not 
affect analysis of the data. No signal was detected for MT1 in the -RT and blind 
samples (see Table 31). 
The control samples exhibited generally higher ΔCT values than the SHR samples. 
The biggest difference is evident between the aorta samples and the brain sample, 
where the concentration of mRNA is several orders of magnitude higher. Calculated 
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(see 4.10) decimal differences between MT1 expression in the eye and the samples 
can be seen in Figure 34. The band intensity observed in the qualitative RT-PCR 
correlates nicely with data from the RT-qPCR (see above). 
 
 
Figure 34: The diagram shows the logarithmic difference in MT1 mRNA expression in the aortas of SHR 
and control rats in relation to MT1 mRNA expression in the eye. Base MT1 expression of the eye is 1.00. 
The lines on the bottom ends of the bars indicate the respective standard deviations. Lower reaching bars 
mean less expression. Groups: bars of samples belonging to the control group printed in green, bars of 
samples belonging to the SHR group are printed in red; D(Eye): decimal difference in expression related to 
MT1 in the brain (ΔΔCTm converted from base 2 to base 10, assuming a linear amplification efficiency of 
100 %). 
Analysis of the mean MT1 mRNA expression levels showed a distinct elevation in 
MT1 mRNA expression in the SHR group compared to the control group of CTm 19.76 
(Sd 1.12) vs 21.76 (Sd 0.97). A graphical representation can be seen in Figure 35. 
Also, the observed mean expression level and standard deviation of the control group 
are comparable with the observed mean expression levels and standard deviations for 
the aortas from two different time points (control vs nighttime vs daytime): CTm 21.76 
(Sd 0.97) vs 21.60 (Sd 0.82) vs 21.84 (Sd 0.84). 
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Figure 35: The diagram shows the mean ΔCTm values of the aortas from the two investigated time points. 
The lines on top of the bars indicate the respective standard deviations. ΔCTm: mean ΔCT value based on 
the ACTB CTm values as reference. 
By calculating the ΔΔCT values for the two groups and conversion to the decimal 
system (see 4.10), the mean difference between the SHR and control rats turned out to 
be about four-fold (4.01). However, the standard deviation is very high (4.19, relative 
standard deviation 104 %). Nevertheless, taking the standard deviation into account, 
the difference in expression ranges from about zero- to eight-fold. This means that the 
expression of mRNA in aortas of SHR is zero to eight times higher than in 
normotensive rats (see Figure 36). A RT-qPCR experiment with a bigger number of 
samples would probably show the difference in mRNA expression to a greater extent. 
It should also be noted that the amplification succeeded in all of the SHR samples’ 
replicates, but not in all replicates of the control samples (18 SHR vs 9 controls). This 
fact can also be attributed to the observed difference in expression levels: because the 
levels of mRNA in the control rats’ aortas are lower than in the SHR’s aortas, 
amplification might easily fail, since the observed CT values are already extremely high 
(CT 36–39; see Table 31). 
 
 
Figure 36: The diagram shows the n-fold expression of MT1 mRNA in SHR aortas compared to control 
aortas. 
In conclusion, we proved significantly higher expression of MT1 mRNA in SHR 
compared to control rat aortas. 
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5.4 Expression of MT2 mRNA in rat aortas 
5.4.1 RT-PCR for MT2 mRNA expression according to the 
established method 
The first RT-PCR experiment concerning MT2 mRNA expression in the aorta was 
performed on the aortas from two different time points (see 4.1.2.) according to the 
method by Ishii et al. [26] modified as described in 5.1.2. 400 ng of cDNA (RNA 
equivalent) per sample or water (no cDNA) were subjected to PCR. A negative sample 
(no cDNA), a -RT sample (A35) and a positive control (brain) were also included in the 
experiment. See 4.6.2 for the general protocol and 4.6.3 for experiment specific 
conditions.  
In the positive control (brain), amplification succeeded and yielded a very strong 
and distinctive band at the expected length. Under close inspection, bands at the 
expected length of 396 bp seemed also to be present in some of the aorta samples 
(A32, A38 and A77). However, bands of other lengths were present too, some of them 
much stronger (A38) than the alleged MT2 bands (see Figure 37). The experiment was 
repeated with similar results (not shown). 
 
 
Figure 37 : MT2 mRNA expression in aortas from two different time points analyzed by RT-PCR. Expected 
length of the PCR product was 390 bp. Daytime group (orange): A31–A38; nighttime group (blue): A75–
A88. 
The bands from the brain sample were excised from the gel and processed for 
sequencing according to 5.4.2. 
5.4.2 Sequencing of the MT2 PCR product from the brain sample 
The DNA from the gel slices was extracted and purified according to the described 
procedure (see 4.8). Concentration measurement of the eluated DNA by photometry 
(see 4.3) revealed a concentration of 5.2 ng / µL. 5 µL of the eluate were analyzed 
using GE to determine the extracted DNA’s purity. Only a singular band at the 
expected length of 390 bp was visible (not shown). The eluate was then sent to MWG 
Eurofins Operon (Ebersberg, Germany) for sequencing (see 4.9) together with aliquots 
containing 30 pmol of each primer (rat_MT2_fwd and rat_MT2_rev, see 4.6.3). 
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MT2    60   GGAGCGCCCCCAAGCAGTGCACACCTTGCGCATCTATCCCGGGCTGCAGCGTCACCATGC  119 
fwd    1                                      TAT-CCGGGCTGCAGCGTCACCATGC  25  
rev    349  GGAGCGCCCCCAAGCAGTGCACACCTTGCGCATCTATCCCGGGCTGCAGCGTCACCATGC  290 
 
MT2    120  CTGACAACAGCTCCATCGCCAACTGCTGTGCGGCCAGCGGGCTGGCAGCGCGCCCTAGTT  179 
fwd    26   CTGACAACAGCTCCATCGCCAACTGCTGTGCGGCCAGCGGGCTGGCAGCGCGCCCTAGTT  85  
rev    289  CTGACAACAGCTCCATCGCCAACTGCTGTGCGGCCAGCGGGCTGGCAGCGCGCCCTAGTT  230 
 
MT2    180  GGCCCGGGTCAGCGGAGGCGGAGCCCCCTGAGACTCCCCGGGCACCCTGGGTGGCTCCCA  239 
fwd    86   GGCCCGGGTCAGCGGAGGCGGAGCCCCCTGAGACTCCCCGGGCACCCTGGGTGGCTCCCA  145 
rev    229  GGCCCGGGTCAGCGGAGGCGGAGCCCCCTGAGACTCCCCGGGCACCCTGGGTGGCTCCCA  170 
 
MT2    240  TGCTATCTACAGTAGTCATTGTCACCACAGCTGTGGACTTCGTGGGGAACCTGCTTGTGA  299 
fwd    146  TGCTATCTACAGTAGTCATTGTCACCACAGCTGTGGACTTCGTGGGGAACCTGCTTGTGA  205 
rev    169  TGCTATCTACAGTAGTCATTGTCACCACAGCTGTGGACTTCGTGGGGAACCTGCTTGTGA  110 
 
MT2    300  TCCTCTCGGTGCTCAGGAACCGCAAGCTGCGGAACGCAGGTAATTTATTTGTGGTGAATC  359 
fwd    206  TCCTCTCGGTGCTCAGGAACCGCAAGCTGCGGAACGCAGGTAATTTATTTGTGGTGAATC  265 
rev    109  TCCTCTCGGTGCTCAGGAACCGCAAGCTGCGGAACGCAGGTAATTTATTTGTGGTGAATC  50  
 
MT2    360  TGGCCTTGGCTGACCTGGTGGTAGCCCTGTACCCTTACCCACTCATCCTTGTGGCCATTC  419 
fwd    266  TGGCCTTGGCTGACCTGGTGGTAGCCCTGTACCCTTACCCACTCATCCTTGTGGCCATTC  325 
rev    49   TGGCCTTGGCTGACCTGGTGGTAGCCCTGTACCCT-ACCCACTCATCCT             2   
 
MT2    420  TCCATGACGGTTGGGTACTTGGGGAGATCCA  450                              
fwd    326  TCCATGACGGTTGGGTACTTGGGGAGATCCA  356                              
Figure 38: Comparison of the sequencing results from the MT2 RT-PCR products of the brain sample and 
the published sequence for MT2 mRNA ([26], RefSeq: NM_001100641.1). Combined length of the 
sequencing results of both primers: 390 bp. E-values: fwd = 0.0, rev = 0.0; fwd: rat_MT2_fwd; rev: 
rat_MT2_rev. 
Sequencing worked well and comparison with the published sequence for the rat 
MT2 mRNA ([26], RefSeq: NM_001100641.1) showed 99 % identity over a length of 
390 bp (expected: 390 bp). This result confirmed the identity of the observed amplicons 
in the brain sample as MT2 and proved that the PCR method by Ishii et al. (2009) 
worked to detect MT2 mRNA. 
5.4.3 Search for and selection of alternative PCR protocols 
Because of the unsatisfactory results with the Ishii primers with regard to MT2 in the 
aorta (sequencing proved its efficacy for the brain sample; 5.4.2), a search in the 
literature for other primers for rat MT2 was performed. The published sequence of MT2 
([26], RefSeq: NM_001100641.1) was used to compare the positions of the varying 
primer pairs. See Table 32 for the results of the search. 
Table 32: Primer pairs for rat MT2 available in the literature. The primers published in the respective 
papers are highlighted in the same way as the corresponding sequence in the drawing of the sequence 
further below. For the reverse primers, the corresponding reverse complements are denoted in brackets. 
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Source  Sequence Product Notes 
Ishii et 
al. [26] 
fwd. 5’-GGAGCGCCCCCAAGCAGTG-3’ 
316 bp  
rev. 
5’-GGATCTCCCCAAGTACCCAACCGTCAT-3’ 
  (ATGACGGTTGGGTACTTGGGGAGATCC) 
Sallinen 
et al. [35] 
fwd. 5’-ATGTTCGCAGTGTTTGTGGTTT-3’ 
65 bp 
for qPCR, 
equiv. to [159] 
and [160] rev. 
5’-ACTGCAAGGCCAATACAGTTGA-3’ 
  (TCAACTGTATTGGCCTTGCAGT) 
Sugden 
et al. [34] 
fwd. 5’-ATCTGTCACAGTGCGACCTACC-3’ 
292 bp 
“outer” primers 
of a nested 
PCR rev. 
5’-TTCTCTCAGCCTTTGCCTTC-3’ 
  (GAAGGCAAAGGCTGAGAGAA) 
Sugden 
et al. [34] 
fwd. 5’-AGCCTCATCTGGCTTCTCAC-3’ 
154 bp 
“inner” primers 
of a nested 
PCR rev. 
5’-TTGGAAGGAGGAAGTGGATG-3’ 
  (CATCCACTTCCTCCTTCCAA) 
Masana 
et al. [36] 
fwd. 5’-CCCTCTACATCAGCCTCA-3’ 
264 bp  
rev. 
5’-CACTGGGTCTCAGGCGTA-3’ 
  (TACGCCTGAGACCCAGTG) 
 
CCTCTTGGTCCCTCCCCACAGCCTCTTCTTAGCACTTGCTGGGCGGGGAGGGGACAGCGGGAGCGCCCCCAAGCAGTG
CACACCTTGCGCATCTATCCCGGGCTGCAGCGTCACCATGCCTGACAACAGCTCCATCGCCAACTGCTGTGCGGCCAG
CGGGCTGGCAGCGCGCCCTAGTTGGCCCGGGTCAGCGGAGGCGGAGCCCCCTGAGACTCCCCGGGCACCCTGGGTGGC
TCCCATGCTATCTACAGTAGTCATTGTCACCACAGCTGTGGACTTCGTGGGGAACCTGCTTGTGATCCTCTCGGTGCT
CAGGAACCGCAAGCTGCGGAACGCAGGTAATTTATTTGTGGTGAATCTGGCCTTGGCTGACCTGGTGGTAGCCCTGTA
CCCTTACCCACTCATCCTTGTGGCCATTCTCCATGACGGTTGGGTACTTGGGGAGATCCACTGTAAGGCCAGTGCCTT
TGTGATGGGCCTGAGTGTCATTGGCTCTGTCTTCAACATCACAGCCATTGCCATCAACCGCTACTGGTGCATCTGTCA
CAGTGCGACCTACCACCGAGCCTGCAGTCAGTGGCATGCTCCCCTCTACATCAGCCTCATCTGGCTTCTCACTCTGGT
GGCCTTGGTGCCCAATTTCTTTGTGGGGTCTCTAGAATATGACCCGCGAATCTATTCCTGCACCTTCATCCAGACAGC
CAGCACCCAATACACTATGGCTGTGGTGGCCATCCACTTCCTCCTTCCAATTGCTGTGGTGTCCTTTTGCTACCTGCG
AATATGGATACTGGTGCTCCAGGCCCGAAGGAAGGCAAAGGCTGAGAGAAAGCTACGCCTGAGACCCAGTGACCTGCG
CAGTTTCCTAACCATGTTCGCAGTGTTTGTGGTTTTCGCCATATGCTGGGCCCCCCTCAACTGTATTGGCCTTGCAGT
GGCCATCAATCCAGAGGCAATGGCTCTTCAGATCCCAGAAGGGCTTTTTGTCACCAGTTACTTCCTAGCTTACTTCAA
CAGCTGCCTTAATGCTATTGTTTATGGGCTTCTGAACCAGAACTTCCGCAGGGAGTACAAGAGGATCCTCTCGGCCCT
CTGGAGCACTGGGCGCTGCTTCCATGATGCTTCCAAATGCCACCTGACTGAGGATTTGCAGGGCCCAGTGCCACCTGC
TGCCATGGCCACCATACCTGTCCAGGAAGGTGCTCTCTAGCCTGCATCAGCTCGTGGACCTAGCAGCAAACCTGTGAA
ATGAGCAGAACGGAATTGCTGTCAGTGCTGTTCAATTACTTGCTCACACTGCAGCCCACAACTGGTGAACTCAAGTGA
CCACAGGGACAAACCTGCAGACACTCCTAATGGCAAACTGGGCACTGGATTCCAATTGGCTGGGACAGAAGTCAAGCT
GTACTCATAAGATGTCATTTTCCCTGCCACCTTGACCTGTTACTGAATGTTGCCTCTTCCTTGAAGGGCCAGGGGAAA
AAGATCTCTTGATTACCTGAGCCGAAAGATCAAAATCTGCAGTGTTGAAGTGAGACTTCGTTCCTATGGAAGGAGAAG
TAACCTACATCTACACTCATCGAACAGCCACTGTAACCCAGAAATCGCAGTTCTGAGAGTTCAGCAATAAGATCGAAG
TCAAGATCTCACTGACTTACGTGCACTCCCATGTCTGTGATGATACTGCTCAAAATGGCCCAGATGTGAAAACATCTG
TTGTATTCAAATGTTCTGATACCCCTTGGCACTTAGATGAATTTCAAGTGCTGGTTCCATTCTTAGCATTTTGGGTAA
AATGCTGTGGGTCAAAGTGGCTGCTTGATTTCAGTCCAACAAAAGTGTTGATACTCCAACCCCC 
Figure 39: Sequence of rat MT2, showing the position of various primer pairs. Exon 1 is printed in blue, 
exon 2 is printed in bordeaux, exon 3 is printed in dark green. See Table 32 for highlight color mapping. 
The underlined portion is part of two overlapping primers (Sequence: modified after [26], 
NM_001100641.1). 
Except for the primers designed by Ishii et al. [26], all primer pairs are located 
exclusively in exon 2 (see Figure 39). This is problematic because not only reversely 
transcribed mRNA, but also traces of genomic DNA in the samples will be amplified in 
the course of the PCR. However, two primer pairs (outer and inner) used by Sugden et 
al. [34] were selected for further investigation of MT2 mRNA expression, because a 
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nested PCR provides a method of amplifying very weak products with high specificity 
(see 4.6.1). 
5.4.4 RT-PCR for MT2 mRNA expression according to the Sugden-
protocol 
A PCR experiment using the selected primers from Sugden et al. [34] was set up. To 
conserve cDNA of the aorta samples, the cDNA from the various rat organs (see 5.1.2) 
was used to test the new primers. 400 ng of cDNA (RNA equivalent) per sample or 
water (no cDNA) were subjected to PCR. A -RT sample (intestine) was included as 
well. See 4.6.2 for the general protocol and 4.6.3 for experiment specific conditions. 
Unfortunately, all samples exhibited strong bands at the expected length of 292 bp. 
in addition to other bands of varying lengths appearing in many samples, the -RT 
sample exhibited a band of similar strength as did the rest of the samples at the 
expected length (Figure 40). This proved that the intra-exon primers from Sugden et al. 
[34] amplified traces of genomic DNA left after the RNA extraction procedure. Also, 
when compared with the results gained by usage of the method and primers by Ishii et 
al. [26] (see 5.4.1), the ubiquitous presence of very strong bands, with almost no 
difference between the samples, seemed rather improbable. 
 
 
Figure 40: MT2 mRNA expression in various rat organs analyzed by RT-PCR according to Sugden et al. 
[34]. Expected length of the PCR product was 390 bp. 
The nested PCR was performed nevertheless with 1 µL PCR product from the 
outer PCR to test the primers for function. It produced bands of high intensity in all 
samples at the expected length of 154 bp (not shown). 
To address the problem of genomic contamination in the extracted RNA, DNAse 
treatment was performed according to the described method (see 4.7). DNAse 
digestion should degrade DNA contaminations in the samples of extracted RNA, 
leaving the RNA intact. After the procedure was completed, the RNA was reversely 
transcribed following the described method (see 4.5). After DNAse treatment, 
amplification using the intra-exon Sugden primers would be expected to happen only in 
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samples containing cDNA (and not genomic DNA) for MT2, thus providing evidence for 
MT2 receptor expression in the respective samples. -RT samples of all DNAse treated 
RNA samples were prepared as well to check if DNAse treatment was successful. 
The method was used on RNA samples of brain and eye from the various rat 
organs gained in 5.1.1., and aliquots of the aorta samples from two different time points 
(see 5.2) with the highest particular total amount of isolated RNA (A35, A36, A37, A81, 
A83 and A88). 
Intactness of the cDNA after reverse transcription was checked via a PCR for  
β-actin according to the established method (see 5.1.2) and proved that the RT worked 
and DNAse treatment did not result in RNA degradation, as correct amplification 
occurred in all samples (data not shown). 
The following PCR experiments for MT2 in the eye and liver according to the 
method after Sugden et al. [34] indicated, however, that some of the reaction 
components were contaminated, because amplification occurred also in the negative 
controls with no cDNA (data not shown). After a series of experiments (data not 
shown), the outer primers of the nested PCR were identified as the source of the 
contamination. Therefore, only the inner primers were used for the following PCR for 
MT2 mRNA expression in the rat aortas. 
In this experiment, six DNAse treated aorta samples from the aortas of two 
different time points were used in a PCR experiment with the inner Sugden primers 
only. The experiment was immediately done with the more “valuable” aorta samples 
instead of the samples from the rat organs, to minimize the risk of another 
contamination. The cycles for this inner PCR had to be changed from 20 to 40 to 
account for the reduced amount of template (because of the lack of a preceding outer 
PCR). A positive control sample (eye), as well as -RT samples of all investigated 
samples were included in the reaction setup. 400 ng cDNA or water (no cDNA) were 
subjected to the PCR reaction. See 4.6.2 for the general protocol and 4.6.3 for 
experiment specific conditions.  
The reaction went well and distinctive bands of the expected length of 154 bp were 
visible in all samples. The blind sample showed no bands, indicating that no 
contamination had occurred. However, all -RT controls still exhibited bands of 154 bp 
length as well, albeit of smaller intensity than their respective +RT counterpart (see 
Figure 41). Also, the bands from the aorta samples were as strong as the band from 
the eye sample, which seemed rather unlikely after the results for MT1 (see 5.3.1). 
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Figure 41: MT2 mRNA expression in rat aortas from two different time points and rat eye as positive 
control analyzed by RT-PCR according to Sugden et al. [34] using the protocol for the inner PCR only. 
Expected length of the PCR product was 154 bp. Daytime group (orange): A35–A37; nighttime group 
(blue): A81–A88. 
These results suggest that DNAse treatment does not work efficiently enough for 
total degradation of genomic DNA in the samples. Therefore, no further experiments 
were conducted using this method. 
5.4.5 Design of new exon spanning primers for MT2 
Based on the described results, new sets of exon spanning primers were designed 
following standard guidelines for primer design [161] using the primer design software 
tool of the National Center for Biotechnology Information [162]. The published 
sequence of MT2 ([26], RefSeq: NM_001100641.1) was used to compare the positions 
of the varying primer pairs (see Figure 42). From a wide selection of possible 
candidates (not shown), the primer pairs MS1_rMT2 and MS2_rMT2 (see 4.6.3 and 
Table 33) were chosen and custom-synthesized by MWG Eurofins Operon (Ebersberg, 
Germany).  
Table 33: Self-designed primer pairs for rat MT2 (MS1_rMT2 and MS2_rMT2) and the Ishii primers for 
comparison (rat_MT2). MS1_rMT2 rev. and MS2_rMT2 rev. are identical. The primers are highlighted in 
the same way as the corresponding sequence in the schematic of the sequence (Figure 42). For the 
reverse primers, the corresponding reverse complements are denoted in brackets. 
Name  Sequence Tm [° C] Product 
rat_MT2 
fwd 5’-GGAGCGCCCCCAAGCAGTG-3’ 65.3 
390 bp 
rev 
5’-GGATCTCCCCAAGTACCCAACCGTCAT-3’ 
  (ATGACGGTTGGGTACTTGGGGAGATCC) 
68.0 
MS1_rMT2 
fwd 5’-TAGCACTTGCTGGGCGGGGA-3’ 60.1 
540 bp 
rev 
5’-AGGCTCGGTGGTAGGTCGCA-3’ 
  (TGCGACCTACCACCGAGCCT) 
59.7 
MS2_rMT2 
fwd 5’-GCGCATCTATCCCGGGCTGC-3’ 60.3 
483 bp 
rev 
5’-AGGCTCGGTGGTAGGTCGCA-3’ 
  (TGCGACCTACCACCGAGCCT) 
59.6 
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CCTCTTGGTCCCTCCCCACAGCCTCTTCTTAGCACTTGCTGGGCGGGGAGGGGACAGCGGGAGCGCCCCCAAGCAGTG
CACACCTTGCGCATCTATCCCGGGCTGCAGCGTCACCATGCCTGACAACAGCTCCATCGCCAACTGCTGTGCGGCCAG
CGGGCTGGCAGCGCGCCCTAGTTGGCCCGGGTCAGCGGAGGCGGAGCCCCCTGAGACTCCCCGGGCACCCTGGGTGGC
TCCCATGCTATCTACAGTAGTCATTGTCACCACAGCTGTGGACTTCGTGGGGAACCTGCTTGTGATCCTCTCGGTGCT
CAGGAACCGCAAGCTGCGGAACGCAGGTAATTTATTTGTGGTGAATCTGGCCTTGGCTGACCTGGTGGTAGCCCTGTA
CCCTTACCCACTCATCCTTGTGGCCATTCTCCATGACGGTTGGGTACTTGGGGAGATCCACTGTAAGGCCAGTGCCTT
TGTGATGGGCCTGAGTGTCATTGGCTCTGTCTTCAACATCACAGCCATTGCCATCAACCGCTACTGGTGCATCTGTCA
CAGTGCGACCTACCACCGAGCCTGCAGTCAGTGGCATGCTCCCCTCTACATCAGCCTCATCTGGCTTCTCACTCTGGT
GGCCTTGGTGCCCAATTTCTTTGTGGGGTCTCTAGAATATGACCCGCGAATCTATTCCTGCACCTTCATCCAGACAGC
CAGCACCCAATACACTATGGCTGTGGTGGCCATCCACTTCCTCCTTCCAATTGCTGTGGTGTCCTTTTGCTACCTGCG
AATATGGATACTGGTGCTCCAGGCCCGAAGGAAGGCAAAGGCTGAGAGAAAGCTACGCCTGAGACCCAGTGACCTGCG
CAGTTTCCTAACCATGTTCGCAGTGTTTGTGGTTTTCGCCATATGCTGGGCCCCCCTCAACTGTATTGGCCTTGCAGT
GGCCATCAATCCAGAGGCAATGGCTCTTCAGATCCCAGAAGGGCTTTTTGTCACCAGTTACTTCCTAGCTTACTTCAA
CAGCTGCCTTAATGCTATTGTTTATGGGCTTCTGAACCAGAACTTCCGCAGGGAGTACAAGAGGATCCTCTCGGCCCT
CTGGAGCACTGGGCGCTGCTTCCATGATGCTTCCAAATGCCACCTGACTGAGGATTTGCAGGGCCCAGTGCCACCTGC
TGCCATGGCCACCATACCTGTCCAGGAAGGTGCTCTCTAGCCTGCATCAGCTCGTGGACCTAGCAGCAAACCTGTGAA
ATGAGCAGAACGGAATTGCTGTCAGTGCTGTTCAATTACTTGCTCACACTGCAGCCCACAACTGGTGAACTCAAGTGA
CCACAGGGACAAACCTGCAGACACTCCTAATGGCAAACTGGGCACTGGATTCCAATTGGCTGGGACAGAAGTCAAGCT
GTACTCATAAGATGTCATTTTCCCTGCCACCTTGACCTGTTACTGAATGTTGCCTCTTCCTTGAAGGGCCAGGGGAAA
AAGATCTCTTGATTACCTGAGCCGAAAGATCAAAATCTGCAGTGTTGAAGTGAGACTTCGTTCCTATGGAAGGAGAAG
TAACCTACATCTACACTCATCGAACAGCCACTGTAACCCAGAAATCGCAGTTCTGAGAGTTCAGCAATAAGATCGAAG
TCAAGATCTCACTGACTTACGTGCACTCCCATGTCTGTGATGATACTGCTCAAAATGGCCCAGATGTGAAAACATCTG
TTGTATTCAAATGTTCTGATACCCCTTGGCACTTAGATGAATTTCAAGTGCTGGTTCCATTCTTAGCATTTTGGGTAA
AATGCTGTGGGTCAAAGTGGCTGCTTGATTTCAGTCCAACAAAAGTGTTGATACTCCAACCCCC 
Figure 42: Sequence of rat MT2, showing the position of the self-designed primer pairs and the Ishii 
primers (see Table 33 for highlight color mapping). Exon 1 is printed in blue, exon 2 is printed in bordeaux, 
exon 3 is printed in dark green. (Sequence: modified after [26], NM_001100641.1). 
The mastermix recipe and temperature program for the primers’ respective PCR 
procedures was designed according to the described method (0). 
These particular two primer pairs were selected because they allow combination 
with the Ishii primers, if necessary, or the execution of a nested PCR, using the Ishii 
primers as inner primers, when using MS1_rMT2 as outer primers. Also, because the 
melting temperatures of these three primer pairs are relatively similar, PCR 
experiments using all three primer pairs could be conducted in one batch. 
5.4.6 RT-PCR for MT2 mRNA expression with the newly designed 
primers 
Assessment of primer functionality and effectiveness 
Three simultaneous PCRs were carried out on the confirmed MT2 expressing brain 
sample (see 5.4.2) from the various rat organs (see 4.1.1) to assess the effectiveness 
of the new primers by comparing their respective band intensities with those derived 
from the Ishii primers. The experiments were performed in one batch. All the PCRs 
worked and produced single, defined bands at the respective expected lengths for MT2. 
The band for the MS2_rMT2 primer was extremely weak, whereas the bands for the 
Ishii and MS1_rMT2 primers were about equal in intensity (data not shown). Therefore, 
the primer pair MS1_rMT2 was used for the next experiment on the aorta samples. 
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RT-PCR for MT2 mRNA expression in rat aortas from two different time 
points 
Six samples of the aortas from two different time points (A31, A35, A36, A37, A81, A83 
and A88; see 4.1.2) and the positive controls brain and eye (see 4.1.1) were 
investigated. 400 ng cDNA or water (no cDNA) were subjected to the PCR reaction 
using the self-designed primers MS1_rMT2. See 4.6.2 for the general protocol and 
4.6.3 for experiment specific conditions. 
Singular bands of the expected length of 540 bp were visible in the eye and brain 
positive controls. In the aorta samples weaker bands at lengths of 500 bp and / or 600 
bp, but not at 540 bp were observed (data not shown). The bands of both lengths from 
the aorta samples and the singular bands of the expected length from the eye and 
brain samples were excised from the gel and processed for sequencing. 
Sequencing of alleged MT2 RT-PCR products 
The excised bands were pooled for a higher DNA yield after extraction: the first pool 
included the bands from the aorta samples with a length of 600 bp; the second pool 
included the bands from the aorta samples with a length of 500 bp; the third pool 
included the bands with a length of 540 bp from the eye and brain positive controls. 
The DNA from the gel slices was extracted and purified according to the described 
procedure (see 4.8). Concentration measurement of the eluated DNAs by photometry 
(see 4.3) revealed concentrations of 5.9 ng / µL (first pool), 7.0 ng / µL (second pool) 
and 8.3 ng / µL (third pool). 5 µL of the eluates were analyzed using GE to determine 
the extracted DNA’s purity. Only singular bands at the expected length for each pool 
were visible (not shown). The eluates were then sent to MWG Eurofins Operon 
(Ebersberg, Germany) for sequencing (see 4.9) together with aliquots containing 30 
pmol of each primer (MS1_rMT2_fwd and MS1_rMT2_rev, see 4.6.3). 
Unfortunately, sequencing worked only for pool three (brain and eye samples). 
Comparison with the published sequence for the rat MT2 mRNA ([26], RefSeq: 
NM_001100641.1) showed 100 % identity over a length of 540 bp (expected: 540 bp). 
This result confirmed the identity of the observed amplicons from the brain and eye 
sample as MT2 and proves that the new method with the self-designed primers is able 
to amplify MT2 in rat tissue correctly. However, for pools one and two (all aorta 
samples), sequencing failed, producing no results. 
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MT2    29   TTAGCACTTGCTGGGCGGGGAGGGGACAGCGGGAGCGCCCCCAAGCAGTGCACACCTTGC  88  
fwd    1                                                 CAGTGCACACCTTGC  15  
rev    278  TTAGCACTTGCTGGGCGGGGAGGGGACAGCGGGAGCGCCCCCAAGCAGTGCACACCTTGC  219 
 
MT2    89   GCATCTATCCCGGGCTGCAGCGTCACCATGCCTGACAACAGCTCCATCGCCAACTGCTGT  148 
fwd    16   GCATCTATCCCGGGCTGCAGCGTCACCATGCCTGACAACAGCTCCATCGCCAACTGCTGT  75  
rev    218  GCATCTATCCCGGGCTGCAGCGTCACCATGCCTGACAACAGCTCCATCGCCAACTGCTGT  159 
 
MT2    149  GCGGCCAGCGGGCTGGCAGCGCGCCCTAGTTGGCCCGGGTCAGCGGAGGCGGAGCCCCCT  208 
fwd    76   GCGGCCAGCGGGCTGGCAGCGCGCCCTAGTTGGCCCGGGTCAGCGGAGGCGGAGCCCCCT  135 
rev    158  GCGGCCAGCGGGCTGGCAGCGCGCCCTAGTTGGCCCGGGTCAGCGGAGGCGGAGCCCCCT  99  
 
MT2    209  GAGACTCCCCGGGCACCCTGGGTGGCTCCCATGCTATCTACAGTAGTCATTGTCACCACA  268 
fwd    136  GAGACTCCCCGGGCACCCTGGGTGGCTCCCATGCTATCTACAGTAGTCATTGTCACCACA  195 
rev    98   GAGACTCCCCGGGCACCCTGGGTGGCTCCCATGCTATCTACAGTAGTCATTGTCACCACA  39  
 
MT2    269  GCTGTGGACTTCGTGGGGAACCTGCTTGTGATCCTCTCGGTGCTCAGGAACCGCAAGCTG  328 
fwd    196  GCTGTGGACTTCGTGGGGAACCTGCTTGTGATCCTCTCGGTGCTCAGGAACCGCAAGCTG  255 
rev    38   GCTGTGGACTTCGTGGGGAACCTGCTTGTGATCCTCTC                        1   
 
MT2    329  CGGAACGCAGGTAATTTATTTGTGGTGAATCTGGCCTTGGCTGACCTGGTGGTAGCCCTG  388 
fwd    256  CGGAACGCAGGTAATTTATTTGTGGTGAATCTGGCCTTGGCTGACCTGGTGGTAGCCCTG  315 
 
MT2    389  TACCCTTACCCACTCATCCTTGTGGCCATTCTCCATGACGGTTGGGTACTTGGGGAGATC  448 
fwd    316  TACCCTTACCCACTCATCCTTGTGGCCATTCTCCATGACGGTTGGGTACTTGGGGAGATC  375 
 
MT2    449  CACTGTAAGGCCAGTGCCTTTGTGATGGGCCTGAGTGTCATTGGCTCTGTCTTCAACATC  508 
fwd    376  CACTGTAAGGCCAGTGCCTTTGTGATGGGCCTGAGTGTCATTGGCTCTGTCTTCAACATC  435 
 
MT2    509  ACAGCCATTGCCATCAACCGCTACTGGTGCATCTGTCACAGTGCGACCTACCACCGAGCC  568 
fwd    436  ACAGCCATTGCCATCAACCGCTACTGGTGCATCTGTCACAGTGCGACCTACCACCGAGCC  495 
 
MT2    569  T  569                                                            
fwd    496  T  496                                                            
Figure 43: Comparison of the sequencing results from pool three (brain and eye) and the published 
sequence for MT2 mRNA (RefSeq NM_001100641.1) Combined length of the sequencing results of both 
primers: 540 bp; E-values: fwd = 0.0, rev = 7E-150; fwd: MS1_rMT2 fwd; rev: MS1_rMT2 rev. 
To ensure that a methodical error was not the cause for the failed sequencing of 
the aorta bands, the experiment was repeated. Similar results as in the experiment 
above were obtained after RT-PCR and sequencing of the bands from the aorta 
samples failed again (data not shown). 
Nested RT-PCR for MT2 mRNA expression in rat aortas from two different 
time points 
The previous experiments already indicated that MT2 mRNA was not expressed in the 
rat aorta. To confirm this hypothesis, a nested PCR, using the self-designed primers as 
outer primers and the Ishii primers as inner primers, was performed. The nested PCR 
should enrich a possibly very faint MT2 amplicon in the rat aorta samples and show 
selectively only single bands of the expected product.  
Again, 400 ng cDNA (RNA equivalent) of the six samples of the aortas from two 
different time points (A31, A35, A36, A37, A81, A83 and A88; see 4.1.2) and the 
positive controls brain and eye (see 4.1.1) were subjected to the outer RT-PCR with 
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the self-designed primers MS1_rMT2. See 4.6.2 for the general protocol and 4.6.3 for 
experiment specific conditions. The two positive controls (brain and eye) were diluted 
1:5 and the eye sample was additionally diluted 1:10 to account for the low amount – if 
any – of MT2 mRNA expected to be present in the aorta samples. A 1:10 dilution of the 
brain sample was also prepared but not included in the experiment because of spillage. 
Analysis of the outer RT-PCR showed again bands at varying lengths and intensities in 
the aorta samples. In contrast to previous PCR (0), almost all aorta samples (except for 
A35) exhibit bands at the observed lengths of 600 and 500 bp. 
 
 
Figure 44: MT2 mRNA expression in rat aortas of two different time points and rat brain and eye as 
positive controls analyzed by RT-PCR according to the self-designed PCR protocol as outer PCR. 
Expected length of the PCR product was 540 bp. Daytime group (orange): A35–A37; nighttime group 
(blue): A81–A88. 
The inner PCR was performed with 1 µL of the PCR products of the outer PCR 
used as template according to the method by Ishii et al. [26] modified as described in 
5.1.3. See 4.6.2 for the general protocol and 4.6.3 for experiment specific conditions. 
The number of cycles was reduced from 40 to 20 to accommodate the use of the 
protocol as an inner PCR. 
 
 
Figure 45: MT2 mRNA expression in rat aortas of two different time points and rat brain and eye as 
positive controls analyzed by RT-PCR according to the modified method by Ishii et al. [26] as inner PCR. 
Expected length of the PCR product was 390 bp. Daytime group (orange): A35–A37; nighttime group 
(blue): A81–A88. 
 
  5 Results 
105 
Amplification occurred only in the three positive controls. The bands were very 
intense and at the expected length of 390 bp. In addition to these bands, a single low 
intensity band occured at approximately 500 bp. No bands whatsoever were visible in 
the aorta samples. The experiment was repeated, yielding the same results (not 
shown). 
From this experiment it was concluded that MT2 mRNA is not expressed in the rat 
aorta. Therefore, no further experiments (aortas from SHR and control rats, qPCR, IF) 
were performed for MT2. 
5.5 Expression analysis of MT1 protein in the rat aorta by IF 
Aortas of control and SHR rats were investigated for MT1 protein expression using IF 
experiments. As mentioned above, because of the results from the mRNA level (no 
MT2 mRNA is present in the rat aorta), experiments for MT2 were not performed. For 
information on antibodies and blocking buffers, see the respective materials and 
methods sections (4.11.6).  
Because of the postulated mechanism of MT1’s influence on blood vessels, where 
MT1 acts through direct activation of smooth muscle cells, causing vasoconstriction 
[61], we first established IF localization of the smooth muscle cell marker α-smooth 
muscle-actin (SM-actin) and the endothelial cell marker pecam-1 in single and double 
stainings for use in possible co-localization experiments with MT1.  
5.5.1 Single stainings for SM-actin and pecam-1 protein 
expression 
The first IF experiments were performed on frozen rat aortas from SHR and control rats 
(prepared by M. Benova, Department of Pathophysiology, Medical University Vienna, in 
2008; see 4.1.4). The aortas were cryo-sectioned according to the described procedure 
(see 4.11.2). 
The aorta sections were stained either for SM-actin or pecam-1 and photographed 
according to the described procedures (see 4.11.4 and 4.11.7). Negative samples 
using the secondary ABs only were prepared as well. See chapter 4.11.8, Table 18 and 
Table 19 for experiment parameters.  
Both single stainings worked well, as shown in Figure 46: There was bright staining 
in the tunica media showing staining for SM-actin. Staining for pecam-1 highlighted 
only the endothelial cells of the tunica intima, as expected. In both cases, the negative 
controls showed no fluorescence, indicating that the observed stainings was due to 
specific binding of the primary ABs only. 
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Figure 46: IF analysis of SM-actin and pecam-1 protein localization in rat aorta sections. A: SM-actin 
positive; B: SM-actin negative; C: pecam-1 positive; D: pecam-1 negative; secondary antibody: Alexa 
Fluor® 568; TA: tunica adventitia; TM: tunica media; TI: tunica intima. 
5.5.2 Double staining for SM-actin + pecam-1 protein expression 
Since the single stainings went well, the same antibodies and samples were used for 
establishment of double staining protocols. 
The aorta sections were stained and photographed according to the described 
procedures for sequential and parallel double staining (see 4.11.4 and 4.11.7). For the 
sequential staining, two groups of samples were investigated: in one group the first 
primary AB was for SM-actin, in the other group the first primary AB was for pecam-1. 
Because the incubation with the primary AB was done overnight, this setup was 
chosen to determine if the duration of the incubation (overnight vs 1 h) with either of the 
two primary antibodies has an effect on the staining. In the parallel experiment, both 
primary ABs were applied overnight simultaneously. Because both primary antibodies 
are detected with secondary antibodies gained from goat, the same blocking buffer was 
used. See chapter 4.11.8, Table 20 for experiment parameters. 
Negative samples using the secondary ABs only were prepared, as well as cross 
negatives, containing a primary antibody and the respective other secondary antibody 
to exclude false positive detections of the secondary antibodies. 
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All staining procedures went well, and the antibodies were selective for their 
respective targets (see Figure 47). 
   
Figure 47: IF analysis of double stainings for SM-actin + pecam-1 protein localization in rat aorta sections. 
A: SM-actin overnight, pecam-1 1h; B: pecam-1 cross negative; C: SM-actin 1h, pecam-1 overnight; 
positive; D: SM-actin cross negative; E: parallel staining positive; F: parallel staining negative; secondary 
antibodies: Alexa Fluor® 647 (pecam-1) and Alexa Fluor® 568 (SM-actin) TA: tunica adventitia; TM: tunica 
media; TI: tunica intima. 
There is a striking – yet not unexpected – difference between the three different 
groups: while the pecam staining was not very strong when the primary AB was only 
applied for 1 hour, the staining was vibrant when the section was incubated with the AB 
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overnight. The actin staining was strong even when the AB was only applied for 1 hour. 
The adventitia exhibited some background fluorescence. 
The cross negatives showed that the secondary antibodies are selective for their 
respective targets. No staining of the “wrong” primary antibody or of the tissue in 
general occurs. The same was observed in the negatives (not shown). 
The parallel staining procedure produced a very nicely stained section, with less 
staining of the adventitia than in the sequential approaches. Since both primary 
antibodies were applied overnight (together), the stainings of both types were very 
vibrant. There was little staining visible in the negative (mostly in the media). 
5.5.3 Single stainings for MT1 protein expression on cryo-sections 
The first IF experiment for MT1 protein expression in the rat aorta was performed on the 
cryo-sectioned aortas. The aorta sections were stained for MT1 using the Abbiotec 
25076 and SC sc-13186 antibodies and were photographed according to the described 
procedures (see 4.11.4 and 4.11.7). Negative samples using the secondary ABs only 
were prepared as well. See chapter 4.11.8, Table 21 and Table 22 for experiment 
parameters. 
All stained sections (representatives are shown in Figure 48) showed some 
background fluorescence, mainly in the elastic lamellae in the tunica media. The 
staining was brighter with the Abbiotec AB (Figure 48, panel A) than with the SC AB 
(Figure 48, panel C). The negative controls showed no staining. However, it has to be 
noted that the exposure time was very high (400 ms) for the red channel (for pecam-1 
or SM-actin, a brighter and much more defined staining was captured at only 150 ms; 
see 5.5.1 and 5.5.2); therefore the specificity of these findings was questionable.  
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Figure 48: IF analysis of stainings for MT1 protein localization in rat aorta cryo-sections. A: Abbiotec 
positive; B: Abbiotec negative; C: SC positive; D: SC negative; secondary antibody: Alexa Fluor® 568; TA: 
tunica adventitia; TM: tunica media; TI: tunica intima. 
Because the staining achieved with the SC AB was especially weak, another 
experiment, using a different secondary antibody and an additional higher 
concentration of the primary antibody, was performed. See chapter 4.11.8, Table 23 for 
experiment parameters. 
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Figure 49: IF analysis of stainings for MT1 protein localization in rat aorta cryo-sections using the SC AB in 
two different concentrations and Alexa Fluor® 647 as secondary AB. A: SC 1:50; B: SC 1:20; C: SC 
negative; TA: tunica adventitia; TM: tunica media; TI: tunica intima. 
There was some staining visible in the sections (mainly in the tunica adventitia; a 
representative is shown in Figure 49) and it was a little stronger in the sections stained 
with the 1:20 diluted antibody (Figure 49, panel B), than with the 1:50 diluted antibody 
(Figure 49, panel A). Grain-like noise was observed scattered over the tissue, in the 
positive sections as in the negative sections, but stronger in the positive sections. 
However, the staining of the adventitia observed in the positive sections is not present 
in the negative section. 
5.5.4 Single stainings for MT1 protein expression on paraffin 
sections 
After the unsatisfactory results from the cryo-sections, the staining for MT1 was 
conducted on the paraffin sections. Aorta sections prepared by H. Uhrova (Department 
of Pathophysiology and Allergy Research, Medical University Vienna; see 4.1.3) were 
used for the following experiments. Because these aortas are the same ones that were 
analyzed for MT1 mRNA expression in 5.3.2, it was already known that the SHR group 
expressed more mRNA than the control group. Therefore it seemed obvious to conduct 
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the experiments on the SHR aortas, because the expression (if any) of MT1 protein in 
the cryo-sections was extremely low. 
In the paraffin section group, positive controls were available: because of the 
results from the MT1 mRNA expression experiments in various rat organs (see 5.1.2 
and 5.1.3), we knew what organs contained mRNA for MT1 in rats. Rats were not 
available at the time, therefore mice were used. All antibodies are selective for proteins 
from human, rat or mice origin, so the use of mouse organs was not a problem. 
R. Stumberger, C. Brünner-Kubath and H. Uhrova (all Department of Pathophysiology 
and Allergy Research, Medical University Vienna) prepared a mouse (mus musculus) 
intestine and brain. H. Uhrova did the HOPE® fixation and paraffin-embedding, as well 
as the sectioning of these organs.  
Stainings using the Abbiotec anti MT1 Antibody 
Sections of mouse brain and intestine were stained together with the aorta sections 
(SHR aortas) for MT1 using the Abbiotec 25076 antibody. The aortas were stained in 
different concentrations of 1:50 and 1:10, while the organs were stained only 1:10. 
Staining and photography was done according to the described procedures (see 4.11.5 
and 4.11.7). Negative samples using the secondary ABs only were prepared as well. 
See chapter 4.11.8, Table 24 for experiment parameters. 
At 1:50 staining was visible in the aortas (a representative is shown in Figure 50) 
which became much more pronounced at 1:10. It seems that the antibody’s target is 
primarily located in the adventitia and also – but to a lesser extent – in the cells of the 
media and intima. The negative control exhibited no staining. 
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Figure 50: IF analysis of stainings for MT1 localization in rat aorta paraffin sections using the Abbiotec AB 
in two different concentrations and Alexa Fluor® 647 as secondary AB. A: Abbiotec 1:50; B: Abbiotec 1:10; 
C: Abbiotec negative; TA: tunica adventitia; TM: tunica media; TI: tunica intima. 
In the brain, staining with the Abbiotec AB produced a marked amount of tissue 
background fluorescence (in contrast to the negative control; Figure 51) as well as 
stained fibers in the brain, and nuclei and meninges of the cerebellum (Figure 52, red 
arrows).  
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Figure 51: IF analysis of the negative control for MT1 localization in mouse brain paraffin sections, using 
the Abbiotec AB and Alexa Fluor® 647 as secondary AB. The framed parts are magnified. The pictures of 
the middle panel correspond to 200 x magnification. 
 
Cerebellum Brain 
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Figure 52: IF analysis of staining for MT1 localization in mouse brain paraffin sections using the Abbiotec 
AB and Alexa Fluor® 647 as secondary AB. The framed parts are magnified. The pictures of the middle 
panel correspond to 200 x magnification. Red arrows mark areas of interest (see main text). 
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In the staining of the intestine, the tissue showed extremely high tissue background 
fluorescence and again staining of the tissue borders. The negative tissue exhibited no 
fluorescence (see Figure 53). 
 
Figure 53: IF analysis of staining for MT1 localization in mouse intestine paraffin sections using the 
Abbiotec AB and Alexa Fluor® 647 as secondary AB. A: Abbiotec positive; B: Abbiotec negative. 
Stainings using the SC anti MT1 antibody 
Sections of both organs were stained with the aorta sections (ASHR 02, ASHR 03 and 
ASHR 06) for MT1 using SC sc-13186 antibody. The aortas were stained in different 
concentrations of 1:50 and 1:20, while the organs were stained only 1:20. Staining and 
photography was done according to the described procedures (4.11.5 and 4.11.7). 
Negative samples using the secondary ABs only were prepared as well. See chapter 
4.11.8, Table 25 for experiment parameters. 
A new batch of antibody was used for this experiment, therefore concentrations of 1:50 
and 1:20 (and not 1:10) were used because it was probable that the staining with the 
new antibody would be stronger than with the old batch. 
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Like with the Abbiotec AB and the cryo-sections, the (weak) staining found was 
mainly located in the tunica adventitia (TA). Also, there was a lot of grain-like noise 
visible in and around the tissue. The staining in the 1:20 (Figure 54, panel B) treated 
sections was a little bit stronger than in the 1:50 treated ones (Figure 54, panel A). 
There was no staining visible in the negatives (Figure 54, panel C). However, some 
grain-like noise can still be seen scattered over the tissue (similar to the – stronger – 
pattern in the cryo-sections, see Figure 49).  
 
Figure 54: IF analysis of stainings for MT1 localization in rat aorta paraffin sections using the SC AB in two 
different concentrations and Alexa Fluor® 647 as secondary AB. A: SC 1:50; B: SC 1:20; C: Abbiotec 
negative; TA: tunica adventitia; TM: tunica media; TI: tunica intima. 
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A lot of background was visible in the negative control of the brain sample (outer 
layer of cerebellum; Figure 55). 
 
 
Figure 55: IF analysis of the negative control for MT1 localization in mouse brain paraffin sections, using 
the SC AB and Alexa Fluor® 647 as secondary AB. The framed parts are magnified. The pictures of the 
middle panel correspond to 200 x magnification. 
  
Cerebellum Brain 
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Like in the brain sample stained with the Abbiotec anti MT1 AB (Figure 52), fibers in 
the brain tissue and the meninges of the cerebellum were stained the strongest (Figure 
56, red arrows). Like in the aorta samples, there was a lot of grain-like noise on and 
around the tissue. 
 
 
Figure 56: IF analysis of staining for MT1 localization in mouse brain paraffin sections using the SC AB 
and Alexa Fluor® 647 as secondary AB. The framed parts are magnified. The pictures of the middle panel 
correspond to 200 x magnification. Red arrows mark areas of interest (see main text). 
In contrast to the staining with the Abbiotec AB (Figure 53), the stained regions of 
tissue (Paneth cells?) in the intestine were much more defined and restricted to specific 
clusters of cells (Figure 58, red arrows). There was no staining in the negative sample. 
There is also notably less noise than in the other negative samples (Figure 57). 
Cerebellum Brain 
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Figure 57: IF analysis of the negative control for MT1 localization in mouse intestine paraffin sections, 
using the Abbiotec AB and Alexa Fluor® 647 as secondary AB. The framed parts are magnified. 
 
Figure 58: IF analysis of staining for MT1 localization in mouse brain paraffin sections using the SC AB 
and Alexa Fluor® 647 as secondary AB. The framed parts are magnified. The bottom right picture shows 
an additional overlay with the respective transmission image. Red arrows mark areas of interest (see main 
text). 
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In conclusion, we showed that specific and strong stainings for MT1 protein 
expression with the available antibodies from SC and Abbiotec are possible (mouse 
brain and intestine). In contrast, the stainings observed in the aorta sections, both 
paraffin as well as cryo-sectioned, were very weak and did not look very specific. The 
best results were obtained with the Abbiotec antibody on paraffin sections, where a 
dilution of 1:10 produced a moderate staining for MT1 in the tunica adventitia. Because 
of this weak expression in tissue layers other than the expected (tunica adventitia), no 
co-localization experiments with pecam-1 (for the tunica intima) or SM-actin (for the 
tunica media) were performed. 
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6 DISCUSSION 
The results are discussed according to the order of the aims of the thesis. 
1)  Establishment of molecular biological methods for demonstration of MT1 and 
MT2 mRNA expression 
The establishment of the methods for RNA extraction and reverse transcription worked 
well and provided no difficulty. RT-PCR method establishment for MT1 worked without 
problems as well, however, for the MT1 RT-PCR, the cycles had to be adjusted from 35 
to 40 and the template cDNA (RNA equivalent) from 200 to 400 ng compared to the 
described method by Ishii et al. [26]. This could indicate worse transcription efficiency 
of our polymerase or reverse transcriptase. 
The observed amplifications for MT1 mRNA in the rat organs are not congruent 
with the results from Ishii et al. [26], as e.g. testes, liver and kidney, which showed the 
strongest expression of all organs in [26], only exhibited weak bands for MT1 in our 
experiment. These results were confirmed by the qPCR, where the observed ΔCT 
values were for the most part congruent with the band intensities from the qualitative 
PCR. In our experiment, the intestine, brain and eye showed the highest expression for 
MT1. The expression in these tissues is well established already [35]. A possible 
explanation of this discrepancy could be variation of expression between different rat 
strains, or expression dependent on the circadian phase state (at least in some 
tissues). However, diurnal variations in MT1 expression have only been reported for 
humans [129] and not for the rat [108]. Of course it is also possible that the observed 
differences in melatonin GPCR mRNA expression are the result of interindividual 
variations, like the ones found for MT1 mRNA expression in the aorta. 
The method for MT2 RT-PCR experiments had to be changed initially, since the 
original protocol according to [26] did not produce any results even for tissues where 
MT2 occurrence is well established, e.g. brain or eye [6]. In contrast to Ishii et al. [26], 
who observed MT2 mRNA expression in most of the investigated tissues (see Figure 
6), RT-qPCR analysis showed that MT2 mRNA was only expressed in 4 out of 10 
tissues (the eye sample was not included in the RT-qPCR experiment) and at very low 
levels. Sallinen et al. [35] also tested various rat organs for MT2 mRNA and 
demonstrated expression in the intestine, the liver and the heart, where no 
amplification was observed in our experiment. Nevertheless, the positive results from 
brain [26, 163], testes [26], kidney [26, 159] and thymus [159] are confirmed in the 
literature for the respective rat tissues. The reasons for the observed differences in 
expression of MT2 might be the same as for MT1 expression. 
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2a)  Expression of MT1 mRNA in the rat aorta 
In experiments performed with aortas from the two different time points, MT1 mRNA 
expression was confirmed in the rat aorta, which is in line with the findings of other 
studies on the rat aorta [108] and other rat [36] and human [127, 129] blood vessels. 
MT1 mRNA was detected in all samples, though at varying intensities. The identity of 
the bands was confirmed by sequencing of the PCR product. The absence of a band in 
one sample and the different intensities in the various samples are interesting because 
they indicate large interindividual differences in MT1 receptor expression between the 
animals. RT-qPCR did indeed confirm these great interindividual differences of MT1 
mRNA expression at the same time of day. 
2b)  Expression of MT2 mRNA in the rat aorta 
Concerning MT2 mRNA, different methods were tried to find an expression of its mRNA 
in the aorta, since various studies reported an expression of MT2 mRNA in the vascular 
system of humans [128] and rats alike [35-36], even if the data is – as discussed in the 
introduction, see 2.6.6 – conflicting. 
The only method that yielded amplification of MT2 in the aorta samples was the 
nested PCR method from Sugden et al. [34], using inter-exon primers. Unfortunately, 
the bands for MT2 persisted even in DNAse treated -RT samples and as long as 
the -RT samples exhibit any bands at all, the results for the normal (+RT) samples are 
not valid, thus indicating presence of genomic DNA. Additionally, with this method, the 
observed bands for MT2 were much stronger than those for MT1. Even if a direct 
comparison is illicit, it seems rather improbable that MT2 would be so readily detectable 
when the aorta samples exhibit only weak MT1 bands, or even, in one case, none at all 
and MT1 is usually higher expressed than MT2 [24].  
The results from the nested PCR using the exon spanning self-designed and Ishii 
primers performed on the rat aortas from two different time points then clearly proved 
that no mRNA for MT2 is present in the rat aorta. Our results support the findings of 
other studies which showed no expression of MT2 mRNA in rat cerebral arteries [132]. 
Preparation or methodical error can be excluded because amplification of MT2 mRNA 
in the positive controls brain and eye worked and was confirmed by sequencing. Based 
on the absence of MT2 mRNA, we did not perform a RT-qPCR or IF staining for MT2 on 
any of the aorta samples. 
3)  Quantification of MT1 mRNA expression difference in the rat aorta depending 
on the time of day 
Maybe as a result of those large interindividual differences, this experiment showed no 
significant difference in expression levels of MT1 mRNA between the two time points. 
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Therefore, it cannot be concluded that MT1 mRNA expression in the aorta is related to 
the time of day, or if it is, the sample size and number of time points in this experiment 
were far too small and too few to detect it with any significance. This confirms the 
results of Benova et al. [108], who did not find any difference in MT1 expression in the 
rat aorta at the protein level and emphasizes the organ specificity of the circadian 
rhythms of this receptor, because in other organs, a circadian expression pattern was 
indeed observed [129, 136]. 
4)  Quantification of MT1 mRNA expression difference in the rat aorta depending 
on BP 
In contrast to this result, both RT-PCR and RT-qPCR experiments showed a significant 
increase (about 4-fold) in MT1 receptor mRNA in SHR when compared to control rats. 
This difference proves that there is indeed some kind of link between hypertension and 
melatonin GPCR expression. However, it seems to occur only in genetically 
predisposed hypertensive animals, since L-NAME induced hypertension did not 
increase MT1 protein expression in the aorta [108]. Then again, even though changes 
in MT1 expression levels were observed as a result of the genetic Alzheimer’s disease 
[135], they were also observed as a result of artificially created ischemia [160], putting 
this hypothesis of genetic influence in perspective. Therefore, other additional 
mechanisms might account for the observed differences. 
Because exogenous melatonin reduces BP in spontaneously hypertensive rats 
[115], and MT2, supposed to have vasodilating effects [61], seems not to be present in 
the aorta, the BP reducing effects of melatonin might be attributed rather to melatonin’s 
non receptor-mediated antioxidative capability [61] or GABAergic influence on the 
central nervous system [109] than effects on the vasculature mediated via GPCRs. 
5)  Localization of MT1 protein in the rat aorta 
Although expression of MT1 mRNA was demonstrated in this study for the rat aorta and 
expression of MT1 protein by western blotting (Prof. M. Zeman, Comenius University of 
Bratislava, Slovakia; personal communication; and [108]), the location of MT1 protein in 
the various layers of the aorta remains questionable.  
The functioning of the staining procedures was confirmed by the stainings for 
pecam-1 and α-SM-actin, which worked fine in single as well as sequential and parallel 
double stainings. These stainings proved that the aorta sections were still antigenic and 
that the endothelium was intact (positive staining with pecam-1). 
When staining for MT1 however, only very weak cell-associated fluorescence, but 
high background noise was observed. These grain-like speckles were only observed 
with the anti-MT1 AB from SC, using Alexa Fluor® 647 as secondary AB, but not with 
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the primary anti-MT1 AB from Abbiotec using the same secondary AB, or the SC 
primary AB with Alexa Fluor® 568 as secondary AB. Therefore, it might be possible 
that this background was the result of formation of unspecific aggregates of the SC AB 
with the Alexa Fluor® 647 secondary antibody. 
Though the combination of the SC antibody with Alexa Fluor® 568 did not result in 
background noise, the observed staining was also very weak. It seems likely that it is 
the result of unspecific adhesion of the primary AB to the tissue, rather than target 
specific binding. The anti-MT1 Abbiotec antibody generally produced stronger stainings 
with less background noise. With both antibodies, the staining was stronger in the 
tunica adventitia than in the other layers of the aorta. This was observed in paraffin 
sections as well as – to a lesser extent – in cryo-sections. However, this staining 
pattern was only seen using Alexa Fluor® 647 as secondary antibody. When used with 
Alexa Fluor® 568, only some extremely faint staining of the tunica media could be 
seen. 
From the proposed vasoconstrictive function of MT1, a localization of the receptor 
in smooth muscle cells was expected. Surprisingly, the only staining for MT1 in aortas 
was associated with the tunica adventitia. However, a similar situation has been 
reported in the literature. Immunohistochemical staining of cerebral vessels from 
Alzheimer patients showed MT1 localization only in the adventitia, too [135]. The 
applied anti-human-MT1 AB is described as being well characterized. Since no other 
studies exist that have investigated MT1 localization in blood vessels, it is possible that 
MT1 indeed is only localized in the tunica adventitia. 
It has to be noted that paraffin embedding is known to mask antigens and the 
tissue we used for cryo-sectioning had already been frozen for more than a year. It is 
possible that the receptor protein, even more so since the expression is very low, had 
already been degraded and was therefore not detectable any more by IF methods. 
Furthermore, the reliability of the available antibodies remains somewhat questionable, 
because other studies indicate that at least a SC AB against human MT1 is rather 
unspecific (Ramezanian and Ellinger, unpublished data). 
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Nonetheless, we can exclude procedural error or degraded antibodies, because 
staining of the positive controls (mouse brain and intestine) worked nicely and 
produced quite interesting results. To our knowledge, no studies on the localization of 
MT1 in the intestine have been performed, and our experiments show highly selective 
staining of what may be Paneth cells at the bottom of the intestinal villi. In the brain, 
specific staining of fibers of yet undetermined nature was shown. One might speculate 
that these fibers are capillaries, which would be of great interest with respect to the 
aims of this thesis. Both of these occurrences of MT1 have to be investigated in a later 
work. 
7 CONCLUSION AND OUTLOOK 
The principal aim of this thesis was to prove the expression of the melatonin GPCRs 
MT1 and MT2 in the rat aorta on mRNA level, thereby helping to understand the 
mechanism by which melatonin contributes to BP regulation.  
We confirmed MT1 is indeed expressed in the rat aorta. We observed no 
differences in expression between samples collected at night and samples collected at 
day, but the sample size (eight from each group) might have been too small for a 
definitive conclusion. However, an about 4-fold increase in mRNA levels was observed 
in aortas from SHR compared to control rats, adding to the evidence of melatonin’s BP 
regulating activity. On the other side, we proved that MT2 mRNA is not expressed in the 
rat aorta. 
Since our results from IF indicate that MT1 is not expressed in the smooth muscle 
cells of the tunica media, and MT2 was shown not to be present in the rat aorta at all, 
the proposed mechanism of action of melatonin’s BP modulating properties [61] might 
have to be reviewed, even if the increase in mRNA in SHR emphasizes a role of MT1 in 
BP regulation. 
 
In future studies, the investigation of a difference in mRNA expression levels of 
MT1 could be redone, using a larger population of samples and perhaps more than two 
time points. Additionally, we discovered very specific localization of MT1 in the mouse 
brain and intestine, which has to be investigated further in additional studies. 
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8 LIST OF ABBREVIATIONS 
CT Difference between two CT values 
CT Difference between two CT values 
AANAT Arylalkylamine-N-transferase 
AB(s) Antibody(ies) 
AC Adenylate cyclase 
ACTB β-actin (in context of qPCR)  
AGA-GE Agarose gel electrophoresis 
approx. approximately 
BP Blood pressure 
bp Base pairs 
BSA Bovine serum albumin 
C Concentration 
cAMP Cyclic adenosine monophosphate 
CCR CC chemokine receptors 
CHS Coronary heart syndrome 
CREB cAMP-response-element-binding-protein 
CT Cycle threshold 
CTRL Control (as part of a sample’s name) 
DAG Diacylglycerol 
DAPI 4',6-diamidino-2-phenylindole 
DNA Deoxyribonucleic acid 
DNAse Deoxyribonuclease 
dNTP(s) Deoxyribonucleotide(s) 
EDTA Ethylenediaminetetraacetic-acid 
GABA Gamma-aminobutyric-acid 
GABAA Gamma-aminobutyric-acid A receptor 
GE Gel electrophoresis 
GPCR G-protein coupled receptor 
GPR50 G protein-coupled receptor 50 
h Hour(s) 
HIOMT Hydroxyindole-O-methyltransferase 
IF Immunofluorescence 
L-NAME N-nitro-L-arginine-methyl-ester 
min Minute(s) 
mRNA Messenger RNA 
MT1 Melatonin receptor 1 
MT2 Melatonin receptor 2 
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NO Nitric oxide 
NOS Nitric oxide synthase 
o/n Overnight 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PCR water DNAse, RNAse, DNA free water 
PFA Paraformaldehyde 
PKA Protein kinase A 
PKC Protein kinase C 
qPCR Real time (quantitative) polymerase chain reaction 
QR2 Quinone reductase 2 
RNA Ribonucleic acid 
RNAse Ribonuclease 
rRNA ribosomal RNA 
rt Room temperature 
RT Reverse transcription 
RT-PCR Reverse transcription polymerase chain reaction 
RT-qPCR Reverse transcription real time (quantitative) polymerase chain reaction 
s Second(s) 
SC Santa Cruz 
SCN Suprachiasmatic nucleus 
Sd Standard deviation 
SHR Spontaneously hypertensive rats 
TAE Tris-acetic-acid-EDTA buffer 
Taq Thermus aquaticus 
TF TissueFAXS, TissueGnostics GmbH 
UV Ultraviolet 
Vol. Volume 
vs Versus 
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